<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><?covid-19-tdm ?><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">85701</article-id><article-id pub-id-type="doi">10.7554/eLife.85701</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Ecology</subject></subj-group><subj-group subj-group-type="heading"><subject>Epidemiology and Global Health</subject></subj-group></article-categories><title-group><article-title>Exploring factors shaping antibiotic resistance patterns in <italic>Streptococcus pneumoniae</italic> during the 2020 COVID-19 pandemic</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-301471"><name><surname>Kovacevic</surname><given-names>Aleksandra</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9740-6207</contrib-id><email>aleksandra.kovacevic@pasteur.fr</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-351153"><name><surname>Smith</surname><given-names>David RM</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-304237"><name><surname>Rahbé</surname><given-names>Eve</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3828-3910</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-304238"><name><surname>Novelli</surname><given-names>Sophie</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-304239"><name><surname>Henriot</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-351150"><name><surname>Varon</surname><given-names>Emmanuelle</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-351151"><name><surname>Cohen</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-351152"><name><surname>Levy</surname><given-names>Corinne</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-233732"><name><surname>Temime</surname><given-names>Laura</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8850-5403</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-120147"><name><surname>Opatowski</surname><given-names>Lulla</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf4"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0495fxg12</institution-id><institution>Institut Pasteur, Université Paris Cité, Epidemiology and Modelling of Antibiotic Evasion (EMAE) unit</institution></institution-wrap><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01ed4t417</institution-id><institution>Université Paris-Saclay, Université de Versailles Saint-Quentin-en-Yvelines, Inserm U1018, CESP, Anti-infective evasion and pharmacoepidemiology team</institution></institution-wrap><addr-line><named-content content-type="city">Montigny-Le-Bretonneux</named-content></addr-line><country>France</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0175hh227</institution-id><institution>Modélisation, épidémiologie et surveillance des risques sanitaires (MESuRS), Conservatoire national des arts et métiers</institution></institution-wrap><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>Health Economics Research Centre, Nuffield Department of Health, University of Oxford</institution></institution-wrap><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0175hh227</institution-id><institution>PACRI unit, Institut Pasteur, Conservatoire national des arts et métiers</institution></institution-wrap><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0175hh227</institution-id><institution>Centre National de Référence des Pneumocoques, Centre Hospitalier Intercommunal de Créteil</institution></institution-wrap><addr-line><named-content content-type="city">Créteil</named-content></addr-line><country>France</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04qe59j94</institution-id><institution>Institut Mondor de Recherche Biomédicale-Groupe de Recherche Clinique Groupe d’Etude des Maladies Infectieuses Néonatales et Infantiles (IMRB-GRC GEMINI), Université Paris Est, 94000</institution></institution-wrap><addr-line><named-content content-type="city">Créteil</named-content></addr-line><country>France</country></aff><aff id="aff8"><label>8</label><institution>Groupe de Pathologie Infectieuse Pédiatrique (GPIP), 06200</institution><addr-line><named-content content-type="city">Nice</named-content></addr-line><country>France</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04n1nkp35</institution-id><institution>Unité Court Séjour, Petits Nourrissons, Service de Néonatologie, Centre Hospitalier, Intercommunal de Créteil</institution></institution-wrap><addr-line><named-content content-type="city">Créteil</named-content></addr-line><country>France</country></aff><aff id="aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03t4ktv29</institution-id><institution>Association Clinique et Thérapeutique Infantile du Val-de-Marne (ACTIV), 94000</institution></institution-wrap><addr-line><named-content content-type="city">Créteil</named-content></addr-line><country>France</country></aff><aff id="aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0495fxg12</institution-id><institution>Association Française de Pédiatrie Ambulatoire (AFPA), 45000</institution></institution-wrap><addr-line><named-content content-type="city">Orléans</named-content></addr-line><country>France</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Bonten</surname><given-names>Marc J</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0575yy874</institution-id><institution>University Medical Center Utrecht</institution></institution-wrap><country>Netherlands</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Harper</surname><given-names>Diane M</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00jmfr291</institution-id><institution>University of Michigan</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>07</day><month>03</month><year>2024</year></pub-date><volume>13</volume><elocation-id>e85701</elocation-id><history><date date-type="received" iso-8601-date="2022-12-20"><day>20</day><month>12</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2024-02-12"><day>12</day><month>02</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-08-09"><day>09</day><month>08</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.08.08.503267"/></event></pub-history><permissions><copyright-statement>© 2024, Kovacevic et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Kovacevic et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-85701-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-85701-figures-v2.pdf"/><abstract><p>Non-pharmaceutical interventions implemented to block SARS-CoV-2 transmission in early 2020 led to global reductions in the incidence of invasive pneumococcal disease (IPD). By contrast, most European countries reported an increase in antibiotic resistance among invasive <italic>Streptococcus pneumoniae</italic> isolates from 2019 to 2020, while an increasing number of studies reported stable pneumococcal carriage prevalence over the same period. To disentangle the impacts of the COVID-19 pandemic on pneumococcal epidemiology in the community setting, we propose a mathematical model formalizing simultaneous transmission of SARS-CoV-2 and antibiotic-sensitive and -resistant strains of <italic>S. pneumoniae</italic>. To test hypotheses underlying these trends five mechanisms were built into the model and examined: (1) a population-wide reduction of antibiotic prescriptions in the community, (2) lockdown effect on pneumococcal transmission, (3) a reduced risk of developing an IPD due to the absence of common respiratory viruses, (4) community azithromycin use in COVID-19 infected individuals, (5) and a longer carriage duration of antibiotic-resistant pneumococcal strains. Among 31 possible pandemic scenarios involving mechanisms individually or in combination, model simulations surprisingly identified only two scenarios that reproduced the reported trends in the general population. They included factors (1), (3), and (4). These scenarios replicated a nearly 50% reduction in annual IPD, and an increase in antibiotic resistance from 20% to 22%, all while maintaining a relatively stable pneumococcal carriage. Exploring further, higher SARS-CoV-2 R<sub>0</sub> values and synergistic within-host virus-bacteria interaction mechanisms could have additionally contributed to the observed antibiotic resistance increase. Our work demonstrates the utility of the mathematical modeling approach in unraveling the complex effects of the COVID-19 pandemic responses on AMR dynamics.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>Streptococcus pneumoniae</kwd><kwd>antibiotic resistance</kwd><kwd>invasive pneumococcal disease</kwd><kwd>virus-bacteria interactions</kwd><kwd>SARS-CoV-2</kwd><kwd>COVID-19 pandemic</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Other</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001665</institution-id><institution>Agence Nationale de la Recherche</institution></institution-wrap></funding-source><award-id>ANR-10-LABX-62 IBEID</award-id><principal-award-recipient><name><surname>Kovacevic</surname><given-names>Aleksandra</given-names></name><name><surname>Opatowski</surname><given-names>Lulla</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100007241</institution-id><institution>Université Paris-Saclay</institution></institution-wrap></funding-source><award-id>AAP Covid-19 2020</award-id><principal-award-recipient><name><surname>Opatowski</surname><given-names>Lulla</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001665</institution-id><institution>Agence Nationale de la Recherche</institution></institution-wrap></funding-source><award-id>SPHINX-17-CE36-0008-01</award-id><principal-award-recipient><name><surname>Temime</surname><given-names>Laura</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004431</institution-id><institution>Fondation de France</institution></institution-wrap></funding-source><award-id>MODCOV Grant 106059</award-id><principal-award-recipient><name><surname>Opatowski</surname><given-names>Lulla</given-names></name><name><surname>Temime</surname><given-names>Laura</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001677</institution-id><institution>Institut National de la Santé et de la Recherche Médicale</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Opatowski</surname><given-names>Lulla</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003762</institution-id><institution>Institut Pasteur</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Opatowski</surname><given-names>Lulla</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100013943</institution-id><institution>Conservatoire National des Arts et Métiers</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Temime</surname><given-names>Laura</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100020875</institution-id><institution>Université de Versailles Saint-Quentin-en-Yvelines</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Opatowski</surname><given-names>Lulla</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The mathematical modeling approach disentangles the impacts of the COVID-19 pandemic on antibiotic resistance in <italic>Streptococcus pneumoniae</italic> in the community setting and identifies the three most plausible driving mechanisms responsible for the observed trends in invasive isolates and pneumococcal carriage.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>In the early 2020, international responses to the coronavirus disease 2019 (COVID-19) pandemic led to unprecedented worldwide change in population mixing, healthcare-seeking behavior, and infection prevention and control practices. This modified the ecology and epidemiology of many infectious diseases at a global scale. Strong impacts of COVID-19 on infectious disease dynamics have been reported for common viral and bacterial respiratory infections, sexually transmitted pathogens like HIV, vector-borne diseases like dengue, and even non-communicable diseases (<xref ref-type="bibr" rid="bib13">Braunstein et al., 2020</xref>; <xref ref-type="bibr" rid="bib14">Brueggemann et al., 2021</xref>; <xref ref-type="bibr" rid="bib18">Chen et al., 2022</xref>; <xref ref-type="bibr" rid="bib76">Palmer et al., 2020</xref>). Antimicrobial resistance (AMR), however, remains one of the leading threats to global health. In 2019, estimates showed that AMR in clinically relevant bacteria was associated with 4.95 million deaths, of which 1.27 million were described as directly attributable to resistance (<xref ref-type="bibr" rid="bib70">Murray et al., 2022</xref>). Impacts of the COVID-19 pandemic on AMR dynamics remain relatively poorly understood.</p><p>A joint report from the WHO and European Centre for Disease Prevention and Control (ECDC) has reported 2020 AMR trends across 29 European countries for eight antibiotic-resistant bacterial pathogens of concern, including <italic>S. pneumoniae</italic> (<xref ref-type="bibr" rid="bib36">European Centre for Disease Prevention and Control and World Health Organization, 2022</xref>). While the situation varies widely across bacterial species, antimicrobial groups, and regions, most European countries, including France, documented an increase in pneumococcal resistance to both penicillin and macrolides between 2019 and 2020. The resistance rates rose from 12.2% in 2019 to 15.6% in 2020 for penicillin and from 14.5% in 2019 to 16.9% in 2020 for macrolides, as reported in the EU/EEA (<xref ref-type="bibr" rid="bib36">European Centre for Disease Prevention and Control and World Health Organization, 2022</xref>). However, increased pneumococcal resistance was accompanied by a sharp worldwide decline in invasive pneumococcal disease (IPD) incidence (<xref ref-type="bibr" rid="bib14">Brueggemann et al., 2021</xref>; <xref ref-type="bibr" rid="bib91">Shaw et al., 2023</xref>).</p><p>Similar declines in bacterial disease during early waves of COVID-19 have been observed in the context of sentinel community-acquired infections in New Zealand (<xref ref-type="bibr" rid="bib33">Duffy et al., 2021</xref>), IPDs in Taiwan (<xref ref-type="bibr" rid="bib19">Chien et al., 2021</xref>) and Hong Kong (<xref ref-type="bibr" rid="bib97">Teng et al., 2022</xref>), and lower respiratory tract infections in China (<xref ref-type="bibr" rid="bib17">Chen et al., 2021</xref>). Yet, surprisingly, a growing number of studies have reported mostly stable pneumococcal carriage throughout the COVID-19 pandemic containment, including among infants in Belgium (<xref ref-type="bibr" rid="bib103">Willen et al., 2021</xref>), children in Vietnam (<xref ref-type="bibr" rid="bib72">Nation et al., 2023</xref>), Serbia (<xref ref-type="bibr" rid="bib78">Petrović et al., 2022</xref>), France (<xref ref-type="bibr" rid="bib86">Rybak et al., 2022</xref>), South Africa (<xref ref-type="bibr" rid="bib74">Olwagen et al., 2024</xref>), and Israel (<xref ref-type="bibr" rid="bib25">Dagan et al., 2023</xref>), adults in Connecticut (<xref ref-type="bibr" rid="bib107">Wyllie et al., 2023</xref>), and households in Seattle (<xref ref-type="bibr" rid="bib10">Bennett et al., 2023</xref>). In contrast, a study conducted in Denmark reported a decrease in pneumococcal carriage among older adults during the COVID-19 lockdown (<xref ref-type="bibr" rid="bib98">Tinggaard et al., 2023</xref>).</p><p>Understanding the cause of these trends is not straightforward, as many responses to the COVID-19 pandemic, such as the implementation of non-pharmaceutical interventions (NPIs), changes in healthcare-seeking behavior, and alterations in antibiotic prescribing, occurred over the period (<xref ref-type="bibr" rid="bib53">Knight et al., 2021</xref>). To gain a comprehensive understanding of the changes in AMR epidemiology during the COVID-19 pandemic, it is essential to simultaneously consider a range of scales and indicators. These include the rates of incidence of invasive bacterial diseases (IBDs), the proportion of antibiotic-resistant isolates among total invasive bacterial isolates, and the prevalence of asymptomatic bacterial carriage in healthy individuals.</p><p>Several mechanisms may underlie the explanation of these contrasting observations. First, NPIs implemented to block SARS-CoV-2 transmission, such as lockdowns and mask mandates, may have led to reduced bacterial transmission. Containment measures also massively reduced circulation of common respiratory viruses, which are known to be associated with IBD (<xref ref-type="bibr" rid="bib32">Domenech de Cellès et al., 2019</xref>; <xref ref-type="bibr" rid="bib94">Smith and Opatowski, 2021</xref>). Second, the lockdown was associated with reductions in primary care consultations (<xref ref-type="bibr" rid="bib44">Homeniuk and Collins, 2021</xref>; <xref ref-type="bibr" rid="bib80">Read et al., 2023</xref>; <xref ref-type="bibr" rid="bib108">Zhang et al., 2021</xref>) leading to a global decrease of antibiotic prescriptions (<xref ref-type="bibr" rid="bib43">Högberg et al., 2021</xref>). In contrast, frequent antibiotic prescribing to COVID-19 outpatients may have exacerbated AMR (<xref ref-type="bibr" rid="bib20">Clancy et al., 2020</xref>; <xref ref-type="bibr" rid="bib53">Knight et al., 2021</xref>). Differences in the duration of pneumococcal carriage may have also played a role (<xref ref-type="bibr" rid="bib60">Lehtinen et al., 2017</xref>). Finally, potential within-host interactions between SARS-CoV-2 and <italic>S. pneumoniae</italic> could also have an impact on infection risk (<xref ref-type="bibr" rid="bib4">Amin-Chowdhury et al., 2021</xref>), although strong evidence for such interactions remains limited (<xref ref-type="bibr" rid="bib106">Wong et al., 2023</xref>).</p><p>Mathematical models incorporating the co-transmission of multiple pathogens within the same host population provide a framework for investigating different hypotheses that underlie the observed patterns in antibiotic resistance and incidence of IPD in <italic>S. pneumoniae</italic> and help to enhance our understanding of the mechanisms involved. Co-circulation models have been used previously to disentangle the public health consequences of interactions between pathogens such as influenza and <italic>S. pneumoniae</italic> (<xref ref-type="bibr" rid="bib6">Arduin et al., 2017</xref>; <xref ref-type="bibr" rid="bib32">Domenech de Cellès et al., 2019</xref>; <xref ref-type="bibr" rid="bib93">Shrestha et al., 2013</xref>) and could similarly be used to understand impacts of the COVID-19 pandemic on pathogens coinciding with SARS-CoV-2. However, in a systematic PubMed search conducted on 4 December 2023, we identified no epidemiological models describing the simultaneous transmission of SARS-CoV-2 and antibiotic-resistant bacteria specific to the community setting (Appendix 1).</p><p>Here, to disentangle how the COVID-19 pandemic has impacted the epidemiological dynamics of antibiotic resistance in <italic>S. pneumoniae</italic>, we propose a mathematical model that formalizes the transmission of SARS-CoV-2 and both antibiotic-sensitive and -resistant strains of <italic>S. pneumoniae</italic> in the community setting, and which includes mechanistic impacts of COVID-19 burden on epidemiological parameters. Through simulation, we assess all possible combinations of these mechanisms to evaluate their overall impact on IPD incidence, antibiotic resistance, and the prevalence of pneumococcal carriage. Furthermore, we assess the changes in the incidence of antibiotic-resistant IPD as we vary the basic reproduction number (R<sub>0</sub>) of SARS-CoV-2 during the first COVID-19 outbreak in Europe. We also consider assumed within-host pathogen interactions between SARS-CoV-2 and <italic>S. pneumoniae</italic>.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Antibiotic resistance trends and incidence of invasive pneumococcal disease in 2020</title><p>In routine surveillance data reported to the European Antimicrobial Resistance Surveillance Network (EARS-Net), most European countries reported an increase in antibiotic resistance in <italic>S. pneumoniae</italic> from 2019 to 2020, as indicated by increases in the proportion of invasive isolates with phenotypic resistance to both penicillin and macrolides (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). On the contrary, the total number of reported invasive isolates in the EU/EEA decreased by 44.3% from 2019 to 2020 (<xref ref-type="bibr" rid="bib36">European Centre for Disease Prevention and Control and World Health Organization, 2022</xref>) suggesting a decrease in incidence of IPD (<xref ref-type="table" rid="app2table1">Appendix 2—table 1</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Antibiotic resistance trends in invasive <italic>Streptococcus pneumoniae</italic> isolates for the years 2019 and 2020.</title><p>(<bold>A</bold>) The proportion of invasive <italic>S. pneumoniae</italic> isolates resistant to penicillin and macrolides (azithromycin/ clarithromycin/ erythromycin) reported to EARS-Net (European Antimicrobial Resistance Surveillance Network) for 24 European countries. Error bars show 95% confidence intervals. (<bold>B</bold>) The proportion of invasive <italic>S. pneumoniae</italic> isolates resistant to penicillin (MIC &gt;0.064 mg/L) and macrolides (erythromycin) according to age. Error bars show 95% confidence intervals. The total number of invasive pneumococcal isolates reported in France decreased by 45.1% from 2019 to 2020 (from 1119–614). Data are provided by the French National Reference Center for Pneumococci.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>European trends in antibiotic resistance in Streptococcus pneumoniae invasive isolates (2019-2020).</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-85701-fig1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85701-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Antibiotic resistance trends in invasive <italic>Streptococcus pneumoniae</italic> isolates in France, 2017–2020.</title><p>The proportion of invasive <italic>S. pneumoniae</italic> isolates resistant to penicillin (<bold>A</bold>) and macrolides (<bold>B</bold>) according to age. Error bars show 95% confidence intervals. Across the period 2017–2020, a consistent decline in antibiotic resistance is observed for both penicillin and macrolides. Notably, this general trend experienced an anomaly in 2020, coinciding with the onset of the COVID-19 pandemic. Data are provided by the French National Reference Center for Pneumococci.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85701-fig1-figsupp1-v2.tif"/></fig></fig-group><p>Invasive pneumococcal isolate data for France provided by the French National Reference Center for Pneumococci (CNRP) revealed similar trends. In France, the total number of reported invasive pneumococcal isolates decreased by 45.1% from 2019 to 2020 (from 1119–614), while antibiotic resistance in <italic>S. pneumoniae</italic> isolates to penicillin and macrolides showed an increasing trend from 26.2% in 2019 to 35.5% in 2020 for penicillin, and from 20.9% in 2019 to 23.0% in 2020 for macrolides (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). General decreasing trend in antibiotic resistance from 2017 to 2019 in <italic>S. pneumoniae</italic> was interrupted in 2020 (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). These variations in antibiotic resistance manifested differently across age, with some age groups showing an increase in antibiotic resistance in 2020 compared to 2019, while others showed no significant change (<xref ref-type="fig" rid="fig1">Figure 1B</xref>).</p></sec><sec id="s2-2"><title>Coinfection model of SARS-CoV-2 and <italic>Streptococcus pneumoniae</italic></title><p>As mentioned above, several mechanisms may underlie the explanation of these contrasting observations (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). COVID-19 NPIs may have led to reduced person-to-person bacterial transmission, potentially contributing to reduced rates of IPD incidence. These containment measures also massively reduced circulation of common respiratory viruses and the incidence of influenza-like-illnesses (ILIs). Respiratory viruses are known triggers and risk factors for developing an IBD from otherwise asymptomatic carriage; in that context, their reduction may have led to reduced infection risk (<xref ref-type="bibr" rid="bib32">Domenech de Cellès et al., 2019</xref>; <xref ref-type="bibr" rid="bib94">Smith and Opatowski, 2021</xref>). Due to reductions in primary care consultations in 2020, 26 European countries reported an estimated average decrease of 18.3% in overall antibiotic consumption, aligning with the global trend of reduced antibiotic prescriptions compared to 2019 (<xref ref-type="bibr" rid="bib43">Högberg et al., 2021</xref>). On the other hand, frequent prescribing of azithromycin, a macrolide antibiotic initially hypothesized to be effective in COVID-19 treatment, has raised concerns for pandemic-associated antimicrobial overuse or misuse and may have exacerbated AMR during and following the first wave of the pandemic (<xref ref-type="bibr" rid="bib20">Clancy et al., 2020</xref>; <xref ref-type="bibr" rid="bib53">Knight et al., 2021</xref>; <xref ref-type="bibr" rid="bib54">Kournoutou and Dinos, 2022</xref>; <xref ref-type="bibr" rid="bib58">Langford et al., 2021</xref>; <xref ref-type="bibr" rid="bib79">PRINCIPLE Trial Collaborative Group, 2021</xref>; <xref ref-type="bibr" rid="bib85">Rusic et al., 2021</xref>). There are still uncertainties about pneumococcal ecology and the evolutionary processes that enable the robust coexistence of strains sensitive and resistant to antibiotics. The role of carriage duration, along with the impact of antibiotic consumption, is also not fully understood in this context. Longer carriage duration of antibiotic-resistant pneumococcal strains is a proposed explanation for this coexistence (<xref ref-type="bibr" rid="bib60">Lehtinen et al., 2017</xref>). If so, antibiotic-resistant pneumococcal strains may have had an advantage during the lockdown period due to smaller clearance rates, ultimately leading to an increase in antibiotic resistance. Finally, among individuals with COVID-19, potential within-host interactions between SARS-CoV-2 and <italic>S. pneumoniae</italic> could also have had an impact on bacterial colonization and infection dynamics (<xref ref-type="bibr" rid="bib4">Amin-Chowdhury et al., 2021</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>A modelling framework describing the transmission of SARS-CoV-2 and <italic>Streptococcus pneumoniae</italic> in the community setting, in the context of both general antibiotic prescribing and azithromycin prescribing for COVID-19 infected individuals.</title><p>(<bold>A</bold>) Non-pharmaceutical interventions (NPIs) implemented to control SARS-CoV-2 transmission (lockdown, face mask use, improved hygiene practices, travel restrictions, quarantine, telemedicine, and physical distancing) may also modify transmission of other pathogens, in addition to impacting antibiotic prescribing due to altered inter-individual contact and health-care seeking behavior. (<bold>B</bold>) SEIR (Susceptible-Exposed-Infected-Recovered) model with antibiotic treatment compartments depicts interaction between SARS-CoV-2 infection and antibiotic prescribing, including both general community prescribing and azithromycin prescribing among individuals infected with SARS-CoV-2. (<bold>C</bold>) Diagram depicting how pneumococcal colonization and the community antibiotic prescribing are affected by the COVID-19 pandemic impacts. Initiation of antibiotic treatment is assumed independent of bacterial carriage, reflecting widespread bystander selection for commensal bacteria like <italic>S. pneumoniae</italic>. For a complete modeling framework, see section S2 in Supporting Information.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85701-fig2-v2.tif"/></fig><p>To test mechanistic impacts of responses to the COVID-19 pandemic on pneumococcal epidemiology, we developed a compartmental, deterministic transmission model describing infection with SARS-CoV-2 being introduced on 1 Jan 2020 (<xref ref-type="fig" rid="fig2">Figure 2B</xref>) after colonization with <italic>S. pneumoniae</italic> reached an equilibrium in a large, well-mixed human population (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Two lockdowns were implemented in the model in agreement with the two lockdowns implemented in France in 2020. The model was parameterized to <italic>S. pneumoniae</italic> and five mechanisms were built in into the model: (1) a population-wide reduction of antibiotic prescriptions in the community by 18% due to the reduced healthcare-seeking behavior, (2) lockdown reducing pneumococcal transmission by 25%, (3) a reduced risk of developing an IPD from asymptomatic carriage due to the absence of common respiratory viruses during the first lockdown (reduced by a factor IPD<sub>risk</sub> = 0.2), which continues after the first lockdown, albeit at a diminished level (IPD<sub>risk</sub> = 0.4), (4) community azithromycin use in 10% of COVID-19 infected individuals, (5) and a longer carriage duration of antibiotic-resistant pneumococcal strains giving them a fitness advantage over antibiotic-resistant strains (40 vs 30 days).</p></sec><sec id="s2-3"><title>Exploring the mechanisms and identifying the optimal scenario for explaining reported trends</title><p>We conducted assessments on five distinct hypotheses, each characterized by a precise underlying mechanism, and explored these hypotheses in combination within 31 pandemic scenarios, along with two pre-pandemic (baseline) scenarios, which assume no SARS-CoV-2 circulation in the population and allow for the same 30-day carriage duration (pre-pandemic 1) of both antibiotic-sensitive and -resistant strains (<italic>d</italic><sub>s</sub>=<italic>d</italic><sub><italic>R</italic></sub>) or a longer, 40-day carriage duration (pre-pandemic 2) of -resistant strains (<italic>d</italic><sub>s</sub><italic>&gt; d</italic><sub><italic>R</italic></sub>) (<xref ref-type="table" rid="table1">Table 1</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Five mechanisms implemented in 31 pandemic scenarios proposed to explain the reported trends of IPD incidence, antibiotic resistance, and pneumococcal carriage in <italic>S. pneumoniae</italic>.</title><p>Scenarios explore all possible combinations of mechanisms proposed to test hypotheses that can explain the reported trends of annual invasive pneumococcal disease incidence (annual no. of cases per 100,000 inhabitants), antibiotic resistance (% of annual antibiotic-resistant IPD cases among total IPD cases), and % change in the pneumococcal carriage prevalence at the end of the first 60-day lockdown compared the prevalence before the lockdown. Model simulations were initiated assuming the initial 20% antibiotic resistance. Two pre-pandemic scenarios assume no SARS-CoV-2 circulation in the population and allow for the same 30-day carriage duration of both antibiotic-sensitive and -resistant strains (<italic>d</italic><sub><italic>S</italic></sub> <italic>= d</italic><sub><italic>R</italic></sub>) or a longer, 40-day carriage duration of -resistant strains (<italic>d<sub>R</sub> &gt; d<sub>S</sub></italic>) . When implemented, these five mechanisms assume 18% reduction in community antibiotic prescribing, a reduced risk of developing an IPD during (0.2) and after the first lockdown (0.4), a 25% reduction in transmission of pneumococcal carriage during the first lockdown, a 10% of azithromycin use among COVID-19 infected individuals, and a longer 40-day carriage duration of -resistant strains. For a full list of parameters see <xref ref-type="table" rid="app2table2">Appendix 2—table 2</xref>. Reported trends in European countries showed a decrease in annual IPD incidence by 44.3% on average, an increase in antibiotic resistance, and generally stable asymptomatic pneumococcal carriage in healthy individuals during the first lockdown period. Only scenarios S19 and S29 fulfill all three reported trends during the COVID-19 pandemic in 2020 simultaneously while accounting for the reported reduction in community antibiotic prescribing (<inline-formula><mml:math id="inf1"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> = carriage duration of antibiotic-sensitive pneumococcal strains; <inline-formula><mml:math id="inf2"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> = carriage duration of antibiotic-resistant pneumococcal strains; PENI = penicillin; ERY = erythromycin).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" colspan="9"/></tr></thead><tbody><tr><td align="left" valign="bottom" rowspan="2"><bold>Scenarios</bold></td><td align="left" valign="bottom" colspan="5"><bold>Mechanisms</bold></td><td align="left" valign="bottom" rowspan="2"><bold>IPD inc</bold>.</td><td align="left" valign="bottom" rowspan="2"><bold>AR (%</bold>)</td><td align="left" valign="bottom" rowspan="2"><bold>Sp. (%</bold>)</td></tr><tr><td align="char" char="." valign="bottom"><bold>1</bold></td><td align="char" char="." valign="bottom"><bold>2</bold></td><td align="char" char="." valign="bottom"><bold>3</bold></td><td align="char" char="." valign="bottom"><bold>4</bold></td><td align="char" char="." valign="bottom"><bold>5</bold></td></tr><tr><td align="left" valign="bottom"><bold><italic>Pre-pandemic 1:</italic> (<italic>d</italic><sub><italic>S</italic></sub> <italic>= d</italic><sub><italic>R</italic></sub>)</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">10.8</td><td align="char" char="." valign="bottom">20.0</td><td align="left" valign="bottom">NA</td></tr><tr><td align="left" valign="bottom"><bold><italic>Pre-pandemic 2: </italic>(<italic>d<sub>R</sub> &gt; d<sub>S</sub></italic>)</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">x</td><td align="char" char="." valign="bottom">11.3</td><td align="char" char="." valign="bottom">20.0</td><td align="left" valign="bottom">NA</td></tr><tr><td align="left" valign="bottom"><italic>Pandemic: S1</italic></td><td align="left" valign="bottom">x</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">10.9</td><td align="char" char="." valign="bottom">19.2</td><td align="char" char="." valign="bottom">+1.3</td></tr><tr><td align="left" valign="bottom"><italic>S2</italic></td><td align="left" valign="bottom"/><td align="left" valign="bottom">x</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">8.9</td><td align="char" char="." valign="bottom">20.1</td><td align="char" char="." valign="bottom">–36.1</td></tr><tr><td align="left" valign="bottom"><italic>S3</italic></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">x</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">5.9</td><td align="char" char="." valign="bottom">20.0</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom"><italic>S4</italic></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">x</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">9.9</td><td align="char" char="." valign="bottom">23.7</td><td align="char" char="." valign="bottom">–9.1</td></tr><tr><td align="left" valign="bottom"><italic>S5</italic></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">x</td><td align="char" char="." valign="bottom">11.3</td><td align="char" char="." valign="bottom">20.0</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom"><italic>S6</italic></td><td align="left" valign="bottom">x</td><td align="left" valign="bottom">x</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">9.1</td><td align="char" char="." valign="bottom">19.4</td><td align="char" char="." valign="bottom">–35.2</td></tr><tr><td align="left" valign="bottom"><italic>S7</italic></td><td align="left" valign="bottom">x</td><td align="left" valign="bottom"/><td align="left" valign="bottom">x</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">6.0</td><td align="char" char="." valign="bottom">19.4</td><td align="char" char="." valign="bottom">+1.3</td></tr><tr><td align="left" valign="bottom"><italic>S8</italic></td><td align="left" valign="bottom">x</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">x</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">10.1</td><td align="char" char="." valign="bottom">22.9</td><td align="char" char="." valign="bottom">–8.0</td></tr><tr><td align="left" valign="bottom"><italic>S9</italic></td><td align="left" valign="bottom">x</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">x</td><td align="char" char="." valign="bottom">11.5</td><td align="char" char="." valign="bottom">19.3</td><td align="char" char="." valign="bottom">+1.3</td></tr><tr><td align="left" valign="bottom"><italic>S10</italic></td><td align="left" valign="bottom"/><td align="left" valign="bottom">x</td><td align="left" valign="bottom">x</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">5.2</td><td align="char" char="." valign="bottom">20.0</td><td align="char" char="." valign="bottom">–36.1</td></tr><tr><td align="left" valign="bottom"><italic>S11</italic></td><td align="left" valign="bottom"/><td align="left" valign="bottom">x</td><td align="left" valign="bottom"/><td align="left" valign="bottom">x</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">8.9</td><td align="char" char="." valign="bottom">20.1</td><td align="char" char="." valign="bottom">–36.1</td></tr><tr><td align="left" valign="bottom"><italic>S12</italic></td><td align="left" valign="bottom"/><td align="left" valign="bottom">x</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">x</td><td align="char" char="." valign="bottom">9.4</td><td align="char" char="." valign="bottom">20.9</td><td align="char" char="." valign="bottom">–34.3</td></tr><tr><td align="left" valign="bottom"><italic>S13</italic></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">x</td><td align="left" valign="bottom">x</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">5.6</td><td align="char" char="." valign="bottom">22.5</td><td align="char" char="." valign="bottom">–9.1</td></tr><tr><td align="left" valign="bottom"><italic>S14</italic></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">x</td><td align="left" valign="bottom"/><td align="left" valign="bottom">x</td><td align="char" char="." valign="bottom">6.2</td><td align="char" char="." valign="bottom">20.0</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom"><italic>S15</italic></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">x</td><td align="left" valign="bottom">x</td><td align="char" char="." valign="bottom">10.4</td><td align="char" char="." valign="bottom">23.4</td><td align="char" char="." valign="bottom">–9.1</td></tr><tr><td align="left" valign="bottom"><italic>S16</italic></td><td align="left" valign="bottom">x</td><td align="left" valign="bottom">x</td><td align="left" valign="bottom">x</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">5.3</td><td align="char" char="." valign="bottom">19.6</td><td align="char" char="." valign="bottom">–35.2</td></tr><tr><td align="left" valign="bottom"><italic>S17</italic></td><td align="left" valign="bottom">x</td><td align="left" valign="bottom">x</td><td align="left" valign="bottom"/><td align="left" valign="bottom">x</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">8.3</td><td align="char" char="." valign="bottom">22.4</td><td align="char" char="." valign="bottom">–41.3</td></tr><tr><td align="left" valign="bottom"><italic>S18</italic></td><td align="left" valign="bottom">x</td><td align="left" valign="bottom">x</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">x</td><td align="char" char="." valign="bottom">9.6</td><td align="char" char="." valign="bottom">20.3</td><td align="char" char="." valign="bottom">–33.5</td></tr><tr><td align="left" valign="bottom"><italic>S19</italic></td><td align="left" valign="bottom">x</td><td align="left" valign="bottom"/><td align="left" valign="bottom">x</td><td align="left" valign="bottom">x</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">5.7</td><td align="char" char="." valign="bottom">22.0</td><td align="char" char="." valign="bottom">–8.0</td></tr><tr><td align="left" valign="bottom"><italic>S20</italic></td><td align="left" valign="bottom">x</td><td align="left" valign="bottom"/><td align="left" valign="bottom">x</td><td align="left" valign="bottom"/><td align="left" valign="bottom">x</td><td align="char" char="." valign="bottom">6.3</td><td align="char" char="." valign="bottom">19.5</td><td align="char" char="." valign="bottom">+1.3</td></tr><tr><td align="left" valign="bottom"><italic>S21</italic></td><td align="left" valign="bottom">x</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">x</td><td align="left" valign="bottom">x</td><td align="char" char="." valign="bottom">10.6</td><td align="char" char="." valign="bottom">22.7</td><td align="char" char="." valign="bottom">–7.9</td></tr><tr><td align="left" valign="bottom"><italic>S22</italic></td><td align="left" valign="bottom"/><td align="left" valign="bottom">x</td><td align="left" valign="bottom">x</td><td align="left" valign="bottom">x</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">5.0</td><td align="char" char="." valign="bottom">22.0</td><td align="char" char="." valign="bottom">–42.1</td></tr><tr><td align="left" valign="bottom"><italic>S23</italic></td><td align="left" valign="bottom"/><td align="left" valign="bottom">x</td><td align="left" valign="bottom">x</td><td align="left" valign="bottom"/><td align="left" valign="bottom">x</td><td align="char" char="." valign="bottom">5.5</td><td align="char" char="." valign="bottom">20.6</td><td align="char" char="." valign="bottom">–34.3</td></tr><tr><td align="left" valign="bottom"><italic>S24</italic></td><td align="left" valign="bottom"/><td align="left" valign="bottom">x</td><td align="left" valign="bottom"/><td align="left" valign="bottom">x</td><td align="left" valign="bottom">x</td><td align="char" char="." valign="bottom">8.7</td><td align="char" char="." valign="bottom">23.9</td><td align="char" char="." valign="bottom">–40.2</td></tr><tr><td align="left" valign="bottom"><italic>S25</italic></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">x</td><td align="left" valign="bottom">x</td><td align="left" valign="bottom">x</td><td align="char" char="." valign="bottom">5.9</td><td align="char" char="." valign="bottom">22.3</td><td align="char" char="." valign="bottom">–9.1</td></tr><tr><td align="left" valign="bottom"><italic>S26</italic></td><td align="left" valign="bottom">x</td><td align="left" valign="bottom">x</td><td align="left" valign="bottom">x</td><td align="left" valign="bottom">x</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">5.0</td><td align="char" char="." valign="bottom">21.6</td><td align="char" char="." valign="bottom">–41.3</td></tr><tr><td align="left" valign="bottom"><italic>S27</italic></td><td align="left" valign="bottom">x</td><td align="left" valign="bottom">x</td><td align="left" valign="bottom">x</td><td align="left" valign="bottom"/><td align="left" valign="bottom">x</td><td align="char" char="." valign="bottom">5.6</td><td align="char" char="." valign="bottom">20.1</td><td align="char" char="." valign="bottom">–33.5</td></tr><tr><td align="left" valign="bottom"><italic>S28</italic></td><td align="left" valign="bottom">x</td><td align="left" valign="bottom">x</td><td align="left" valign="bottom"/><td align="left" valign="bottom">x</td><td align="left" valign="bottom">x</td><td align="char" char="." valign="bottom">8.8</td><td align="char" char="." valign="bottom">23.2</td><td align="char" char="." valign="bottom">–39.4</td></tr><tr><td align="left" valign="bottom"><italic>S29</italic></td><td align="left" valign="bottom">x</td><td align="left" valign="bottom"/><td align="left" valign="bottom">x</td><td align="left" valign="bottom">x</td><td align="left" valign="bottom">x</td><td align="char" char="." valign="bottom">5.9</td><td align="char" char="." valign="bottom">21.8</td><td align="char" char="." valign="bottom">–7.9</td></tr><tr><td align="left" valign="bottom"><italic>S30</italic></td><td align="left" valign="bottom"/><td align="left" valign="bottom">x</td><td align="left" valign="bottom">x</td><td align="left" valign="bottom">x</td><td align="left" valign="bottom">x</td><td align="char" char="." valign="bottom">5.2</td><td align="char" char="." valign="bottom">22.5</td><td align="char" char="." valign="bottom">–40.2</td></tr><tr><td align="left" valign="bottom"><italic>S31</italic></td><td align="left" valign="bottom">x</td><td align="left" valign="bottom">x</td><td align="left" valign="bottom">x</td><td align="left" valign="bottom">x</td><td align="left" valign="bottom">x</td><td align="char" char="." valign="bottom">5.3</td><td align="char" char="." valign="bottom">22.1</td><td align="char" char="." valign="bottom">–39.4</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom" colspan="4"/><td align="left" valign="bottom" colspan="3"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><bold>REPORTED TRENDS:</bold></td><td align="left" valign="bottom" colspan="4"><bold>IPD inc</bold>.</td><td align="left" valign="bottom" colspan="3"><bold>AR (%</bold>)</td><td align="left" valign="bottom"><bold>Sp. (%</bold>)</td></tr><tr><td align="left" valign="bottom">Pre-pandemic (FR, 2019)</td><td align="char" char="." valign="bottom" colspan="4">10.5 [10.3–10.7]</td><td align="char" char="." valign="bottom" colspan="3">26.2 (PENI) and 20.9 (ERY)</td><td align="left" valign="bottom">NA</td></tr><tr><td align="left" valign="bottom">Pandemic (FR, 2020)</td><td align="char" char="." valign="bottom" colspan="4">5.8 [5.7–5.9]</td><td align="char" char="." valign="bottom" colspan="3">35.5 (PENI) and 23.0 (ERY)</td><td align="left" valign="bottom">Stable</td></tr><tr><td align="left" valign="bottom"><bold><italic>Pandemic (EU/EEA, 2020)</italic></bold><break/><bold><italic>General trends</italic></bold></td><td align="left" valign="bottom" colspan="4"><bold><italic>Decrease by 44.3% on avg.</italic></bold></td><td align="left" valign="bottom" colspan="3"><bold><italic>Majority of EU countries report an increase</italic></bold></td><td align="left" valign="bottom"><bold><italic>Generally stable</italic></bold></td></tr></tbody></table><table-wrap-foot><fn><p>Mechanisms: (1) Reduced community antibiotic prescribing; (2) Lockdown effect on reducing transmission of S. pneumoniae; (3) Reduced risk of developing an IPD; (4) Community azithromycin use in COVID-19 infected individuals; (5) Longer carriage duration of antibiotic-resistant pneumococcal strains.</p></fn></table-wrap-foot></table-wrap><p>We assessed how different combinations of mechanisms may impact: (i) a change in the annual IPD incidence as compared to the pre-pandemic (baseline) period, (ii) antibiotic resistance rate in IPDs, defined as the annual number of antibiotic-resistant IPD cases over the total number of IPD cases, and (iii) daily prevalences of antibiotic-resistant and total pneumococcal carriage in a simulated population of 100,000 individuals (see <xref ref-type="table" rid="app2table2">Appendix 2—table 2</xref> for parameter values). To identify scenarios most compatible with the reported trends, results from model simulations were compared to reported data trends from France in 2020 and more broadly to general EU/EEA reported trends that followed similar patterns. Surprisingly only two scenarios were compatible with reported trends. Scenarios S19 and S29 univocally reproduced increased antibiotic resistance in the general population (AR%) accompanied by a reduction in the annual IPD incidence by almost 50% (IPD inc) with generally stable pneumococcal carriage prevalence in healthy individuals during lockdown (Sp.). In contrast, model simulations revealed that a reduction in the community antibiotic consumption alone (–18%) could not explain the reported trends and generally led to a reduction of antibiotic resistance (<xref ref-type="table" rid="table1">Table 1</xref>, see scenario S1). Assuming a longer duration of antibiotic-resistant pneumococcal carriage alone did not explain either the rise in antibiotic resistance (<xref ref-type="table" rid="table1">Table 1</xref>, see scenario S5). Hypothesizing that lockdown reduced the transmission of pneumococcal carriage (by 25%) in addition to a reduced community antibiotic prescribing did not seem probable since, in simulations, this yielded a major reduction in pneumococcal carriage during containment measures in all scenarios where this mechanism was implemented. On the other hand, considering an indirect impact of lockdown on pneumococcal carriage where we implemented a reduction factor for the risk of developing and IPD from otherwise asymptomatic carriage due to the absence of viral respiratory infections during (<italic>IPD<sub>risk</sub></italic> = 0.2) and after lockdown (<italic>IPD<sub>risk</sub></italic> = 0.4) reproduced the reported reduction in the annual IPD incidence while maintaining a stable prevalence of pneumococcal carriage during lockdown (<xref ref-type="table" rid="table1">Table 1</xref>, see scenario S3). By itself however, this scenario did not allow to observe an increase in antibiotic resistance.</p><p>When we combined reduced antibiotic prescribing and a reduced risk of developing an IPD with community azithromycin use in a proportion of COVID-19 infected individuals, which remains in the body for an additional 15.5 days after the last dose, in a single scenario, this scenario satisfied the observed trends in AMR (<xref ref-type="table" rid="table1">Table 1</xref>, see scenario S19). A similar outcome was observed in scenario S29 when adding a longer carriage duration of antibiotic resistant strains on top of this, however, in the absence of community azithromycin use in COVID-19 infected (<xref ref-type="table" rid="table1">Table 1</xref>, see scenario S1, S5, S3, S19, and S20) trends of increasing antibiotic resistance cannot be reproduced. Therefore, our best model scenario for describing the observed trends combined: (1) a reduction in the overall community antibiotic consumption; (2) the assumption that lockdown effectively reduced SARS-CoV-2 transmission including transmission of other respiratory viruses, but not pneumococcal carriage transmission, indirectly reducing the risk of developing an IPD; (3) either identical or longer carriage durations of antibiotic-resistant strains compared to antibiotic-sensitive strains, and (4) the community azithromycin use in a proportion of COVID-19 infected individuals.</p></sec><sec id="s2-4"><title>Effect of age</title><p>Next, we used the pandemic scenario S19 that best explains the reported trends to test the model using different parameter combinations to mimic different subpopulations (children and the elderly) considering that SARS-CoV-2 infection risk, pneumococcal disease risk, disease severity, bacterial carriage prevalence, and antibiotic prescribing are all highly heterogeneous across age groups. Using scenario S19, we initialized the model with lower and higher baseline carriage prevalence (10%, 20%, and 30%) (<xref ref-type="bibr" rid="bib21">Cohen et al., 2023</xref>; <xref ref-type="bibr" rid="bib83">Rose et al., 2021</xref>; <xref ref-type="bibr" rid="bib86">Rybak et al., 2022</xref>; <xref ref-type="bibr" rid="bib98">Tinggaard et al., 2023</xref>; <xref ref-type="bibr" rid="bib101">Wang et al., 2017</xref>), we varied durations of pneumococcal carriage (20, 30, and 45 days), pneumococcal invasion rate, and considered reductions of antibiotic consumption at various levels (–13%, –18%, and –39%) consistent with the French data along with a range of community azithromycin use in COVID-19 infected (0–20%). For a full list of parameters see <xref ref-type="table" rid="app2table2">Appendix 2—table 2</xref>. Simulations showed that annual IPD incidence decreased between 43% and 51% compared to the pre-pandemic (baseline) scenario for children, the elderly, and the general population (<xref ref-type="fig" rid="fig3">Figure 3</xref>, grey bars). Although the overall antibiotic prescribing in the community was reduced (between 13% and 39%), antibiotic resistance is expected to increase (from 20.1% up to 23.6% in the elderly and from 32.8% up to 36.0% in children) compared to the pre-pandemic period in all age groups and in all scenarios where azithromycin was used in COVID-19 infected individuals (<xref ref-type="fig" rid="fig3">Figure 3</xref>, red bars). Daily prevalence of total pneumococcal carriage remained relatively stable, exhibiting higher levels of decrease with increased azithromycin use, while the prevalence of antibiotic-resistant pneumococcal carriage is expected to increase since clearance of antibiotic-susceptible strains due to azithromycin use shifts the competitive balance in favor of the existing resistant strains (<xref ref-type="fig" rid="fig3">Figure 3</xref>, third panel).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Annual incidence of invasive pneumococcal disease (IPD), antibiotic resistance (AR%), and pneumococcal carriage prevalence for three different subpopulations.</title><p>(<bold>A</bold>) The elderly (≥65 years-old) (<bold>B</bold>) general population (all ages), and (<bold>C</bold>) children (&lt;5 years-old). Using pandemic scenario S19, which includes a combination of three different mechanisms: reduced community antibiotic prescribing, a reduced risk of developing an IPD, and community azithromycin use in COVID-19 infected individuals, we ran model simulations for three different subpopulations. For a full list of parameter values see <xref ref-type="table" rid="app2table2">Appendix 2—table 2</xref>. Annual IPD incidence (grey bars) decreased between 43% and 51% relative to the pre-pandemic (baseline) period with magnitude of a decrease depending on an age group and the level of azithromycin use in COVID-19 infected individuals. Antibiotic resistance (red bars) increased compared to the pre-pandemic (baseline) period in all age groups whenever azithromycin was used in COVID-19 infected. Black arrows indicate model outcomes that approximate the reported trends in antibiotic resistance in France for different age groups. Daily prevalence of total pneumococcal carriage remained relatively stable (solid-colored lines), exhibiting higher levels of decrease with increased azithromycin use. The prevalence of antibiotic-resistant pneumococcal carriage increased (dashed colored lines) over time in relation to SARS-CoV-2 outbreak (black dashed line) and higher azithromycin use. Highlighted time intervals (days 75–135 and 305–365) represent two lockdown periods.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85701-fig3-v2.tif"/></fig><p>General trends produced in model simulations using scenario S19 remained unchanged across different age groups. The extent of the impact depended on the combined magnitude of a decrease in the general antibiotic use in the community and a degree of azithromycin use in COVID-19 infected individuals belonging to a particular age group or a subpopulation. In the elderly (≥65 years-old) and the general population, antibiotic resistance is expected to increase due to azithromycin use in COVID-19 infected. Black arrows indicate model outcomes that approximate the reported trends in antibiotic resistance in France for different age groups including general population (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Only in instances when there was no azithromycin use in COVID-19 infected individuals, we observed a decrease in antibiotic resistance relative to the pre-pandemic period (e.g. children &lt;5 years-old). When combining the largest decrease in overall antibiotic use with no or minimal azithromycin use in COVID-19 infected individuals, we expect to see the largest decrease or no change in antibiotic resistance relative to the pre-pandemic period.</p></sec><sec id="s2-5"><title>Effect of SARS-CoV-2 basic reproduction number (R<sub>0</sub>) and within-host pathogen interactions on AMR</title><p>Considering that model simulations reproduced an absolute increase in antibiotic resistance comparable to that of 2% reported for macrolides in France but did not reproduce the reported larger increase in penicillin resistance, which was more than a 9% rise (35.5% relative increase) in France, we explored additional factors that may have amplified this increase. Using model scenario S19, we show that an association between higher values of SARS-CoV-2 R<sub>0</sub> and a greater percentage of COVID-19 infected individuals taking azithromycin leads to increased cumulative incidence of antibiotic-resistant IPDs and elevated antibiotic resistance (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). For example, if pre-lockdown R<sub>0</sub> of SARS-CoV-2 was 3.8 instead of 3.2, model simulations predict an increase of 3.5% (23.5%) in antibiotic resistance from the pre-pandemic levels instead of 2%. As the R<sub>0</sub> value increases, the impact of azithromycin use becomes more pronounced.</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>The impact of varying SARS-CoV-2 R<sub>0</sub> and percentage of COVID-19 infected individuals taking azithromycin in scenario S19 on antibiotic resistance (%) and the annual incidence of antibiotic-resistant invasive pneumococcal disease (IPD).</title><p>Hypothetical within-host interactions contribute to an excess incidence of antibiotic-resistant IPDs. (<bold>A</bold>) Cumulative incidence of antibiotic-resistant IPDs and antibiotic resistance increase with greater values of SARS-CoV-2 R<sub>0</sub> and higher percentage of the COVID-19 infected individuals taking azithromycin. The reproduction number for SARS-CoV-2 (R<sub>0</sub>) in the community corresponds to the most common estimates of R<sub>0</sub> in France and other European countries ranging from R<sub>0</sub>=2–4 (<xref ref-type="bibr" rid="bib2">Allieta et al., 2022</xref>; <xref ref-type="bibr" rid="bib27">D’Arienzo and Coniglio, 2020</xref>; <xref ref-type="bibr" rid="bib30">Di Domenico et al., 2020</xref>; <xref ref-type="bibr" rid="bib37">Flaxman et al., 2020</xref>; <xref ref-type="bibr" rid="bib62">Liu et al., 2020</xref>; <xref ref-type="bibr" rid="bib84">Roux et al., 2020</xref>; <xref ref-type="bibr" rid="bib88">Salje et al., 2020</xref>). (<bold>B</bold>) Annual excess in cumulative antibiotic-resistant IPD incidence in scenario S19 due to synergistic within-host ecological interactions compared to the same scenario with no within-host interactions and no azithromycin use (1.17 resistant IPD cases/100,000 inhabitants). A rate of disease progression increased by a factor <inline-formula><mml:math id="inf3"><mml:msub><mml:mrow><mml:mi>ψ</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:math></inline-formula> (no within-host interaction) and <inline-formula><mml:math id="inf4"><mml:msub><mml:mrow><mml:mi>ψ</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>40</mml:mn></mml:math></inline-formula> in scenario S19 applied to the general population assuming azithromycin use in 10% of the infected individuals resulted in approximately 0.06 and 0.75 additional cases of antibiotic-resistant disease per 100,000 inhabitants over the course of 1 year, respectively, compared to the scenario S19 assuming no within-host interaction and no azithromycin use (indicated by the black arrow). For more details, see <xref ref-type="fig" rid="app2fig1">Appendix 2—figure 1</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85701-fig4-v2.tif"/></fig><p>Assuming within-host interactions where SARS-CoV-2 infection favors progression from pneumococcal colonization to disease <inline-formula><mml:math id="inf5"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>ψ</mml:mi><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mo>&gt;</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula> , we found that surges in COVID-19 cases accompanied by increasing levels of azithromycin use lead to excess number of cases caused by antibiotic-resistant strains. Indeed, a rate of disease progression increased by a factor <inline-formula><mml:math id="inf6"><mml:msub><mml:mrow><mml:mi>ψ</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>40</mml:mn></mml:math></inline-formula> in scenario S19 with 10% of infected using azithromycin applied to the general population results in approximately 0.75 additional cases of antibiotic-resistant disease per 100,000 inhabitants over the course of 1 year compared to 0.06 additional cases if there are no within-host interactions (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). This represents 5% rise in resistance from the pre-pandemic levels (25% relative increase).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>We propose a novel co-circulation model describing the spread of SARS-CoV-2 and antibiotic-resistant bacteria in a community setting to show how human behavioral responses to the COVID-19 pandemic can differentially impact antibiotic resistance. Our model simulations assessed different hypotheses proposed to explain the observed trends of antibiotic resistance, IPD incidence, and pneumococcal carriage. We identified the most plausible mechanisms underlying the observed patterns of resistance and disease incidence, showing how lockdowns indirectly substantially reduce the incidence of IPD, while surges in COVID-19 cases accompanied by antibiotic prescribing in COVID-19 infected individuals increase antibiotic resistance.</p><p>Many studies have reported trends on the incidence of community-acquired bacterial infections since the onset of the pandemic (<xref ref-type="bibr" rid="bib14">Brueggemann et al., 2021</xref>; <xref ref-type="bibr" rid="bib91">Shaw et al., 2023</xref>). There was a significant reduction in the risk of invasive disease caused by <italic>S. pneumoniae</italic> (risk ratio 0·47; 95% CI 0·40–0·55; <xref ref-type="bibr" rid="bib91">Shaw et al., 2023</xref>). Initially, this observation seemed to support the hypothesis that NPIs implemented to control SARS-CoV-2 transmission may have simultaneously reduced the incidence of bacterial infections by preventing bacterial transmission and acquisition (<xref ref-type="bibr" rid="bib14">Brueggemann et al., 2021</xref>; <xref ref-type="bibr" rid="bib48">Kadambari et al., 2022</xref>). Indeed, the scenario of lockdown impact on pneumococcal transmission reproduced such trends. However, incorporating a mechanism of reduced risk for developing an IPD due to the absence of circulation of common respiratory viruses led to similar estimates of the relative reduction in IPD incidence as reported in the EU/EEA for 2020 (<xref ref-type="bibr" rid="bib14">Brueggemann et al., 2021</xref>; <xref ref-type="bibr" rid="bib36">European Centre for Disease Prevention and Control and World Health Organization, 2022</xref>). This finding, coupled with the outcome of other studies that found a generally stable pneumococcal carriage prevalence in healthy individuals, both children and adults, during COVID-19 containment measures (<xref ref-type="bibr" rid="bib72">Nation et al., 2023</xref>; <xref ref-type="bibr" rid="bib78">Petrović et al., 2022</xref>; <xref ref-type="bibr" rid="bib86">Rybak et al., 2022</xref>; <xref ref-type="bibr" rid="bib103">Willen et al., 2021</xref>; <xref ref-type="bibr" rid="bib107">Wyllie et al., 2023</xref>), supports the alternative hypothesis. This explanation accounts for the decreased incidence of IPD, rather than attributing it to reduced pneumococcal transmission, which resulted in a significant reduction in carriage according to the simulations (<xref ref-type="bibr" rid="bib94">Smith and Opatowski, 2021</xref>). Furthermore, a study in Vietnam found that reductions in IPD associated with NPIs may be due to reductions in overall pneumococcal carriage density rather than carriage prevalence, driven by reductions in capsular pneumococcal carriage density frequently implicated in IPD (<xref ref-type="bibr" rid="bib72">Nation et al., 2023</xref>). Considering that common respiratory viruses such as influenza increase pneumococcal carriage density, which contributes to transmission and disease, this hypothesis seems plausible (<xref ref-type="bibr" rid="bib3">Alpkvist et al., 2015</xref>; <xref ref-type="bibr" rid="bib29">Diavatopoulos et al., 2010</xref>; <xref ref-type="bibr" rid="bib65">McCullers et al., 2010</xref>; <xref ref-type="bibr" rid="bib92">Short et al., 2012</xref>; <xref ref-type="bibr" rid="bib105">Wolter et al., 2014</xref>).</p><p>Globally, community antibiotic consumption dropped during the first year of the COVID-19 pandemic compared to the pre-pandemic period. Decreasing temporal trends were observed in England (<xref ref-type="bibr" rid="bib46">Hussain et al., 2021</xref>), Canada (<xref ref-type="bibr" rid="bib64">Mamun et al., 2021</xref>), the United States (<xref ref-type="bibr" rid="bib15">Buehrle et al., 2021</xref>), China (<xref ref-type="bibr" rid="bib108">Zhang et al., 2021</xref>), South Korea (<xref ref-type="bibr" rid="bib87">Ryu et al., 2021</xref>), New Zealand (<xref ref-type="bibr" rid="bib33">Duffy et al., 2021</xref>), and across European countries (<xref ref-type="bibr" rid="bib43">Högberg et al., 2021</xref>). In France in particular, the number of antibiotic prescriptions decreased by 18.2% in the general population; however, this reduction ranged from 13% to 39% for the oldest and youngest age groups, respectively (<xref ref-type="bibr" rid="bib8">Bara et al., 2022</xref>). These trends in antibiotic prescribing may largely be explained by reduced incidence of seasonal respiratory tract infections and reduced primary care consultations (<xref ref-type="bibr" rid="bib5">Andrews et al., 2022</xref>; <xref ref-type="bibr" rid="bib44">Homeniuk and Collins, 2021</xref>). On the other hand, the advent of telemedicine, pandemic-induced patient stress, and increased antibiotic demand may have partly offset prescription reductions due to decreased consultations and healthcare-seeking behavior (<xref ref-type="bibr" rid="bib45">Hsu, 2020</xref>; <xref ref-type="bibr" rid="bib80">Read et al., 2023</xref>). In a global analysis of antimicrobial sales, Khouja et al. found that antibiotic consumption initially increased by approximately 7% in March 2020, prior to subsequent declines through to August 2020 (<xref ref-type="bibr" rid="bib52">Khouja et al., 2022</xref>). While overall antibiotic prescribing may have decreased, prescription of specific antibiotics has increased, particularly those associated with COVID-19 patient management. Across continents, a rise of 10% in monthly COVID-19 cases exhibited a correlative trend with elevated macrolide sales of 0.8%, 1.3%, and 1.5% in Europe, North America, and Africa, respectively (<xref ref-type="bibr" rid="bib71">Nandi et al., 2023</xref>).</p><p>Community consumption of azithromycin, a macrolide, increased during the first year of the pandemic in multiple countries with significant variation across geographic locations and with greatest prescribing among older patients (<xref ref-type="bibr" rid="bib8">Bara et al., 2022</xref>; <xref ref-type="bibr" rid="bib9">Bednarčuk et al., 2023</xref>; <xref ref-type="bibr" rid="bib12">Bogdanić et al., 2022</xref>; <xref ref-type="bibr" rid="bib23">Crisafulli et al., 2021</xref>; <xref ref-type="bibr" rid="bib77">Parveen et al., 2020</xref>; <xref ref-type="bibr" rid="bib102">Weill et al., 2021</xref>). In an outpatient setting in southern Italy between February 2020 and January 2021, azithromycin represented 42.1% of all drug prescriptions to individuals diagnosed with COVID-19, while all other antibiotics combined represented just 20.9% (<xref ref-type="bibr" rid="bib23">Crisafulli et al., 2021</xref>). A study in northwest London across two epidemic waves between January and August 2020 found that, among COVID-19 patients prescribed an antibiotic by a general practitioner during the study period, 31.5% received their prescription within 14 days of a positive SARS-CoV-2 test (<xref ref-type="bibr" rid="bib110">Zhu et al., 2021</xref>). Two large USA-based studies have also described early pandemic antibiotic prescribing among COVID-19 patients. From April 2020 to April 2021, approximately 30% of outpatient COVID-19–related visits among Medicare beneficiaries (≥65 years-old) have resulted in a filled antibiotic prescription, 50.7% of which were for azithromycin (<xref ref-type="bibr" rid="bib99">Tsay et al., 2022</xref>). For 0-to-5 year-olds and 45-to-64 year-olds, 4% and 16% of outpatient COVID-19–related visits have resulted in a filled antibiotic prescription, respectively (<xref ref-type="bibr" rid="bib104">Wittman et al., 2023</xref>). In the Alsace region in France, there was a clear peak azithromycin prescribing during the first wave of the COVID-19 (<xref ref-type="bibr" rid="bib26">Danion et al., 2023</xref>). During the first lockdown in France, community azithromycin consumption increased by 25.9%, with the increase varying from 13.4% to 47.3% depending on the week (<xref ref-type="bibr" rid="bib102">Weill et al., 2021</xref>), while the overall number of azithromycin prescriptions across France in 2020 increased by 10.1% relative to 2019 (<xref ref-type="bibr" rid="bib8">Bara et al., 2022</xref>). Azithromycin treatment usually lasts 3–5 days depending on the disease, but the drug stays in the system for about 15.5 days after the last dose due to the long half-life of more than 60 hr (<xref ref-type="bibr" rid="bib38">Foulds et al., 1990</xref>; <xref ref-type="bibr" rid="bib40">Girard et al., 2005</xref>). On the other hand, penicillin has an elimination half-life of approximately 1.4 hr and leaves the body in 7.7 hr after the last dose. This suggests that if azithromycin consumption increased during the first year of the pandemic, antibiotic exposure time also increased as a result, although the overall number of antibiotic prescriptions decreased. Moreover, the use of azithromycin has been associated with selection of both macrolide and non-macrolide resistance (<xref ref-type="bibr" rid="bib31">Doan et al., 2020</xref>). In a study investigating the direct effect of antibiotic exposure on resistance in the oral streptococcal flora of healthy volunteers, use of azithromycin (500 mg once daily for 3 days) significantly increased the proportion of macrolide-resistant streptococci in healthy individuals (<xref ref-type="bibr" rid="bib63">Malhotra-Kumar et al., 2007</xref>). Resistance peaked at day four in the azithromycin group and this increase remained significantly higher in the azithromycin group than in the placebo group until day 180 (<xref ref-type="bibr" rid="bib63">Malhotra-Kumar et al., 2007</xref>). A clinical trial of mass azithromycin distributions for treating trachoma in Ethiopia resulted in an increase in resistant <italic>S. pneumoniae</italic> isolates among children under the age of 10 (<xref ref-type="bibr" rid="bib51">Keenan et al., 2018</xref>; <xref ref-type="bibr" rid="bib50">Keenan et al., 2015</xref>).</p><p>Our model simulations show that antibiotic resistance increases with surges in SARS-CoV-2 infections when there is a corresponding increase in azithromycin use, but that lockdowns can moderate this increasing trend by effectively limiting transmission of SARS-CoV-2 (<xref ref-type="bibr" rid="bib88">Salje et al., 2020</xref>). Conversely, surges in azithromycin prescribing during SARS-CoV-2 outbreaks in the absence of effective measures to prevent transmission, as reported in certain regions and pandemic periods, may cause substantial increases in antibiotic resistance. Our model successfully captured the main trends of antibiotic resistance and IPD incidence observed in Europe in 2020 for <italic>S. pneumoniae</italic>. However, not all European countries reported an increase in antibiotic resistance. This inter-country heterogeneity may not be due only to heterogeneity of antibiotic use as shown in our model but may be attributed to other pandemic factors not directly implemented or assumed in the model scenario, such as different adherence to COVID-19 control measures across countries and different age groups, including impacts on disease surveillance and data reporting during the pandemic. Real-life scenarios are significantly more complicated and involve multiple alterations of many pandemic factors at different points in time and heterogeneity across populations (e.g. antibiotic prescribing increases in some demographic groups and decreases in others, multiple lockdowns, curfews, or telework).</p><p>In our model simulations, we used SARS-CoV-2 parameter value R<sub>0</sub>=3.2 (<xref ref-type="bibr" rid="bib62">Liu et al., 2020</xref>) in the absence of population immunity, best reflecting epidemiological dynamics from early in the pandemic. The most common estimates of SARS-CoV-2 R<sub>0</sub> in France and other European countries ranged from R<sub>0</sub>=2–4 (<xref ref-type="bibr" rid="bib37">Flaxman et al., 2020</xref>; <xref ref-type="bibr" rid="bib62">Liu et al., 2020</xref>). Modeling results suggest that higher SARS-CoV-2 R<sub>0</sub> estimates combined with higher proportion of COVID-19 infected individuals using azithromycin exacerbated impacts of COVID-19 on antibiotic resistance (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). However, the overall impacts of COVID-19 on AMR are difficult to predict, likely vary over the short, medium, and long term, and depend on the organism, setting, and subpopulation considered.</p><p>SARS-CoV-2 bacterial coinfection has been reported relatively rarely over the course of the pandemic, suggesting that most COVID-19 patients probably do not require antibiotic therapy (<xref ref-type="bibr" rid="bib39">Garcia-Vidal et al., 2021</xref>; <xref ref-type="bibr" rid="bib49">Karami et al., 2021</xref>; <xref ref-type="bibr" rid="bib57">Langford et al., 2020</xref>), although extensive prophylactic antibiotic use may have limited observed co-infection incidence. The inflammatory immune response resulting from COVID-19 likely predisposes patients to subsequent progression to an IBD to some extent (<xref ref-type="bibr" rid="bib90">Sender et al., 2021</xref>), but antibiotic use may also favor progression to IBD for patients colonized with drug-resistant strains (<xref ref-type="bibr" rid="bib7">Baggs et al., 2018</xref>). We do not explicitly model the dynamics of interaction since strong evidence for such interactions remains limited (<xref ref-type="bibr" rid="bib106">Wong et al., 2023</xref>). The results presented in <xref ref-type="fig" rid="fig4">Figure 4B</xref> suggest that such within-host interactions could have important consequences for the resistant IPD incidence during COVID-19 waves, especially in the elderly and high-risk groups. The model’s structure allows for easy integration of mechanistic interactions as more information becomes available on this phenomenon.</p><p>Our study focused on the general community, but COVID-19 distinctly influenced AMR in hospitals and long-term care facilities. Extensive antibiotic use in COVID-19 patients and disruptions to antibiotic stewardship programs may have increased antibiotic-resistant carriage in these settings. A meta-analysis conducted on studies published until June 2020 found that 68–81% of hospitalized COVID-19 patients and 74–94% in intensive care received antibiotics (<xref ref-type="bibr" rid="bib68">Monnet and Harbarth, 2020</xref>). The disorganization in hospitals during the COVID-19 pandemic might have reduced antibiotic resistance surveillance, allowing resistant organisms to spread. However, the early implementation of antibiotic stewardship programs in March 2020, patient isolation, and widespread use of personal protective equipment (PPE) have mitigated this increase to some degree (<xref ref-type="bibr" rid="bib42">Henig et al., 2021</xref>; <xref ref-type="bibr" rid="bib68">Monnet and Harbarth, 2020</xref>; <xref ref-type="bibr" rid="bib89">Seaton et al., 2020</xref>; <xref ref-type="bibr" rid="bib100">Van Laethem et al., 2021</xref>). Models analyzing these impacts in hospitals contribute to understanding COVID-19’s specific role in the antibiotic resistance burden in different settings (<xref ref-type="bibr" rid="bib95">Smith et al., 2023</xref>).</p><p>A limitation of our model is the lack of age structure and contact patterns between age groups, as SARS-CoV-2 infection risk, pneumococcal disease risk, disease severity, bacterial carriage prevalence and antibiotic prescribing are all highly heterogeneous across age groups. While this choice was made to keep the model as simple as possible, we tested the model using different parameter combinations to mimic different subpopulations (children and ≥65 years-old). This included varying durations of pneumococcal carriage, initializing the model with lower and higher baseline carriage prevalence, considering reductions of general antibiotic consumption at various levels, and varying a percentage of COVID-19 infected individuals using azithromycin. Simulations of the different age groups individually interestingly reproduced realistic trends by age.</p><p>In conclusion, we introduce the first epidemiological model outlining the impact of the COVID-19 pandemic on the dynamics of AMR in the community. Our work demonstrates the utility of mathematical modeling approach in unraveling the complex effects of the COVID-19 pandemic responses AMR dynamics. While our model was structured and parameterized based upon <italic>S. pneumoniae</italic>, its adaptability allows for application to various bacteria and epidemiological scenarios in the community (e.g. impacts of SARS-CoV-2-bacteria interactions in the context of seasonal outbreaks of endemic pathogens). Future research would benefit from fitting the model to real-world data for different bacterial species to enhance our understanding of AMR trends.</p></sec><sec id="s4" sec-type="methods"><title>Methods</title><sec id="s4-1"><title><italic>Streptococcus pneumoniae</italic> surveillance data</title><p>Antibiotic resistance trends reported in 2019 and 2020, provided by EARS-Net (European Antimicrobial Resistance Surveillance Network) were acquired from a joint 2022 report on AMR during 2020 by WHO and ECDC (<xref ref-type="bibr" rid="bib36">European Centre for Disease Prevention and Control and World Health Organization, 2022</xref>). The annual incidence of <italic>S. pneumoniae</italic> invasive isolates for 2019 and 2020 was measured as the number of invasive isolates from blood or cerebrospinal fluid. The proportion of resistant isolates represents the proportion of isolates with phenotypic resistance to penicillin and macrolides using standardized bacterial culture methods and EUCAST breakpoints. Out of 28 European countries that reported antibiotic resistance data for <italic>S. pneumoniae</italic>, 24 countries had enough samples to establish 2019–2020 resistance trends for penicillin and macrolides. The resistance data for France, which were subsequently analyzed, were provided by the CNRP (The French National Reference Center for Pneumococci).</p></sec><sec id="s4-2"><title>Model structure</title><p>We developed a pathogen co-circulation model (<xref ref-type="fig" rid="app2fig2">Appendix 2—figure 2</xref>) written using systems of ordinary differential equations (ODEs) (Appendix 2-Equations; code available on <ext-link ext-link-type="uri" xlink:href="https://github.com/alekskovacevic/antibiotic_resistance">GitHub</ext-link>, copy archived at <xref ref-type="bibr" rid="bib55">Kovacevic, 2024</xref>). The model simultaneously describes potential infection with SARS-CoV-2 and colonization with antibiotic-sensitive and/or -resistant strains of <italic>S. pneumoniae</italic> in a well-mixed community population. SARS-CoV-2 infection is modeled by a Susceptible-Exposed-Infectious-Recovered (SEIR) process where individuals become exposed to SARS-CoV-2 at rate <italic>β</italic><sub><italic>C</italic></sub> upon contact with other infected individuals. Infection begins with a non-infectious exposed period lasting 1/<italic>ε</italic>days and is followed by an infectious period lasting <inline-formula><mml:math id="inf7"><mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:math></inline-formula> days, eventually leading to recovery and immunization against future re-infection. Waning immunity and competitive multi-strain SARS-CoV-2 dynamics are not considered.</p><p>Individuals in S, E, I, and R compartments can be uncolonized with <italic>S. pneumoniae</italic> (U), colonized with either a drug-sensitive (C<sup>S</sup>) or a drug-resistant strain (C<sup>R</sup>), or co-colonized with two strains (C<sup>SS</sup>, C<sup>RR</sup>, C<sup>SR</sup>). Colonization with each respective strain is acquired at rates <inline-formula><mml:math id="inf8"><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="inf9"><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mi>f</mml:mi></mml:math></inline-formula> upon contact with other colonized individuals (<xref ref-type="table" rid="app2table2">Appendix 2—table 2</xref>). We assume a metabolic cost of resistance, whereby the drug-resistant strain has a reduced intrinsic transmission rate relative to the drug-sensitive strain due to reduced fitness, <italic>f</italic>. Bacterial carriage is cleared naturally after an average duration of <inline-formula><mml:math id="inf10"><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mfrac></mml:math></inline-formula> days, which we assume to be the same for all types of carriers in our baseline scenario (in the scenarios assuming longer carriage duration of antibiotic-resistant strains, <inline-formula><mml:math id="inf11"><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mfrac></mml:math></inline-formula> and <inline-formula><mml:math id="inf12"><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mfrac></mml:math></inline-formula>). We further assume that some share of the population is exposed to antibiotics at any given time, independent of bacterial carriage, with individuals initiating antibiotic therapy at rate <inline-formula><mml:math id="inf13"><mml:mi>τ</mml:mi></mml:math></inline-formula>, which lasts for an average duration of <inline-formula><mml:math id="inf14"><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:mfrac></mml:math></inline-formula> days. Another model assumption is that a proportion <inline-formula><mml:math id="inf15"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> of those infected with COVID-19 in the community (between 0% and 20% of individuals in an I compartment) receive azithromycin prescription from general practitioner reflecting azithromycin prescriptions in the early pandemic, while the rest of the infectious individuals (<inline-formula><mml:math id="inf16"><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>) are exposed to the baseline antibiotic therapy. We assume baseline treatment duration of 7 days, on average, regardless of the antibiotic prescribed and without any assumed persistence of the antibiotic in the system after the last dose <inline-formula><mml:math id="inf17"><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:mfrac></mml:math></inline-formula> . In case of antibiotic treatment with azithromycin for COVID-19 infected individuals we assume the treatment lasts three days with antibiotics remaining in the system for additional 15.5 days after the last dose for a total of 18.5 days of antibiotic exposure where COVID-19 recovered individuals <inline-formula><mml:math id="inf18"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> treated with azithromycin retain azithromycin in their system for an additional 11.5 days <inline-formula><mml:math id="inf19"><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></inline-formula> after COVID-19 recovery. Individuals treated with antibiotics are unable to acquire the sensitive strain. Antibiotics are assumed to clear colonization with sensitive strains at a rate <inline-formula><mml:math id="inf20"><mml:mi>ω</mml:mi></mml:math></inline-formula> while having no direct impact on colonization with resistant strains. This bacterial colonization process results in antibiotic selection for resistance via competition for limited hosts, facilitates epidemiological coexistence between strains and is adapted from previous models of <italic>S. pneumoniae</italic> (<xref ref-type="bibr" rid="bib22">Colijn et al., 2010</xref>; <xref ref-type="bibr" rid="bib61">Lipsitch et al., 2009</xref>; <xref ref-type="bibr" rid="bib69">Mulberry et al., 2020</xref>). For a full list of parameter values see <xref ref-type="table" rid="app2table2">Appendix 2—table 2</xref>.</p></sec><sec id="s4-3"><title>Simulation in an early COVID-19 pandemic context</title><p>ODEs were integrated numerically using the R package deSolve to simulate and quantify epidemiological dynamics (<xref ref-type="bibr" rid="bib96">Soetaert et al., 2010</xref>). First, bacterial dynamics were simulated until endemic equilibrium was achieved, under the assumption that <italic>S. pneumoniae</italic> was at endemic equilibrium upon the emergence of COVID-19. Second, using equilibrium states as initial conditions and re-initializing simulation time to <italic>t</italic>=0, a single SARS-CoV-2 infected individual was introduced into the population and ODEs were again integrated numerically to <italic>t</italic>=365 days. Parameter values used for simulation were taken from prior studies prioritizing French data and are provided in <xref ref-type="table" rid="app2table2">Appendix 2—table 2</xref>.</p><p>These simulations were conducted in the context of an ‘early pandemic scenario’ coinciding with the implementation of population-wide NPIs to slow SARS-CoV-2 transmission. This was conceived as the implementation of two 60 day lockdown periods starting on day 75 and on day 305 in response to the simulated surge in COVID-19 cases. Lockdowns were assumed to have three major potential impacts on population behavior and, in turn, the transmission dynamics of SARS-CoV-2 and <italic>S. pneumoniae</italic>. These impacts were incorporated into simulations by modifying epidemiological parameters in the model coincident with lockdowns. Three such modifications were considered and switched on and off, considering all possible combinations. First, lockdown led to reduced SARS-CoV-2 transmissibility by a factor <inline-formula><mml:math id="inf21"><mml:msub><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> . Second, lockdown led to a population-wide change in antibiotic initiation rate by a factor <italic>a</italic> (representing modified healthcare-seeking behavior leading to a reduction in the number of antibiotic prescriptions). Finally, lockdowns changed the pneumococcal disease risk by a factor <inline-formula><mml:math id="inf22"><mml:msub><mml:mrow><mml:mi>I</mml:mi><mml:mi>P</mml:mi><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> (representing a reduced risk of developing an IPD due to the absence of other respiratory viruses).</p><sec id="s4-3-1"><title>Effect of SARS-CoV-2 basic reproduction number (R<sub>0</sub>) on AMR</title><p>Impacts of SARS-CoV-2 on antibiotic-resistant IPD incidence may also depend on the characteristics of locally circulating SARS-CoV-2 R<sub>0</sub>. To account for potential impacts of SARS-CoV-2 transmissibility and azithromycin use in the community, in simulations we varied (i) values of <italic>R</italic><sub>0</sub> (basic reproduction number) for SARS-CoV-2 in France (<inline-formula><mml:math id="inf23"><mml:mn>2</mml:mn><mml:mo>≤</mml:mo><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>≤</mml:mo><mml:mn>4</mml:mn></mml:math></inline-formula>) and (ii) the proportion of the COVID-19 infected individuals using azithromycin at simulation outset (from 0% to 20%).</p></sec><sec id="s4-3-2"><title>Effect of within-host interactions on AMR</title><p>SARS-CoV-2 infection may impact progression from bacterial colonization to IBD at the within-host level. To incorporate this mechanism in our model, we included a within-host interaction term in scenario S19: the ecological interaction term <inline-formula><mml:math id="inf24"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>ψ</mml:mi><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula> increases the rate of progression to invasive disease among colonized individuals who are also infected with SARS-CoV-2. The equations for calculating daily IPD incidence assuming within-host interactions due to SARS-CoV-2 co-infection with accompanying details can be found in Appendix 2.</p></sec></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>received consulting fees from Pfizer, Sanofi, MSD, and GSK, including travel grants from Pfizer and payments from Symposium Pfizer, MSD, GSK, and Sanofi, and participated in advisory/data safety monitoring board at Pfizer, Sanofi, MSD, and GSK</p></fn><fn fn-type="COI-statement" id="conf3"><p>received travel grants from Pfizer and payments from Symposium Pfizer and MSD</p></fn><fn fn-type="COI-statement" id="conf4"><p>received a research grant from Pfizer and Sanofi Pasteur on unrelated topics through her institution</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Formal analysis, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Investigation, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Investigation, Writing – original draft</p></fn><fn fn-type="con" id="con5"><p>Investigation, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Funding acquisition, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Supervision, Funding acquisition, Methodology, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-85701-mdarchecklist1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Source Data 1 contains the numerical data used to generate Figure 1.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdullahi</surname><given-names>O</given-names></name><name><surname>Karani</surname><given-names>A</given-names></name><name><surname>Tigoi</surname><given-names>CC</given-names></name><name><surname>Mugo</surname><given-names>D</given-names></name><name><surname>Kungu</surname><given-names>S</given-names></name><name><surname>Wanjiru</surname><given-names>E</given-names></name><name><surname>Jomo</surname><given-names>J</given-names></name><name><surname>Musyimi</surname><given-names>R</given-names></name><name><surname>Lipsitch</surname><given-names>M</given-names></name><name><surname>Scott</surname><given-names>JAG</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Rates of acquisition and clearance of pneumococcal serotypes in the nasopharynges of children in Kilifi District, Kenya</article-title><source>The Journal of Infectious Diseases</source><volume>206</volume><fpage>1020</fpage><lpage>1029</lpage><pub-id pub-id-type="doi">10.1093/infdis/jis447</pub-id><pub-id pub-id-type="pmid">22829650</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allieta</surname><given-names>M</given-names></name><name><surname>Allieta</surname><given-names>A</given-names></name><name><surname>Rossi Sebastiano</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>COVID-19 outbreak in Italy: estimation of reproduction numbers over 2 months prior to phase 2</article-title><source>Zeitschrift Fur Gesundheitswissenschaften = Journal of Public Health</source><volume>30</volume><fpage>2719</fpage><lpage>2727</lpage><pub-id pub-id-type="doi">10.1007/s10389-021-01567-1</pub-id><pub-id pub-id-type="pmid">34036037</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alpkvist</surname><given-names>H</given-names></name><name><surname>Athlin</surname><given-names>S</given-names></name><name><surname>Nauclér</surname><given-names>P</given-names></name><name><surname>Herrmann</surname><given-names>B</given-names></name><name><surname>Abdeldaim</surname><given-names>G</given-names></name><name><surname>Slotved</surname><given-names>HC</given-names></name><name><surname>Hedlund</surname><given-names>J</given-names></name><name><surname>Strålin</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Clinical and microbiological factors associated with high nasopharyngeal pneumococcal density in patients with pneumococcal pneumonia</article-title><source>PLOS ONE</source><volume>10</volume><elocation-id>e0140112</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0140112</pub-id><pub-id pub-id-type="pmid">26466142</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amin-Chowdhury</surname><given-names>Z</given-names></name><name><surname>Aiano</surname><given-names>F</given-names></name><name><surname>Mensah</surname><given-names>A</given-names></name><name><surname>Sheppard</surname><given-names>CL</given-names></name><name><surname>Litt</surname><given-names>D</given-names></name><name><surname>Fry</surname><given-names>NK</given-names></name><name><surname>Andrews</surname><given-names>N</given-names></name><name><surname>Ramsay</surname><given-names>ME</given-names></name><name><surname>Ladhani</surname><given-names>SN</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>impact of the coronavirus disease 2019 (COVID-19) Pandemic on Invasive Pneumococcal Disease and Risk of Pneumococcal Coinfection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Prospective National Cohort Study, England</article-title><source>Clinical Infectious Diseases</source><volume>72</volume><fpage>e65</fpage><lpage>e75</lpage><pub-id pub-id-type="doi">10.1093/cid/ciaa1728</pub-id><pub-id pub-id-type="pmid">33196783</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrews</surname><given-names>A</given-names></name><name><surname>Bou-Antoun</surname><given-names>S</given-names></name><name><surname>Guy</surname><given-names>R</given-names></name><name><surname>Brown</surname><given-names>CS</given-names></name><name><surname>Hopkins</surname><given-names>S</given-names></name><name><surname>Gerver</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Respiratory antibacterial prescribing in primary care and the COVID-19 pandemic in England, winter season 2020-21</article-title><source>The Journal of Antimicrobial Chemotherapy</source><volume>77</volume><fpage>799</fpage><lpage>802</lpage><pub-id pub-id-type="doi">10.1093/jac/dkab443</pub-id><pub-id pub-id-type="pmid">34897486</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arduin</surname><given-names>H</given-names></name><name><surname>Domenech de Cellès</surname><given-names>M</given-names></name><name><surname>Guillemot</surname><given-names>D</given-names></name><name><surname>Watier</surname><given-names>L</given-names></name><name><surname>Opatowski</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>An agent-based model simulation of influenza interactions at the host level: insight into the influenza-related burden of pneumococcal infections</article-title><source>BMC Infectious Diseases</source><volume>17</volume><elocation-id>382</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-017-2464-z</pub-id><pub-id pub-id-type="pmid">28577533</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baggs</surname><given-names>J</given-names></name><name><surname>Jernigan</surname><given-names>JA</given-names></name><name><surname>Halpin</surname><given-names>AL</given-names></name><name><surname>Epstein</surname><given-names>L</given-names></name><name><surname>Hatfield</surname><given-names>KM</given-names></name><name><surname>McDonald</surname><given-names>LC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Risk of subsequent sepsis within 90 days after a hospital stay by type of antibiotic exposure</article-title><source>Clinical Infectious Diseases</source><volume>66</volume><fpage>1004</fpage><lpage>1012</lpage><pub-id pub-id-type="doi">10.1093/cid/cix947</pub-id><pub-id pub-id-type="pmid">29136126</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bara</surname><given-names>W</given-names></name><name><surname>Brun-Buisson</surname><given-names>C</given-names></name><name><surname>Coignard</surname><given-names>B</given-names></name><name><surname>Watier</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Outpatient antibiotic prescriptions in france: patients and providers characteristics and impact of the COVID-19 Pandemic</article-title><source>Antibiotics</source><volume>11</volume><elocation-id>643</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics11050643</pub-id><pub-id pub-id-type="pmid">35625287</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bednarčuk</surname><given-names>N</given-names></name><name><surname>Golić Jelić</surname><given-names>A</given-names></name><name><surname>Stoisavljević Šatara</surname><given-names>S</given-names></name><name><surname>Stojaković</surname><given-names>N</given-names></name><name><surname>Marković Peković</surname><given-names>V</given-names></name><name><surname>Stojiljković</surname><given-names>MP</given-names></name><name><surname>Popović</surname><given-names>N</given-names></name><name><surname>Škrbić</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Antibiotic Utilization during COVID-19: are we over-prescribing?</article-title><source>Antibiotics</source><volume>12</volume><elocation-id>308</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics12020308</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bennett</surname><given-names>JC</given-names></name><name><surname>Emanuels</surname><given-names>A</given-names></name><name><surname>Heimonen</surname><given-names>J</given-names></name><name><surname>O’Hanlon</surname><given-names>J</given-names></name><name><surname>Hughes</surname><given-names>JP</given-names></name><name><surname>Han</surname><given-names>PD</given-names></name><name><surname>Chow</surname><given-names>EJ</given-names></name><name><surname>Ogokeh</surname><given-names>CE</given-names></name><name><surname>Rolfes</surname><given-names>MA</given-names></name><name><surname>Lockwood</surname><given-names>CM</given-names></name><name><surname>Pfau</surname><given-names>B</given-names></name><name><surname>Uyeki</surname><given-names>TM</given-names></name><name><surname>Shendure</surname><given-names>J</given-names></name><name><surname>Hoag</surname><given-names>S</given-names></name><name><surname>Fay</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Sibley</surname><given-names>TR</given-names></name><name><surname>Rogers</surname><given-names>JH</given-names></name><name><surname>Starita</surname><given-names>LM</given-names></name><name><surname>Englund</surname><given-names>JA</given-names></name><name><surname>Chu</surname><given-names>HY</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title><italic>Streptococcus pneumoniae</italic> nasal carriage patterns with and without common respiratory virus detections in households in Seattle, WA, USA before and during the COVID-19 pandemic</article-title><source>Frontiers in Pediatrics</source><volume>11</volume><elocation-id>1198278</elocation-id><pub-id pub-id-type="doi">10.3389/fped.2023.1198278</pub-id><pub-id pub-id-type="pmid">37484765</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhowmick</surname><given-names>S</given-names></name><name><surname>Sokolov</surname><given-names>IM</given-names></name><name><surname>Lentz</surname><given-names>HHK</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Decoding the double trouble: A mathematical modelling of co-infection dynamics of SARS-CoV-2 and influenza-like illness</article-title><source>Bio Systems</source><volume>224</volume><elocation-id>104827</elocation-id><pub-id pub-id-type="doi">10.1016/j.biosystems.2023.104827</pub-id><pub-id pub-id-type="pmid">36626949</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bogdanić</surname><given-names>N</given-names></name><name><surname>Močibob</surname><given-names>L</given-names></name><name><surname>Vidović</surname><given-names>T</given-names></name><name><surname>Soldo</surname><given-names>A</given-names></name><name><surname>Begovać</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Azithromycin consumption during the COVID-19 pandemic in Croatia, 2020</article-title><source>PLOS ONE</source><volume>17</volume><elocation-id>e0263437</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0263437</pub-id><pub-id pub-id-type="pmid">35108332</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braunstein</surname><given-names>SL</given-names></name><name><surname>Lazar</surname><given-names>R</given-names></name><name><surname>Wahnich</surname><given-names>A</given-names></name><name><surname>Daskalakis</surname><given-names>DC</given-names></name><name><surname>Blackstock</surname><given-names>OJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>COVID-19 infection among people with HIV in New York City: a population-level analysis of matched surveillance data</article-title><source>SSRN Electronic Journal</source><volume>01</volume><elocation-id>3675416</elocation-id><pub-id pub-id-type="doi">10.2139/ssrn.3675416</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brueggemann</surname><given-names>AB</given-names></name><name><surname>Jansen van Rensburg</surname><given-names>MJ</given-names></name><name><surname>Shaw</surname><given-names>D</given-names></name><name><surname>McCarthy</surname><given-names>ND</given-names></name><name><surname>Jolley</surname><given-names>KA</given-names></name><name><surname>Maiden</surname><given-names>MCJ</given-names></name><name><surname>van der Linden</surname><given-names>MPG</given-names></name><name><surname>Amin-Chowdhury</surname><given-names>Z</given-names></name><name><surname>Bennett</surname><given-names>DE</given-names></name><name><surname>Borrow</surname><given-names>R</given-names></name><name><surname>Brandileone</surname><given-names>MCC</given-names></name><name><surname>Broughton</surname><given-names>K</given-names></name><name><surname>Campbell</surname><given-names>R</given-names></name><name><surname>Cao</surname><given-names>B</given-names></name><name><surname>Casanova</surname><given-names>C</given-names></name><name><surname>Choi</surname><given-names>EH</given-names></name><name><surname>Chu</surname><given-names>YW</given-names></name><name><surname>Clark</surname><given-names>SA</given-names></name><name><surname>Claus</surname><given-names>H</given-names></name><name><surname>Coelho</surname><given-names>J</given-names></name><name><surname>Corcoran</surname><given-names>M</given-names></name><name><surname>Cottrell</surname><given-names>S</given-names></name><name><surname>Cunney</surname><given-names>RJ</given-names></name><name><surname>Dalby</surname><given-names>T</given-names></name><name><surname>Davies</surname><given-names>H</given-names></name><name><surname>de Gouveia</surname><given-names>L</given-names></name><name><surname>Deghmane</surname><given-names>AE</given-names></name><name><surname>Demczuk</surname><given-names>W</given-names></name><name><surname>Desmet</surname><given-names>S</given-names></name><name><surname>Drew</surname><given-names>RJ</given-names></name><name><surname>du Plessis</surname><given-names>M</given-names></name><name><surname>Erlendsdottir</surname><given-names>H</given-names></name><name><surname>Fry</surname><given-names>NK</given-names></name><name><surname>Fuursted</surname><given-names>K</given-names></name><name><surname>Gray</surname><given-names>SJ</given-names></name><name><surname>Henriques-Normark</surname><given-names>B</given-names></name><name><surname>Hale</surname><given-names>T</given-names></name><name><surname>Hilty</surname><given-names>M</given-names></name><name><surname>Hoffmann</surname><given-names>S</given-names></name><name><surname>Humphreys</surname><given-names>H</given-names></name><name><surname>Ip</surname><given-names>M</given-names></name><name><surname>Jacobsson</surname><given-names>S</given-names></name><name><surname>Johnston</surname><given-names>J</given-names></name><name><surname>Kozakova</surname><given-names>J</given-names></name><name><surname>Kristinsson</surname><given-names>KG</given-names></name><name><surname>Krizova</surname><given-names>P</given-names></name><name><surname>Kuch</surname><given-names>A</given-names></name><name><surname>Ladhani</surname><given-names>SN</given-names></name><name><surname>Lâm</surname><given-names>TT</given-names></name><name><surname>Lebedova</surname><given-names>V</given-names></name><name><surname>Lindholm</surname><given-names>L</given-names></name><name><surname>Litt</surname><given-names>DJ</given-names></name><name><surname>Martin</surname><given-names>I</given-names></name><name><surname>Martiny</surname><given-names>D</given-names></name><name><surname>Mattheus</surname><given-names>W</given-names></name><name><surname>McElligott</surname><given-names>M</given-names></name><name><surname>Meehan</surname><given-names>M</given-names></name><name><surname>Meiring</surname><given-names>S</given-names></name><name><surname>Mölling</surname><given-names>P</given-names></name><name><surname>Morfeldt</surname><given-names>E</given-names></name><name><surname>Morgan</surname><given-names>J</given-names></name><name><surname>Mulhall</surname><given-names>RM</given-names></name><name><surname>Muñoz-Almagro</surname><given-names>C</given-names></name><name><surname>Murdoch</surname><given-names>DR</given-names></name><name><surname>Murphy</surname><given-names>J</given-names></name><name><surname>Musilek</surname><given-names>M</given-names></name><name><surname>Mzabi</surname><given-names>A</given-names></name><name><surname>Perez-Argüello</surname><given-names>A</given-names></name><name><surname>Perrin</surname><given-names>M</given-names></name><name><surname>Perry</surname><given-names>M</given-names></name><name><surname>Redin</surname><given-names>A</given-names></name><name><surname>Roberts</surname><given-names>R</given-names></name><name><surname>Roberts</surname><given-names>M</given-names></name><name><surname>Rokney</surname><given-names>A</given-names></name><name><surname>Ron</surname><given-names>M</given-names></name><name><surname>Scott</surname><given-names>KJ</given-names></name><name><surname>Sheppard</surname><given-names>CL</given-names></name><name><surname>Siira</surname><given-names>L</given-names></name><name><surname>Skoczyńska</surname><given-names>A</given-names></name><name><surname>Sloan</surname><given-names>M</given-names></name><name><surname>Slotved</surname><given-names>HC</given-names></name><name><surname>Smith</surname><given-names>AJ</given-names></name><name><surname>Song</surname><given-names>JY</given-names></name><name><surname>Taha</surname><given-names>MK</given-names></name><name><surname>Toropainen</surname><given-names>M</given-names></name><name><surname>Tsang</surname><given-names>D</given-names></name><name><surname>Vainio</surname><given-names>A</given-names></name><name><surname>van Sorge</surname><given-names>NM</given-names></name><name><surname>Varon</surname><given-names>E</given-names></name><name><surname>Vlach</surname><given-names>J</given-names></name><name><surname>Vogel</surname><given-names>U</given-names></name><name><surname>Vohrnova</surname><given-names>S</given-names></name><name><surname>von Gottberg</surname><given-names>A</given-names></name><name><surname>Zanella</surname><given-names>RC</given-names></name><name><surname>Zhou</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data</article-title><source>The Lancet. Digital Health</source><volume>3</volume><fpage>e360</fpage><lpage>e370</lpage><pub-id pub-id-type="doi">10.1016/S2589-7500(21)00077-7</pub-id><pub-id pub-id-type="pmid">34045002</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buehrle</surname><given-names>DJ</given-names></name><name><surname>Wagener</surname><given-names>MM</given-names></name><name><surname>Nguyen</surname><given-names>MH</given-names></name><name><surname>Clancy</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Trends in outpatient antibiotic prescriptions in the united states during the covid-19 pandemic in 2020</article-title><source>JAMA Network Open</source><volume>4</volume><elocation-id>e2126114</elocation-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2021.26114</pub-id><pub-id pub-id-type="pmid">34550387</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cascante-Vega</surname><given-names>J</given-names></name><name><surname>Galanti</surname><given-names>M</given-names></name><name><surname>Schley</surname><given-names>K</given-names></name><name><surname>Pei</surname><given-names>S</given-names></name><name><surname>Shaman</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Inference of transmission dynamics and retrospective forecast of invasive meningococcal disease</article-title><source>PLOS Computational Biology</source><volume>19</volume><elocation-id>e1011564</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1011564</pub-id><pub-id pub-id-type="pmid">37889910</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Effect of the “Normalized Epidemic Prevention and Control Requirements” on hospital-acquired and community-acquired infections in China</article-title><source>BMC Infectious Diseases</source><volume>21</volume><elocation-id>1178</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-021-06886-y</pub-id><pub-id pub-id-type="pmid">34814857</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Lourenço</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Cazelles</surname><given-names>B</given-names></name><name><surname>Dong</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Jit</surname><given-names>M</given-names></name><name><surname>Bosse</surname><given-names>NI</given-names></name><name><surname>Abbott</surname><given-names>S</given-names></name><name><surname>Velayudhan</surname><given-names>R</given-names></name><name><surname>Wilder-Smith</surname><given-names>A</given-names></name><name><surname>Tian</surname><given-names>H</given-names></name><name><surname>Brady</surname><given-names>OJ</given-names></name><name><surname>Procter</surname><given-names>SR</given-names></name><name><surname>Wong</surname><given-names>KL</given-names></name><name><surname>Hellewell</surname><given-names>J</given-names></name><name><surname>Davies</surname><given-names>NG</given-names></name><name><surname>Jarvis</surname><given-names>CI</given-names></name><name><surname>McCarthy</surname><given-names>CV</given-names></name><name><surname>Medley</surname><given-names>G</given-names></name><name><surname>Meakin</surname><given-names>SR</given-names></name><name><surname>Rosello</surname><given-names>A</given-names></name><name><surname>Finch</surname><given-names>E</given-names></name><name><surname>Lowe</surname><given-names>R</given-names></name><name><surname>Pearson</surname><given-names>CAB</given-names></name><name><surname>Clifford</surname><given-names>S</given-names></name><name><surname>Quilty</surname><given-names>BJ</given-names></name><name><surname>Flasche</surname><given-names>S</given-names></name><name><surname>Gibbs</surname><given-names>HP</given-names></name><name><surname>Chapman</surname><given-names>LAC</given-names></name><name><surname>Atkins</surname><given-names>KE</given-names></name><name><surname>Hodgson</surname><given-names>D</given-names></name><name><surname>Barnard</surname><given-names>RC</given-names></name><name><surname>Russell</surname><given-names>TW</given-names></name><name><surname>Klepac</surname><given-names>P</given-names></name><name><surname>Jafari</surname><given-names>Y</given-names></name><name><surname>Eggo</surname><given-names>RM</given-names></name><name><surname>Mee</surname><given-names>P</given-names></name><name><surname>Quaife</surname><given-names>M</given-names></name><name><surname>Endo</surname><given-names>A</given-names></name><name><surname>Funk</surname><given-names>S</given-names></name><name><surname>Hué</surname><given-names>S</given-names></name><name><surname>Kucharski</surname><given-names>AJ</given-names></name><name><surname>Edmunds</surname><given-names>WJ</given-names></name><name><surname>O’Reilly</surname><given-names>K</given-names></name><name><surname>Pung</surname><given-names>R</given-names></name><name><surname>Villabona-Arenas</surname><given-names>CJ</given-names></name><name><surname>Gimma</surname><given-names>A</given-names></name><name><surname>Abbas</surname><given-names>K</given-names></name><name><surname>Prem</surname><given-names>K</given-names></name><name><surname>Knight</surname><given-names>GM</given-names></name><name><surname>Sun</surname><given-names>FY</given-names></name><name><surname>Waites</surname><given-names>W</given-names></name><name><surname>Munday</surname><given-names>JD</given-names></name><name><surname>Koltai</surname><given-names>M</given-names></name><name><surname>Sandmann</surname><given-names>FG</given-names></name><name><surname>Tully</surname><given-names>DC</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Measuring the effects of COVID-19-related disruption on dengue transmission in southeast Asia and Latin America: a statistical modelling study</article-title><source>The Lancet. Infectious Diseases</source><volume>22</volume><fpage>657</fpage><lpage>667</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(22)00025-1</pub-id><pub-id pub-id-type="pmid">35247320</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chien</surname><given-names>Y-C</given-names></name><name><surname>Lee</surname><given-names>Y-L</given-names></name><name><surname>Liu</surname><given-names>P-Y</given-names></name><name><surname>Lu</surname><given-names>M-C</given-names></name><name><surname>Shao</surname><given-names>P-L</given-names></name><name><surname>Lu</surname><given-names>P-L</given-names></name><name><surname>Cheng</surname><given-names>S-H</given-names></name><name><surname>Lin</surname><given-names>C-Y</given-names></name><name><surname>Wu</surname><given-names>T-S</given-names></name><name><surname>Yen</surname><given-names>M-Y</given-names></name><name><surname>Wang</surname><given-names>L-S</given-names></name><name><surname>Liu</surname><given-names>C-P</given-names></name><name><surname>Lee</surname><given-names>W-S</given-names></name><name><surname>Shi</surname><given-names>Z-Y</given-names></name><name><surname>Chen</surname><given-names>Y-S</given-names></name><name><surname>Wang</surname><given-names>F-D</given-names></name><name><surname>Tseng</surname><given-names>S-H</given-names></name><name><surname>Chen</surname><given-names>Y-H</given-names></name><name><surname>Sheng</surname><given-names>W-H</given-names></name><name><surname>Lee</surname><given-names>C-M</given-names></name><name><surname>Chen</surname><given-names>Y-H</given-names></name><name><surname>Ko</surname><given-names>W-C</given-names></name><name><surname>Hsueh</surname><given-names>P-R</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>National surveillance of antimicrobial susceptibilities to dalbavancin, telavancin, tedizolid, eravacycline, omadacycline and other comparator antibiotics and serotype distribution of invasive Streptococcus pneumoniae isolates in adults: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) programme in 2017–2020</article-title><source>Journal of Global Antimicrobial Resistance</source><volume>26</volume><fpage>308</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1016/j.jgar.2021.07.005</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clancy</surname><given-names>CJ</given-names></name><name><surname>Buehrle</surname><given-names>DJ</given-names></name><name><surname>Nguyen</surname><given-names>MH</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>PRO: The COVID-19 pandemic will result in increased antimicrobial resistance rates</article-title><source>JAC-Antimicrobial Resistance</source><volume>2</volume><elocation-id>dlaa049</elocation-id><pub-id pub-id-type="doi">10.1093/jacamr/dlaa049</pub-id><pub-id pub-id-type="pmid">34192248</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>R</given-names></name><name><surname>Bidet</surname><given-names>P</given-names></name><name><surname>Varon</surname><given-names>E</given-names></name><name><surname>Béchet</surname><given-names>S</given-names></name><name><surname>Cohen</surname><given-names>JF</given-names></name><name><surname>Bonacorsi</surname><given-names>S</given-names></name><name><surname>Levy</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Unprecedentedly high rates of Group A Streptococcus nasopharyngeal carriage in infants and toddlers in France, 2022-2023</article-title><source>Infectious Diseases Now</source><volume>53</volume><elocation-id>104720</elocation-id><pub-id pub-id-type="doi">10.1016/j.idnow.2023.104720</pub-id><pub-id pub-id-type="pmid">37196808</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colijn</surname><given-names>C</given-names></name><name><surname>Cohen</surname><given-names>T</given-names></name><name><surname>Fraser</surname><given-names>C</given-names></name><name><surname>Hanage</surname><given-names>W</given-names></name><name><surname>Goldstein</surname><given-names>E</given-names></name><name><surname>Givon-Lavi</surname><given-names>N</given-names></name><name><surname>Dagan</surname><given-names>R</given-names></name><name><surname>Lipsitch</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>What is the mechanism for persistent coexistence of drug-susceptible and drug-resistant strains of Streptococcus pneumoniae?</article-title><source>Journal of the Royal Society, Interface</source><volume>7</volume><fpage>905</fpage><lpage>919</lpage><pub-id pub-id-type="doi">10.1098/rsif.2009.0400</pub-id><pub-id pub-id-type="pmid">19940002</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crisafulli</surname><given-names>S</given-names></name><name><surname>Ientile</surname><given-names>V</given-names></name><name><surname>L’Abbate</surname><given-names>L</given-names></name><name><surname>Fontana</surname><given-names>A</given-names></name><name><surname>Linguiti</surname><given-names>C</given-names></name><name><surname>Manna</surname><given-names>S</given-names></name><name><surname>Mercaldo</surname><given-names>M</given-names></name><name><surname>Pagliaro</surname><given-names>C</given-names></name><name><surname>Vezzaro</surname><given-names>M</given-names></name><name><surname>Santacà</surname><given-names>K</given-names></name><name><surname>Lora</surname><given-names>R</given-names></name><name><surname>Moretti</surname><given-names>U</given-names></name><name><surname>Reno</surname><given-names>C</given-names></name><name><surname>Fantini</surname><given-names>MP</given-names></name><name><surname>Corrao</surname><given-names>S</given-names></name><name><surname>Barbato</surname><given-names>D</given-names></name><name><surname>Tari</surname><given-names>M</given-names></name><name><surname>Trifirò</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>COVID-19 Patient Management in Outpatient Setting: A Population-Based Study from Southern Italy</article-title><source>Journal of Clinical Medicine</source><volume>11</volume><elocation-id>51</elocation-id><pub-id pub-id-type="doi">10.3390/jcm11010051</pub-id><pub-id pub-id-type="pmid">35011810</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dagan</surname><given-names>R</given-names></name><name><surname>Barkai</surname><given-names>G</given-names></name><name><surname>Givon-Lavi</surname><given-names>N</given-names></name><name><surname>Sharf</surname><given-names>AZ</given-names></name><name><surname>Vardy</surname><given-names>D</given-names></name><name><surname>Cohen</surname><given-names>T</given-names></name><name><surname>Lipsitch</surname><given-names>M</given-names></name><name><surname>Greenberg</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Seasonality of antibiotic-resistant streptococcus pneumoniae that causes acute otitis media: a clue for an antibiotic-restriction policy?</article-title><source>The Journal of Infectious Diseases</source><volume>197</volume><fpage>1094</fpage><lpage>1102</lpage><pub-id pub-id-type="doi">10.1086/528995</pub-id><pub-id pub-id-type="pmid">18419528</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dagan</surname><given-names>R</given-names></name><name><surname>van der Beek</surname><given-names>BA</given-names></name><name><surname>Ben-Shimol</surname><given-names>S</given-names></name><name><surname>Greenberg</surname><given-names>D</given-names></name><name><surname>Shemer-Avni</surname><given-names>Y</given-names></name><name><surname>Weinberger</surname><given-names>DM</given-names></name><name><surname>Danino</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>The COVID-19 pandemic as an opportunity for unravelling the causative association between respiratory viruses and pneumococcus-associated disease in young children: a prospective study</article-title><source>EBioMedicine</source><volume>90</volume><elocation-id>104493</elocation-id><pub-id pub-id-type="doi">10.1016/j.ebiom.2023.104493</pub-id><pub-id pub-id-type="pmid">36857965</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danion</surname><given-names>F</given-names></name><name><surname>Margue</surname><given-names>M</given-names></name><name><surname>Ruch</surname><given-names>Y</given-names></name><name><surname>Séverac</surname><given-names>F</given-names></name><name><surname>Hansmann</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Seasonal variation in azithromycin prescription</article-title><source>The Lancet. Infectious Diseases</source><volume>23</volume><fpage>277</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(23)00009-9</pub-id><pub-id pub-id-type="pmid">36736337</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D’Arienzo</surname><given-names>M</given-names></name><name><surname>Coniglio</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Assessment of the SARS-CoV-2 basic reproduction number, R0, based on the early phase of COVID-19 outbreak in Italy</article-title><source>Biosafety and Health</source><volume>2</volume><fpage>57</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.bsheal.2020.03.004</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>NG</given-names></name><name><surname>Flasche</surname><given-names>S</given-names></name><name><surname>Jit</surname><given-names>M</given-names></name><name><surname>Atkins</surname><given-names>KE</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Within-host dynamics shape antibiotic resistance in commensal bacteria</article-title><source>Nature Ecology &amp; Evolution</source><volume>3</volume><fpage>440</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1038/s41559-018-0786-x</pub-id><pub-id pub-id-type="pmid">30742105</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diavatopoulos</surname><given-names>DA</given-names></name><name><surname>Short</surname><given-names>KR</given-names></name><name><surname>Price</surname><given-names>JT</given-names></name><name><surname>Wilksch</surname><given-names>JJ</given-names></name><name><surname>Brown</surname><given-names>LE</given-names></name><name><surname>Briles</surname><given-names>DE</given-names></name><name><surname>Strugnell</surname><given-names>RA</given-names></name><name><surname>Wijburg</surname><given-names>OL</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Influenza A virus facilitates Streptococcus pneumoniae transmission and disease</article-title><source>FASEB Journal</source><volume>24</volume><fpage>1789</fpage><lpage>1798</lpage><pub-id pub-id-type="doi">10.1096/fj.09-146779</pub-id><pub-id pub-id-type="pmid">20097876</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Domenico</surname><given-names>L</given-names></name><name><surname>Pullano</surname><given-names>G</given-names></name><name><surname>Sabbatini</surname><given-names>CE</given-names></name><name><surname>Boëlle</surname><given-names>P-Y</given-names></name><name><surname>Colizza</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Impact of lockdown on COVID-19 epidemic in Île-de-France and possible exit strategies</article-title><source>BMC Medicine</source><volume>18</volume><elocation-id>240</elocation-id><pub-id pub-id-type="doi">10.1186/s12916-020-01698-4</pub-id><pub-id pub-id-type="pmid">32727547</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doan</surname><given-names>T</given-names></name><name><surname>Worden</surname><given-names>L</given-names></name><name><surname>Hinterwirth</surname><given-names>A</given-names></name><name><surname>Arzika</surname><given-names>AM</given-names></name><name><surname>Maliki</surname><given-names>R</given-names></name><name><surname>Abdou</surname><given-names>A</given-names></name><name><surname>Zhong</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Cook</surname><given-names>C</given-names></name><name><surname>Lebas</surname><given-names>E</given-names></name><name><surname>O’Brien</surname><given-names>KS</given-names></name><name><surname>Oldenburg</surname><given-names>CE</given-names></name><name><surname>Chow</surname><given-names>ED</given-names></name><name><surname>Porco</surname><given-names>TC</given-names></name><name><surname>Lipsitch</surname><given-names>M</given-names></name><name><surname>Keenan</surname><given-names>JD</given-names></name><name><surname>Lietman</surname><given-names>TM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Macrolide and nonmacrolide resistance with mass azithromycin distribution</article-title><source>The New England Journal of Medicine</source><volume>383</volume><fpage>1941</fpage><lpage>1950</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2002606</pub-id><pub-id pub-id-type="pmid">33176084</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Domenech de Cellès</surname><given-names>M</given-names></name><name><surname>Arduin</surname><given-names>H</given-names></name><name><surname>Lévy-Bruhl</surname><given-names>D</given-names></name><name><surname>Georges</surname><given-names>S</given-names></name><name><surname>Souty</surname><given-names>C</given-names></name><name><surname>Guillemot</surname><given-names>D</given-names></name><name><surname>Watier</surname><given-names>L</given-names></name><name><surname>Opatowski</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Unraveling the seasonal epidemiology of pneumococcus</article-title><source>PNAS</source><volume>116</volume><fpage>1802</fpage><lpage>1807</lpage><pub-id pub-id-type="doi">10.1073/pnas.1812388116</pub-id><pub-id pub-id-type="pmid">30642967</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duffy</surname><given-names>E</given-names></name><name><surname>Thomas</surname><given-names>M</given-names></name><name><surname>Hills</surname><given-names>T</given-names></name><name><surname>Ritchie</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The impacts of New Zealand’s COVID-19 epidemic response on community antibiotic use and hospitalisation for pneumonia, peritonsillar abscess and rheumatic fever</article-title><source>The Lancet Regional Health</source><volume>12</volume><elocation-id>100162</elocation-id><pub-id pub-id-type="doi">10.1016/j.lanwpc.2021.100162</pub-id><pub-id pub-id-type="pmid">34124704</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ekdahl</surname><given-names>K</given-names></name><name><surname>Ahlinder</surname><given-names>I</given-names></name><name><surname>Hansson</surname><given-names>HB</given-names></name><name><surname>Melander</surname><given-names>E</given-names></name><name><surname>Mölstad</surname><given-names>S</given-names></name><name><surname>Söderström</surname><given-names>M</given-names></name><name><surname>Persson</surname><given-names>K</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Duration of nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae: experiences from the South Swedish Pneumococcal Intervention Project</article-title><source>Clinical Infectious Diseases</source><volume>25</volume><fpage>1113</fpage><lpage>1117</lpage><pub-id pub-id-type="doi">10.1086/516103</pub-id><pub-id pub-id-type="pmid">9402367</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elias</surname><given-names>C</given-names></name><name><surname>Sekri</surname><given-names>A</given-names></name><name><surname>Leblanc</surname><given-names>P</given-names></name><name><surname>Cucherat</surname><given-names>M</given-names></name><name><surname>Vanhems</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The incubation period of COVID-19: A meta-analysis</article-title><source>International Journal of Infectious Diseases</source><volume>104</volume><fpage>708</fpage><lpage>710</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2021.01.069</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="book"><person-group person-group-type="author"><collab>European Centre for Disease Prevention and Control</collab><collab>World Health Organization</collab></person-group><year iso-8601-date="2022">2022</year><source>Antimicrobial Resistance Surveillance in Europe: 2022: 2020 Data</source><publisher-loc>LU</publisher-loc><publisher-name>Publications Office</publisher-name></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flaxman</surname><given-names>S</given-names></name><name><surname>Mishra</surname><given-names>S</given-names></name><name><surname>Gandy</surname><given-names>A</given-names></name><name><surname>Unwin</surname><given-names>HJT</given-names></name><name><surname>Mellan</surname><given-names>TA</given-names></name><name><surname>Coupland</surname><given-names>H</given-names></name><name><surname>Whittaker</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Berah</surname><given-names>T</given-names></name><name><surname>Eaton</surname><given-names>JW</given-names></name><name><surname>Monod</surname><given-names>M</given-names></name><name><surname>Ghani</surname><given-names>AC</given-names></name><name><surname>Donnelly</surname><given-names>CA</given-names></name><name><surname>Riley</surname><given-names>S</given-names></name><name><surname>Vollmer</surname><given-names>MAC</given-names></name><name><surname>Ferguson</surname><given-names>NM</given-names></name><name><surname>Okell</surname><given-names>LC</given-names></name><name><surname>Bhatt</surname><given-names>S</given-names></name><collab>Imperial College COVID-19 Response Team</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe</article-title><source>Nature</source><volume>584</volume><fpage>257</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2405-7</pub-id><pub-id pub-id-type="pmid">32512579</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foulds</surname><given-names>G</given-names></name><name><surname>Shepard</surname><given-names>RM</given-names></name><name><surname>Johnson</surname><given-names>RB</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>The pharmacokinetics of azithromycin in human serum and tissues</article-title><source>The Journal of Antimicrobial Chemotherapy</source><volume>25 Suppl A</volume><fpage>73</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1093/jac/25.suppl_a.73</pub-id><pub-id pub-id-type="pmid">2154441</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Vidal</surname><given-names>C</given-names></name><name><surname>Sanjuan</surname><given-names>G</given-names></name><name><surname>Moreno-García</surname><given-names>E</given-names></name><name><surname>Puerta-Alcalde</surname><given-names>P</given-names></name><name><surname>Garcia-Pouton</surname><given-names>N</given-names></name><name><surname>Chumbita</surname><given-names>M</given-names></name><name><surname>Fernandez-Pittol</surname><given-names>M</given-names></name><name><surname>Pitart</surname><given-names>C</given-names></name><name><surname>Inciarte</surname><given-names>A</given-names></name><name><surname>Bodro</surname><given-names>M</given-names></name><name><surname>Morata</surname><given-names>L</given-names></name><name><surname>Ambrosioni</surname><given-names>J</given-names></name><name><surname>Grafia</surname><given-names>I</given-names></name><name><surname>Meira</surname><given-names>F</given-names></name><name><surname>Macaya</surname><given-names>I</given-names></name><name><surname>Cardozo</surname><given-names>C</given-names></name><name><surname>Casals</surname><given-names>C</given-names></name><name><surname>Tellez</surname><given-names>A</given-names></name><name><surname>Castro</surname><given-names>P</given-names></name><name><surname>Marco</surname><given-names>F</given-names></name><name><surname>García</surname><given-names>F</given-names></name><name><surname>Mensa</surname><given-names>J</given-names></name><name><surname>Martínez</surname><given-names>JA</given-names></name><name><surname>Soriano</surname><given-names>A</given-names></name><collab>COVID-19 Researchers Group</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study</article-title><source>Clinical Microbiology and Infection</source><volume>27</volume><fpage>83</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2020.07.041</pub-id><pub-id pub-id-type="pmid">32745596</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Girard</surname><given-names>D</given-names></name><name><surname>Finegan</surname><given-names>SM</given-names></name><name><surname>Dunne</surname><given-names>MW</given-names></name><name><surname>Lame</surname><given-names>ME</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models</article-title><source>The Journal of Antimicrobial Chemotherapy</source><volume>56</volume><fpage>365</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1093/jac/dki241</pub-id><pub-id pub-id-type="pmid">16002421</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grant</surname><given-names>J</given-names></name><name><surname>Saux</surname><given-names>NL</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Duration of antibiotic therapy for common infections</article-title><source>Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal Officiel de l’Association Pour La Microbiologie Medicale et l’infectiologie Canada</source><volume>6</volume><fpage>181</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.3138/jammi-2021-04-29</pub-id><pub-id pub-id-type="pmid">36337760</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henig</surname><given-names>O</given-names></name><name><surname>Kehat</surname><given-names>O</given-names></name><name><surname>Meijer</surname><given-names>SE</given-names></name><name><surname>Chikly</surname><given-names>A</given-names></name><name><surname>Weiss-Meilik</surname><given-names>A</given-names></name><name><surname>Egoz</surname><given-names>E</given-names></name><name><surname>Ben-Ami</surname><given-names>R</given-names></name><name><surname>Paran</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Antibiotic Use during the COVID-19 pandemic in a tertiary hospital with an ongoing antibiotic stewardship program</article-title><source>Antibiotics</source><volume>10</volume><elocation-id>1056</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics10091056</pub-id><pub-id pub-id-type="pmid">34572638</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Högberg</surname><given-names>LD</given-names></name><name><surname>Vlahović-Palčevski</surname><given-names>V</given-names></name><name><surname>Pereira</surname><given-names>C</given-names></name><name><surname>Weist</surname><given-names>K</given-names></name><name><surname>Monnet</surname><given-names>DL</given-names></name><collab>ESAC-Net study group</collab><collab>ESAC-Net study group participants</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Decrease in community antibiotic consumption during the COVID-19 pandemic, EU/EEA, 2020</article-title><source>Euro Surveillance</source><volume>26</volume><elocation-id>2101020</elocation-id><pub-id pub-id-type="doi">10.2807/1560-7917.ES.2021.26.46.2101020</pub-id><pub-id pub-id-type="pmid">34794534</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Homeniuk</surname><given-names>R</given-names></name><name><surname>Collins</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>How COVID-19 has affected general practice consultations and income: general practitioner cross-sectional population survey evidence from Ireland</article-title><source>BMJ Open</source><volume>11</volume><elocation-id>e044685</elocation-id><pub-id pub-id-type="doi">10.1136/bmjopen-2020-044685</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>How covid-19 is accelerating the threat of antimicrobial resistance</article-title><source>BMJ</source><volume>369</volume><elocation-id>m1983</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.m1983</pub-id><pub-id pub-id-type="pmid">32423901</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hussain</surname><given-names>AZ</given-names></name><name><surname>Paudyal</surname><given-names>V</given-names></name><name><surname>Hadi</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Impact of the COVID-19 Pandemic on the Prescribing Patterns of First-Line Antibiotics in English Primary Care: A Longitudinal Analysis of National Prescribing Dataset</article-title><source>Antibiotics</source><volume>10</volume><elocation-id>591</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics10050591</pub-id><pub-id pub-id-type="pmid">34067546</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenness</surname><given-names>SM</given-names></name><name><surname>Le Guillou</surname><given-names>A</given-names></name><name><surname>Chandra</surname><given-names>C</given-names></name><name><surname>Mann</surname><given-names>LM</given-names></name><name><surname>Sanchez</surname><given-names>T</given-names></name><name><surname>Westreich</surname><given-names>D</given-names></name><name><surname>Marcus</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Projected HIV and bacterial sexually transmitted infection incidence following COVID-19-related sexual distancing and clinical service interruption</article-title><source>The Journal of Infectious Diseases</source><volume>223</volume><fpage>1019</fpage><lpage>1028</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiab051</pub-id><pub-id pub-id-type="pmid">33507308</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kadambari</surname><given-names>S</given-names></name><name><surname>Goldacre</surname><given-names>R</given-names></name><name><surname>Morris</surname><given-names>E</given-names></name><name><surname>Goldacre</surname><given-names>MJ</given-names></name><name><surname>Pollard</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Indirect effects of the covid-19 pandemic on childhood infection in England: population based observational study</article-title><source>BMJ</source><volume>376</volume><elocation-id>e067519</elocation-id><pub-id pub-id-type="doi">10.1136/bmj-2021-067519</pub-id><pub-id pub-id-type="pmid">35022215</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karami</surname><given-names>Z</given-names></name><name><surname>Knoop</surname><given-names>BT</given-names></name><name><surname>Dofferhoff</surname><given-names>ASM</given-names></name><name><surname>Blaauw</surname><given-names>MJT</given-names></name><name><surname>Janssen</surname><given-names>NA</given-names></name><name><surname>van Apeldoorn</surname><given-names>M</given-names></name><name><surname>Kerckhoffs</surname><given-names>APM</given-names></name><name><surname>van de Maat</surname><given-names>JS</given-names></name><name><surname>Hoogerwerf</surname><given-names>JJ</given-names></name><name><surname>ten Oever</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Few bacterial co-infections but frequent empiric antibiotic use in the early phase of hospitalized patients with COVID-19: results from a multicentre retrospective cohort study in The Netherlands</article-title><source>Infectious Diseases</source><volume>53</volume><fpage>102</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1080/23744235.2020.1839672</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keenan</surname><given-names>JD</given-names></name><name><surname>Klugman</surname><given-names>KP</given-names></name><name><surname>McGee</surname><given-names>L</given-names></name><name><surname>Vidal</surname><given-names>JE</given-names></name><name><surname>Chochua</surname><given-names>S</given-names></name><name><surname>Hawkins</surname><given-names>P</given-names></name><name><surname>Cevallos</surname><given-names>V</given-names></name><name><surname>Gebre</surname><given-names>T</given-names></name><name><surname>Tadesse</surname><given-names>Z</given-names></name><name><surname>Emerson</surname><given-names>PM</given-names></name><name><surname>Jorgensen</surname><given-names>JH</given-names></name><name><surname>Gaynor</surname><given-names>BD</given-names></name><name><surname>Lietman</surname><given-names>TM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Evidence for clonal expansion after antibiotic selection pressure: pneumococcal multilocus sequence types before and after mass azithromycin treatments</article-title><source>The Journal of Infectious Diseases</source><volume>211</volume><fpage>988</fpage><lpage>994</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiu552</pub-id><pub-id pub-id-type="pmid">25293366</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keenan</surname><given-names>JD</given-names></name><name><surname>Bailey</surname><given-names>RL</given-names></name><name><surname>West</surname><given-names>SK</given-names></name><name><surname>Arzika</surname><given-names>AM</given-names></name><name><surname>Hart</surname><given-names>J</given-names></name><name><surname>Weaver</surname><given-names>J</given-names></name><name><surname>Kalua</surname><given-names>K</given-names></name><name><surname>Mrango</surname><given-names>Z</given-names></name><name><surname>Ray</surname><given-names>KJ</given-names></name><name><surname>Cook</surname><given-names>C</given-names></name><name><surname>Lebas</surname><given-names>E</given-names></name><name><surname>O’Brien</surname><given-names>KS</given-names></name><name><surname>Emerson</surname><given-names>PM</given-names></name><name><surname>Porco</surname><given-names>TC</given-names></name><name><surname>Leitman</surname><given-names>TM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mass azithromycin distribution for reducing childhood mortality in sub-Saharan Africa</article-title><source>The New England Journal of Medicine</source><volume>378</volume><fpage>1583</fpage><lpage>1592</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1715474</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khouja</surname><given-names>T</given-names></name><name><surname>Mitsantisuk</surname><given-names>K</given-names></name><name><surname>Tadrous</surname><given-names>M</given-names></name><name><surname>Suda</surname><given-names>KJ</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Global consumption of antimicrobials: impact of the WHO Global Action Plan on Antimicrobial Resistance and 2019 coronavirus pandemic (COVID-19)</article-title><source>Journal of Antimicrobial Chemotherapy</source><volume>77</volume><fpage>1491</fpage><lpage>1499</lpage><pub-id pub-id-type="doi">10.1093/jac/dkac028</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knight</surname><given-names>GM</given-names></name><name><surname>Glover</surname><given-names>RE</given-names></name><name><surname>McQuaid</surname><given-names>CF</given-names></name><name><surname>Olaru</surname><given-names>ID</given-names></name><name><surname>Gallandat</surname><given-names>K</given-names></name><name><surname>Leclerc</surname><given-names>QJ</given-names></name><name><surname>Fuller</surname><given-names>NM</given-names></name><name><surname>Willcocks</surname><given-names>SJ</given-names></name><name><surname>Hasan</surname><given-names>R</given-names></name><name><surname>van Kleef</surname><given-names>E</given-names></name><name><surname>Chandler</surname><given-names>CI</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Antimicrobial resistance and COVID-19: Intersections and implications</article-title><source>eLife</source><volume>10</volume><elocation-id>e64139</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.64139</pub-id><pub-id pub-id-type="pmid">33588991</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kournoutou</surname><given-names>GG</given-names></name><name><surname>Dinos</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Azithromycin through the Lens of the COVID-19 Treatment</article-title><source>Antibiotics</source><volume>11</volume><elocation-id>1063</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics11081063</pub-id><pub-id pub-id-type="pmid">36009932</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Kovacevic</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>antibiotic_resistance</data-title><version designator="swh:1:rev:2e1a778298d23145d46d8d3f702a21ec16e57996">swh:1:rev:2e1a778298d23145d46d8d3f702a21ec16e57996</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:db75008f81b8b1494e623f024b566ddc0e59e4a0;origin=https://github.com/alekskovacevic/antibiotic_resistance;visit=swh:1:snp:3399afe72a09fca6904c379bf83475ddb356c27e;anchor=swh:1:rev:2e1a778298d23145d46d8d3f702a21ec16e57996">https://archive.softwareheritage.org/swh:1:dir:db75008f81b8b1494e623f024b566ddc0e59e4a0;origin=https://github.com/alekskovacevic/antibiotic_resistance;visit=swh:1:snp:3399afe72a09fca6904c379bf83475ddb356c27e;anchor=swh:1:rev:2e1a778298d23145d46d8d3f702a21ec16e57996</ext-link></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuitunen</surname><given-names>I</given-names></name><name><surname>Jääskeläinen</surname><given-names>J</given-names></name><name><surname>Korppi</surname><given-names>M</given-names></name><name><surname>Renko</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Antibiotic treatment duration for community-acquired pneumonia in outpatient children in high-income countries-a systematic review and meta-analysis</article-title><source>Clinical Infectious Diseases</source><volume>76</volume><fpage>e1123</fpage><lpage>e1128</lpage><pub-id pub-id-type="doi">10.1093/cid/ciac374</pub-id><pub-id pub-id-type="pmid">35579504</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langford</surname><given-names>BJ</given-names></name><name><surname>So</surname><given-names>M</given-names></name><name><surname>Raybardhan</surname><given-names>S</given-names></name><name><surname>Leung</surname><given-names>V</given-names></name><name><surname>Westwood</surname><given-names>D</given-names></name><name><surname>MacFadden</surname><given-names>DR</given-names></name><name><surname>Soucy</surname><given-names>JPR</given-names></name><name><surname>Daneman</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis</article-title><source>Clinical Microbiology and Infection</source><volume>26</volume><fpage>1622</fpage><lpage>1629</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2020.07.016</pub-id><pub-id pub-id-type="pmid">32711058</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langford</surname><given-names>BJ</given-names></name><name><surname>So</surname><given-names>M</given-names></name><name><surname>Raybardhan</surname><given-names>S</given-names></name><name><surname>Leung</surname><given-names>V</given-names></name><name><surname>Soucy</surname><given-names>JPR</given-names></name><name><surname>Westwood</surname><given-names>D</given-names></name><name><surname>Daneman</surname><given-names>N</given-names></name><name><surname>MacFadden</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis</article-title><source>Clinical Microbiology and Infection</source><volume>27</volume><fpage>520</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2020.12.018</pub-id><pub-id pub-id-type="pmid">33418017</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lauer</surname><given-names>SA</given-names></name><name><surname>Grantz</surname><given-names>KH</given-names></name><name><surname>Bi</surname><given-names>Q</given-names></name><name><surname>Jones</surname><given-names>FK</given-names></name><name><surname>Zheng</surname><given-names>Q</given-names></name><name><surname>Meredith</surname><given-names>HR</given-names></name><name><surname>Azman</surname><given-names>AS</given-names></name><name><surname>Reich</surname><given-names>NG</given-names></name><name><surname>Lessler</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The Incubation Period of Coronavirus Disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application</article-title><source>Annals of Internal Medicine</source><volume>172</volume><fpage>577</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.7326/M20-0504</pub-id><pub-id pub-id-type="pmid">32150748</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehtinen</surname><given-names>S</given-names></name><name><surname>Blanquart</surname><given-names>F</given-names></name><name><surname>Croucher</surname><given-names>NJ</given-names></name><name><surname>Turner</surname><given-names>P</given-names></name><name><surname>Lipsitch</surname><given-names>M</given-names></name><name><surname>Fraser</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Evolution of antibiotic resistance is linked to any genetic mechanism affecting bacterial duration of carriage</article-title><source>PNAS</source><volume>114</volume><fpage>1075</fpage><lpage>1080</lpage><pub-id pub-id-type="doi">10.1073/pnas.1617849114</pub-id><pub-id pub-id-type="pmid">28096340</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipsitch</surname><given-names>M</given-names></name><name><surname>Colijn</surname><given-names>C</given-names></name><name><surname>Cohen</surname><given-names>T</given-names></name><name><surname>Hanage</surname><given-names>WP</given-names></name><name><surname>Fraser</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>No coexistence for free: neutral null models for multistrain pathogens</article-title><source>Epidemics</source><volume>1</volume><fpage>2</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.epidem.2008.07.001</pub-id><pub-id pub-id-type="pmid">21352747</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Gayle</surname><given-names>AA</given-names></name><name><surname>Wilder-Smith</surname><given-names>A</given-names></name><name><surname>Rocklöv</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The reproductive number of COVID-19 is higher compared to SARS coronavirus</article-title><source>Journal of Travel Medicine</source><volume>27</volume><elocation-id>021</elocation-id><pub-id pub-id-type="doi">10.1093/jtm/taaa021</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malhotra-Kumar</surname><given-names>S</given-names></name><name><surname>Lammens</surname><given-names>C</given-names></name><name><surname>Coenen</surname><given-names>S</given-names></name><name><surname>Van Herck</surname><given-names>K</given-names></name><name><surname>Goossens</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study</article-title><source>The Lancet</source><volume>369</volume><fpage>482</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(07)60235-9</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mamun</surname><given-names>AA</given-names></name><name><surname>Saatchi</surname><given-names>A</given-names></name><name><surname>Xie</surname><given-names>M</given-names></name><name><surname>Lishman</surname><given-names>H</given-names></name><name><surname>Blondel-Hill</surname><given-names>E</given-names></name><name><surname>Marra</surname><given-names>F</given-names></name><name><surname>Patrick</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Community antibiotic use at the population level during the SARS-CoV-2 Pandemic in British Columbia, Canada</article-title><source>Open Forum Infectious Diseases</source><volume>8</volume><elocation-id>ofab185</elocation-id><pub-id pub-id-type="doi">10.1093/ofid/ofab185</pub-id><pub-id pub-id-type="pmid">34183981</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCullers</surname><given-names>JA</given-names></name><name><surname>McAuley</surname><given-names>JL</given-names></name><name><surname>Browall</surname><given-names>S</given-names></name><name><surname>Iverson</surname><given-names>AR</given-names></name><name><surname>Boyd</surname><given-names>KL</given-names></name><name><surname>Henriques Normark</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Influenza enhances susceptibility to natural acquisition of and disease due to Streptococcus pneumoniae in ferrets</article-title><source>The Journal of Infectious Diseases</source><volume>202</volume><fpage>1287</fpage><lpage>1295</lpage><pub-id pub-id-type="doi">10.1086/656333</pub-id><pub-id pub-id-type="pmid">20822454</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melegaro</surname><given-names>A</given-names></name><name><surname>Gay</surname><given-names>NJ</given-names></name><name><surname>Medley</surname><given-names>GF</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Estimating the transmission parameters of pneumococcal carriage in households</article-title><source>Epidemiology and Infection</source><volume>132</volume><fpage>433</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1017/s0950268804001980</pub-id><pub-id pub-id-type="pmid">15188713</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melnyk</surname><given-names>AH</given-names></name><name><surname>Wong</surname><given-names>A</given-names></name><name><surname>Kassen</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The fitness costs of antibiotic resistance mutations</article-title><source>Evolutionary Applications</source><volume>8</volume><fpage>273</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1111/eva.12196</pub-id><pub-id pub-id-type="pmid">25861385</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monnet</surname><given-names>DL</given-names></name><name><surname>Harbarth</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Will coronavirus disease (COVID-19) have an impact on antimicrobial resistance?</article-title><source>Euro Surveillance</source><volume>25</volume><elocation-id>2001886</elocation-id><pub-id pub-id-type="doi">10.2807/1560-7917.ES.2020.25.45.2001886</pub-id><pub-id pub-id-type="pmid">33183403</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulberry</surname><given-names>N</given-names></name><name><surname>Rutherford</surname><given-names>A</given-names></name><name><surname>Colijn</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Systematic comparison of coexistence in models of drug-sensitive and drug-resistant pathogen strains</article-title><source>Theoretical Population Biology</source><volume>133</volume><fpage>150</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1016/j.tpb.2019.12.001</pub-id><pub-id pub-id-type="pmid">31887315</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>CJL</given-names></name><name><surname>Ikuta</surname><given-names>KS</given-names></name><name><surname>Sharara</surname><given-names>F</given-names></name><name><surname>Swetschinski</surname><given-names>L</given-names></name><name><surname>Robles Aguilar</surname><given-names>G</given-names></name><name><surname>Gray</surname><given-names>A</given-names></name><name><surname>Han</surname><given-names>C</given-names></name><name><surname>Bisignano</surname><given-names>C</given-names></name><name><surname>Rao</surname><given-names>P</given-names></name><name><surname>Wool</surname><given-names>E</given-names></name><name><surname>Johnson</surname><given-names>SC</given-names></name><name><surname>Browne</surname><given-names>AJ</given-names></name><name><surname>Chipeta</surname><given-names>MG</given-names></name><name><surname>Fell</surname><given-names>F</given-names></name><name><surname>Hackett</surname><given-names>S</given-names></name><name><surname>Haines-Woodhouse</surname><given-names>G</given-names></name><name><surname>Kashef Hamadani</surname><given-names>BH</given-names></name><name><surname>Kumaran</surname><given-names>EAP</given-names></name><name><surname>McManigal</surname><given-names>B</given-names></name><name><surname>Achalapong</surname><given-names>S</given-names></name><name><surname>Agarwal</surname><given-names>R</given-names></name><name><surname>Akech</surname><given-names>S</given-names></name><name><surname>Albertson</surname><given-names>S</given-names></name><name><surname>Amuasi</surname><given-names>J</given-names></name><name><surname>Andrews</surname><given-names>J</given-names></name><name><surname>Aravkin</surname><given-names>A</given-names></name><name><surname>Ashley</surname><given-names>E</given-names></name><name><surname>Babin</surname><given-names>F-X</given-names></name><name><surname>Bailey</surname><given-names>F</given-names></name><name><surname>Baker</surname><given-names>S</given-names></name><name><surname>Basnyat</surname><given-names>B</given-names></name><name><surname>Bekker</surname><given-names>A</given-names></name><name><surname>Bender</surname><given-names>R</given-names></name><name><surname>Berkley</surname><given-names>JA</given-names></name><name><surname>Bethou</surname><given-names>A</given-names></name><name><surname>Bielicki</surname><given-names>J</given-names></name><name><surname>Boonkasidecha</surname><given-names>S</given-names></name><name><surname>Bukosia</surname><given-names>J</given-names></name><name><surname>Carvalheiro</surname><given-names>C</given-names></name><name><surname>Castañeda-Orjuela</surname><given-names>C</given-names></name><name><surname>Chansamouth</surname><given-names>V</given-names></name><name><surname>Chaurasia</surname><given-names>S</given-names></name><name><surname>Chiurchiù</surname><given-names>S</given-names></name><name><surname>Chowdhury</surname><given-names>F</given-names></name><name><surname>Clotaire Donatien</surname><given-names>R</given-names></name><name><surname>Cook</surname><given-names>AJ</given-names></name><name><surname>Cooper</surname><given-names>B</given-names></name><name><surname>Cressey</surname><given-names>TR</given-names></name><name><surname>Criollo-Mora</surname><given-names>E</given-names></name><name><surname>Cunningham</surname><given-names>M</given-names></name><name><surname>Darboe</surname><given-names>S</given-names></name><name><surname>Day</surname><given-names>NPJ</given-names></name><name><surname>De Luca</surname><given-names>M</given-names></name><name><surname>Dokova</surname><given-names>K</given-names></name><name><surname>Dramowski</surname><given-names>A</given-names></name><name><surname>Dunachie</surname><given-names>SJ</given-names></name><name><surname>Duong Bich</surname><given-names>T</given-names></name><name><surname>Eckmanns</surname><given-names>T</given-names></name><name><surname>Eibach</surname><given-names>D</given-names></name><name><surname>Emami</surname><given-names>A</given-names></name><name><surname>Feasey</surname><given-names>N</given-names></name><name><surname>Fisher-Pearson</surname><given-names>N</given-names></name><name><surname>Forrest</surname><given-names>K</given-names></name><name><surname>Garcia</surname><given-names>C</given-names></name><name><surname>Garrett</surname><given-names>D</given-names></name><name><surname>Gastmeier</surname><given-names>P</given-names></name><name><surname>Giref</surname><given-names>AZ</given-names></name><name><surname>Greer</surname><given-names>RC</given-names></name><name><surname>Gupta</surname><given-names>V</given-names></name><name><surname>Haller</surname><given-names>S</given-names></name><name><surname>Haselbeck</surname><given-names>A</given-names></name><name><surname>Hay</surname><given-names>SI</given-names></name><name><surname>Holm</surname><given-names>M</given-names></name><name><surname>Hopkins</surname><given-names>S</given-names></name><name><surname>Hsia</surname><given-names>Y</given-names></name><name><surname>Iregbu</surname><given-names>KC</given-names></name><name><surname>Jacobs</surname><given-names>J</given-names></name><name><surname>Jarovsky</surname><given-names>D</given-names></name><name><surname>Javanmardi</surname><given-names>F</given-names></name><name><surname>Jenney</surname><given-names>AWJ</given-names></name><name><surname>Khorana</surname><given-names>M</given-names></name><name><surname>Khusuwan</surname><given-names>S</given-names></name><name><surname>Kissoon</surname><given-names>N</given-names></name><name><surname>Kobeissi</surname><given-names>E</given-names></name><name><surname>Kostyanev</surname><given-names>T</given-names></name><name><surname>Krapp</surname><given-names>F</given-names></name><name><surname>Krumkamp</surname><given-names>R</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Kyu</surname><given-names>HH</given-names></name><name><surname>Lim</surname><given-names>C</given-names></name><name><surname>Lim</surname><given-names>K</given-names></name><name><surname>Limmathurotsakul</surname><given-names>D</given-names></name><name><surname>Loftus</surname><given-names>MJ</given-names></name><name><surname>Lunn</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Manoharan</surname><given-names>A</given-names></name><name><surname>Marks</surname><given-names>F</given-names></name><name><surname>May</surname><given-names>J</given-names></name><name><surname>Mayxay</surname><given-names>M</given-names></name><name><surname>Mturi</surname><given-names>N</given-names></name><name><surname>Munera-Huertas</surname><given-names>T</given-names></name><name><surname>Musicha</surname><given-names>P</given-names></name><name><surname>Musila</surname><given-names>LA</given-names></name><name><surname>Mussi-Pinhata</surname><given-names>MM</given-names></name><name><surname>Naidu</surname><given-names>RN</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Nanavati</surname><given-names>R</given-names></name><name><surname>Nangia</surname><given-names>S</given-names></name><name><surname>Newton</surname><given-names>P</given-names></name><name><surname>Ngoun</surname><given-names>C</given-names></name><name><surname>Novotney</surname><given-names>A</given-names></name><name><surname>Nwakanma</surname><given-names>D</given-names></name><name><surname>Obiero</surname><given-names>CW</given-names></name><name><surname>Ochoa</surname><given-names>TJ</given-names></name><name><surname>Olivas-Martinez</surname><given-names>A</given-names></name><name><surname>Olliaro</surname><given-names>P</given-names></name><name><surname>Ooko</surname><given-names>E</given-names></name><name><surname>Ortiz-Brizuela</surname><given-names>E</given-names></name><name><surname>Ounchanum</surname><given-names>P</given-names></name><name><surname>Pak</surname><given-names>GD</given-names></name><name><surname>Paredes</surname><given-names>JL</given-names></name><name><surname>Peleg</surname><given-names>AY</given-names></name><name><surname>Perrone</surname><given-names>C</given-names></name><name><surname>Phe</surname><given-names>T</given-names></name><name><surname>Phommasone</surname><given-names>K</given-names></name><name><surname>Plakkal</surname><given-names>N</given-names></name><name><surname>Ponce-de-Leon</surname><given-names>A</given-names></name><name><surname>Raad</surname><given-names>M</given-names></name><name><surname>Ramdin</surname><given-names>T</given-names></name><name><surname>Rattanavong</surname><given-names>S</given-names></name><name><surname>Riddell</surname><given-names>A</given-names></name><name><surname>Roberts</surname><given-names>T</given-names></name><name><surname>Robotham</surname><given-names>JV</given-names></name><name><surname>Roca</surname><given-names>A</given-names></name><name><surname>Rosenthal</surname><given-names>VD</given-names></name><name><surname>Rudd</surname><given-names>KE</given-names></name><name><surname>Russell</surname><given-names>N</given-names></name><name><surname>Sader</surname><given-names>HS</given-names></name><name><surname>Saengchan</surname><given-names>W</given-names></name><name><surname>Schnall</surname><given-names>J</given-names></name><name><surname>Scott</surname><given-names>JAG</given-names></name><name><surname>Seekaew</surname><given-names>S</given-names></name><name><surname>Sharland</surname><given-names>M</given-names></name><name><surname>Shivamallappa</surname><given-names>M</given-names></name><name><surname>Sifuentes-Osornio</surname><given-names>J</given-names></name><name><surname>Simpson</surname><given-names>AJ</given-names></name><name><surname>Steenkeste</surname><given-names>N</given-names></name><name><surname>Stewardson</surname><given-names>AJ</given-names></name><name><surname>Stoeva</surname><given-names>T</given-names></name><name><surname>Tasak</surname><given-names>N</given-names></name><name><surname>Thaiprakong</surname><given-names>A</given-names></name><name><surname>Thwaites</surname><given-names>G</given-names></name><name><surname>Tigoi</surname><given-names>C</given-names></name><name><surname>Turner</surname><given-names>C</given-names></name><name><surname>Turner</surname><given-names>P</given-names></name><name><surname>van Doorn</surname><given-names>HR</given-names></name><name><surname>Velaphi</surname><given-names>S</given-names></name><name><surname>Vongpradith</surname><given-names>A</given-names></name><name><surname>Vongsouvath</surname><given-names>M</given-names></name><name><surname>Vu</surname><given-names>H</given-names></name><name><surname>Walsh</surname><given-names>T</given-names></name><name><surname>Walson</surname><given-names>JL</given-names></name><name><surname>Waner</surname><given-names>S</given-names></name><name><surname>Wangrangsimakul</surname><given-names>T</given-names></name><name><surname>Wannapinij</surname><given-names>P</given-names></name><name><surname>Wozniak</surname><given-names>T</given-names></name><name><surname>Young Sharma</surname><given-names>TEMW</given-names></name><name><surname>Yu</surname><given-names>KC</given-names></name><name><surname>Zheng</surname><given-names>P</given-names></name><name><surname>Sartorius</surname><given-names>B</given-names></name><name><surname>Lopez</surname><given-names>AD</given-names></name><name><surname>Stergachis</surname><given-names>A</given-names></name><name><surname>Moore</surname><given-names>C</given-names></name><name><surname>Dolecek</surname><given-names>C</given-names></name><name><surname>Naghavi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis</article-title><source>The Lancet</source><volume>399</volume><fpage>629</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)02724-0</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nandi</surname><given-names>A</given-names></name><name><surname>Pecetta</surname><given-names>S</given-names></name><name><surname>Bloom</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Global antibiotic use during the COVID-19 pandemic: analysis of pharmaceutical sales data from 71 countries, 2020–2022</article-title><source>eClinicalMedicine</source><volume>57</volume><elocation-id>101848</elocation-id><pub-id pub-id-type="doi">10.1016/j.eclinm.2023.101848</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nation</surname><given-names>ML</given-names></name><name><surname>Manna</surname><given-names>S</given-names></name><name><surname>Tran</surname><given-names>HP</given-names></name><name><surname>Nguyen</surname><given-names>CD</given-names></name><name><surname>Vy</surname><given-names>LTT</given-names></name><name><surname>Uyen</surname><given-names>DY</given-names></name><name><surname>Phuong</surname><given-names>TL</given-names></name><name><surname>Dai</surname><given-names>VTT</given-names></name><name><surname>Ortika</surname><given-names>BD</given-names></name><name><surname>Wee-Hee</surname><given-names>AC</given-names></name><name><surname>Beissbarth</surname><given-names>J</given-names></name><name><surname>Hinds</surname><given-names>J</given-names></name><name><surname>Bright</surname><given-names>K</given-names></name><name><surname>Smith-Vaughan</surname><given-names>H</given-names></name><name><surname>Nguyen</surname><given-names>TV</given-names></name><name><surname>Mulholland</surname><given-names>K</given-names></name><name><surname>Temple</surname><given-names>B</given-names></name><name><surname>Satzke</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Impact of COVID-19 Nonpharmaceutical Interventions on Pneumococcal Carriage Prevalence and Density in Vietnam</article-title><source>Microbiology Spectrum</source><volume>11</volume><elocation-id>e0361522</elocation-id><pub-id pub-id-type="doi">10.1128/spectrum.03615-22</pub-id><pub-id pub-id-type="pmid">36645282</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olesen</surname><given-names>SW</given-names></name><name><surname>Lipsitch</surname><given-names>M</given-names></name><name><surname>Grad</surname><given-names>YH</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The role of “spillover” in antibiotic resistance</article-title><source>PNAS</source><volume>117</volume><fpage>29063</fpage><lpage>29068</lpage><pub-id pub-id-type="doi">10.1073/pnas.2013694117</pub-id><pub-id pub-id-type="pmid">33139558</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olwagen</surname><given-names>CP</given-names></name><name><surname>Downs</surname><given-names>SL</given-names></name><name><surname>Izu</surname><given-names>A</given-names></name><name><surname>Tharasimbi</surname><given-names>L</given-names></name><name><surname>Van Der Merwe</surname><given-names>L</given-names></name><name><surname>Nunes</surname><given-names>MC</given-names></name><name><surname>Madhi</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Bacterial nasopharyngeal colonisation in children in South Africa before and during the COVID-19 pandemic: an observational study</article-title><source>The Lancet. Microbe</source><volume>5</volume><fpage>e34</fpage><lpage>e42</lpage><pub-id pub-id-type="doi">10.1016/S2666-5247(23)00260-4</pub-id><pub-id pub-id-type="pmid">38048806</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Opatowski</surname><given-names>L</given-names></name><name><surname>Varon</surname><given-names>E</given-names></name><name><surname>Dupont</surname><given-names>C</given-names></name><name><surname>Temime</surname><given-names>L</given-names></name><name><surname>van der Werf</surname><given-names>S</given-names></name><name><surname>Gutmann</surname><given-names>L</given-names></name><name><surname>Boëlle</surname><given-names>P-Y</given-names></name><name><surname>Watier</surname><given-names>L</given-names></name><name><surname>Guillemot</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Assessing pneumococcal meningitis association with viral respiratory infections and antibiotics: insights from statistical and mathematical models</article-title><source>Proceedings of the Royal Society B</source><volume>280</volume><elocation-id>20130519</elocation-id><pub-id pub-id-type="doi">10.1098/rspb.2013.0519</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palmer</surname><given-names>K</given-names></name><name><surname>Monaco</surname><given-names>A</given-names></name><name><surname>Kivipelto</surname><given-names>M</given-names></name><name><surname>Onder</surname><given-names>G</given-names></name><name><surname>Maggi</surname><given-names>S</given-names></name><name><surname>Michel</surname><given-names>JP</given-names></name><name><surname>Prieto</surname><given-names>R</given-names></name><name><surname>Sykara</surname><given-names>G</given-names></name><name><surname>Donde</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The potential long-term impact of the COVID-19 outbreak on patients with non-communicable diseases in Europe: consequences for healthy ageing</article-title><source>Aging Clinical and Experimental Research</source><volume>32</volume><fpage>1189</fpage><lpage>1194</lpage><pub-id pub-id-type="doi">10.1007/s40520-020-01601-4</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parveen</surname><given-names>M</given-names></name><name><surname>Molla</surname><given-names>MMA</given-names></name><name><surname>Yeasmin</surname><given-names>M</given-names></name><name><surname>Nafisa</surname><given-names>T</given-names></name><name><surname>Barna</surname><given-names>AA</given-names></name><name><surname>Ghosh</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Evidences on Irrational anti-microbial prescribing and consumption among COVID-19 positive patients and possible mitigation strategies: a descriptive cross sectional study</article-title><source>Bangladesh Journal of Infectious Diseases</source><volume>7</volume><fpage>S3</fpage><lpage>S7</lpage><pub-id pub-id-type="doi">10.3329/bjid.v7i00.50155</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrović</surname><given-names>V</given-names></name><name><surname>Milosavljević</surname><given-names>B</given-names></name><name><surname>Djilas</surname><given-names>M</given-names></name><name><surname>Marković</surname><given-names>M</given-names></name><name><surname>Vuković</surname><given-names>V</given-names></name><name><surname>Andrijević</surname><given-names>I</given-names></name><name><surname>Ristić</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Pneumococcal nasopharyngeal carriage in children under 5 years of age at an outpatient healthcare facility in Novi Sad, Serbia during the COVID-19 pandemic</article-title><source>IJID Regions</source><volume>4</volume><fpage>88</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/j.ijregi.2022.07.001</pub-id><pub-id pub-id-type="pmid">35865274</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>PRINCIPLE Trial Collaborative Group</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial</article-title><source>Lancet</source><volume>397</volume><fpage>1063</fpage><lpage>1074</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)00461-X</pub-id><pub-id pub-id-type="pmid">33676597</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Read</surname><given-names>B</given-names></name><name><surname>McLeod</surname><given-names>M</given-names></name><name><surname>Tonkin-Crine</surname><given-names>S</given-names></name><name><surname>Ashiru-Oredope</surname><given-names>D</given-names></name><name><surname>Quigley</surname><given-names>A</given-names></name><name><surname>Brown</surname><given-names>CS</given-names></name><name><surname>Lecky</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Changes in public health-seeking behaviours for self-limiting respiratory tract infections across England during the COVID-19 pandemic</article-title><source>European Journal of Public Health</source><volume>33</volume><fpage>987</fpage><lpage>993</lpage><pub-id pub-id-type="doi">10.1093/eurpub/ckad136</pub-id><pub-id pub-id-type="pmid">37561411</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rebelo</surname><given-names>JS</given-names></name><name><surname>Domingues</surname><given-names>CPF</given-names></name><name><surname>Dionisio</surname><given-names>F</given-names></name><name><surname>Gomes</surname><given-names>MC</given-names></name><name><surname>Botelho</surname><given-names>A</given-names></name><name><surname>Nogueira</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>COVID-19 lockdowns may reduce resistance genes diversity in the human microbiome and the need for antibiotics</article-title><source>International Journal of Molecular Sciences</source><volume>22</volume><elocation-id>6891</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22136891</pub-id><pub-id pub-id-type="pmid">34206965</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhee</surname><given-names>C</given-names></name><name><surname>Baker</surname><given-names>M</given-names></name><name><surname>Vaidya</surname><given-names>V</given-names></name><name><surname>Tucker</surname><given-names>R</given-names></name><name><surname>Resnick</surname><given-names>A</given-names></name><name><surname>Morris</surname><given-names>CA</given-names></name><name><surname>Klompas</surname><given-names>M</given-names></name><collab>CDC Prevention Epicenters Program</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Incidence of Nosocomial COVID-19 in patients hospitalized at a large us academic medical center</article-title><source>JAMA Network Open</source><volume>3</volume><elocation-id>e2020498</elocation-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.20498</pub-id><pub-id pub-id-type="pmid">32902653</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rose</surname><given-names>MA</given-names></name><name><surname>Laurenz</surname><given-names>M</given-names></name><name><surname>Sprenger</surname><given-names>R</given-names></name><name><surname>Imöhl</surname><given-names>M</given-names></name><name><surname>van der Linden</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>nasopharyngeal carriage in children after the introduction of generalized infant pneumococcal conjugate vaccine immunization in Germany</article-title><source>Frontiers in Medicine</source><volume>8</volume><elocation-id>719481</elocation-id><pub-id pub-id-type="doi">10.3389/fmed.2021.719481</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Roux</surname><given-names>J</given-names></name><name><surname>Massonnaud</surname><given-names>C</given-names></name><name><surname>Crépey</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>COVID-19: One-Month Impact of the French Lockdown on the Epidemic Burden</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2020.04.22.20075705</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rusic</surname><given-names>D</given-names></name><name><surname>Vilovic</surname><given-names>M</given-names></name><name><surname>Bukic</surname><given-names>J</given-names></name><name><surname>Leskur</surname><given-names>D</given-names></name><name><surname>Seselja Perisin</surname><given-names>A</given-names></name><name><surname>Kumric</surname><given-names>M</given-names></name><name><surname>Martinovic</surname><given-names>D</given-names></name><name><surname>Petric</surname><given-names>A</given-names></name><name><surname>Modun</surname><given-names>D</given-names></name><name><surname>Bozic</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Implications of COVID-19 Pandemic on the Emergence of Antimicrobial Resistance: Adjusting the Response to Future Outbreaks</article-title><source>Life</source><volume>11</volume><elocation-id>220</elocation-id><pub-id pub-id-type="doi">10.3390/life11030220</pub-id><pub-id pub-id-type="pmid">33801799</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rybak</surname><given-names>A</given-names></name><name><surname>Levy</surname><given-names>C</given-names></name><name><surname>Angoulvant</surname><given-names>F</given-names></name><name><surname>Auvrignon</surname><given-names>A</given-names></name><name><surname>Gembara</surname><given-names>P</given-names></name><name><surname>Danis</surname><given-names>K</given-names></name><name><surname>Vaux</surname><given-names>S</given-names></name><name><surname>Levy-Bruhl</surname><given-names>D</given-names></name><name><surname>van der Werf</surname><given-names>S</given-names></name><name><surname>Béchet</surname><given-names>S</given-names></name><name><surname>Bonacorsi</surname><given-names>S</given-names></name><name><surname>Assad</surname><given-names>Z</given-names></name><name><surname>Lazzati</surname><given-names>A</given-names></name><name><surname>Michel</surname><given-names>M</given-names></name><name><surname>Kaguelidou</surname><given-names>F</given-names></name><name><surname>Faye</surname><given-names>A</given-names></name><name><surname>Cohen</surname><given-names>R</given-names></name><name><surname>Varon</surname><given-names>E</given-names></name><name><surname>Ouldali</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>association of nonpharmaceutical interventions during the COVID-19 pandemic with invasive pneumococcal disease, pneumococcal carriage, and respiratory viral Infections among children in france</article-title><source>JAMA Network Open</source><volume>5</volume><elocation-id>e2218959</elocation-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.18959</pub-id><pub-id pub-id-type="pmid">35763298</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryu</surname><given-names>S</given-names></name><name><surname>Hwang</surname><given-names>Y</given-names></name><name><surname>Ali</surname><given-names>ST</given-names></name><name><surname>Kim</surname><given-names>DS</given-names></name><name><surname>Klein</surname><given-names>EY</given-names></name><name><surname>Lau</surname><given-names>EHY</given-names></name><name><surname>Cowling</surname><given-names>BJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Decreased use of broad-spectrum antibiotics during the coronavirus disease 2019 epidemic in South Korea</article-title><source>The Journal of Infectious Diseases</source><volume>224</volume><fpage>949</fpage><lpage>955</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiab208</pub-id><pub-id pub-id-type="pmid">33856455</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salje</surname><given-names>H</given-names></name><name><surname>Tran Kiem</surname><given-names>C</given-names></name><name><surname>Lefrancq</surname><given-names>N</given-names></name><name><surname>Courtejoie</surname><given-names>N</given-names></name><name><surname>Bosetti</surname><given-names>P</given-names></name><name><surname>Paireau</surname><given-names>J</given-names></name><name><surname>Andronico</surname><given-names>A</given-names></name><name><surname>Hozé</surname><given-names>N</given-names></name><name><surname>Richet</surname><given-names>J</given-names></name><name><surname>Dubost</surname><given-names>CL</given-names></name><name><surname>Le Strat</surname><given-names>Y</given-names></name><name><surname>Lessler</surname><given-names>J</given-names></name><name><surname>Levy-Bruhl</surname><given-names>D</given-names></name><name><surname>Fontanet</surname><given-names>A</given-names></name><name><surname>Opatowski</surname><given-names>L</given-names></name><name><surname>Boelle</surname><given-names>PY</given-names></name><name><surname>Cauchemez</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Estimating the burden of SARS-CoV-2 in France</article-title><source>Science</source><volume>369</volume><fpage>208</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1126/science.abc3517</pub-id><pub-id pub-id-type="pmid">32404476</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seaton</surname><given-names>RA</given-names></name><name><surname>Gibbons</surname><given-names>CL</given-names></name><name><surname>Cooper</surname><given-names>L</given-names></name><name><surname>Malcolm</surname><given-names>W</given-names></name><name><surname>McKinney</surname><given-names>R</given-names></name><name><surname>Dundas</surname><given-names>S</given-names></name><name><surname>Griffith</surname><given-names>D</given-names></name><name><surname>Jeffreys</surname><given-names>D</given-names></name><name><surname>Hamilton</surname><given-names>K</given-names></name><name><surname>Choo-Kang</surname><given-names>B</given-names></name><name><surname>Brittain</surname><given-names>S</given-names></name><name><surname>Guthrie</surname><given-names>D</given-names></name><name><surname>Sneddon</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Survey of antibiotic and antifungal prescribing in patients with suspected and confirmed COVID-19 in Scottish hospitals</article-title><source>The Journal of Infection</source><volume>81</volume><fpage>952</fpage><lpage>960</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2020.09.024</pub-id><pub-id pub-id-type="pmid">32987097</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sender</surname><given-names>V</given-names></name><name><surname>Hentrich</surname><given-names>K</given-names></name><name><surname>Henriques-Normark</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>virus-induced changes of the respiratory tract environment promote secondary infections with <italic>Streptococcus pneumoniae</italic></article-title><source>Frontiers in Cellular and Infection Microbiology</source><volume>11</volume><elocation-id>643326</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2021.643326</pub-id><pub-id pub-id-type="pmid">33828999</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>D</given-names></name><name><surname>Abad</surname><given-names>R</given-names></name><name><surname>Amin-Chowdhury</surname><given-names>Z</given-names></name><name><surname>Bautista</surname><given-names>A</given-names></name><name><surname>Bennett</surname><given-names>D</given-names></name><name><surname>Broughton</surname><given-names>K</given-names></name><name><surname>Cao</surname><given-names>B</given-names></name><name><surname>Casanova</surname><given-names>C</given-names></name><name><surname>Choi</surname><given-names>EH</given-names></name><name><surname>Chu</surname><given-names>Y-W</given-names></name><name><surname>Claus</surname><given-names>H</given-names></name><name><surname>Coelho</surname><given-names>J</given-names></name><name><surname>Corcoran</surname><given-names>M</given-names></name><name><surname>Cottrell</surname><given-names>S</given-names></name><name><surname>Cunney</surname><given-names>R</given-names></name><name><surname>Cuypers</surname><given-names>L</given-names></name><name><surname>Dalby</surname><given-names>T</given-names></name><name><surname>Davies</surname><given-names>H</given-names></name><name><surname>de Gouveia</surname><given-names>L</given-names></name><name><surname>Deghmane</surname><given-names>A-E</given-names></name><name><surname>Demczuk</surname><given-names>W</given-names></name><name><surname>Desmet</surname><given-names>S</given-names></name><name><surname>Domenech</surname><given-names>M</given-names></name><name><surname>Drew</surname><given-names>R</given-names></name><name><surname>du Plessis</surname><given-names>M</given-names></name><name><surname>Duarte</surname><given-names>C</given-names></name><name><surname>Erlendsdóttir</surname><given-names>H</given-names></name><name><surname>Fry</surname><given-names>NK</given-names></name><name><surname>Fuursted</surname><given-names>K</given-names></name><name><surname>Hale</surname><given-names>T</given-names></name><name><surname>Henares</surname><given-names>D</given-names></name><name><surname>Henriques-Normark</surname><given-names>B</given-names></name><name><surname>Hilty</surname><given-names>M</given-names></name><name><surname>Hoffmann</surname><given-names>S</given-names></name><name><surname>Humphreys</surname><given-names>H</given-names></name><name><surname>Ip</surname><given-names>M</given-names></name><name><surname>Jacobsson</surname><given-names>S</given-names></name><name><surname>Johnson</surname><given-names>C</given-names></name><name><surname>Johnston</surname><given-names>J</given-names></name><name><surname>Jolley</surname><given-names>KA</given-names></name><name><surname>Kawabata</surname><given-names>A</given-names></name><name><surname>Kozakova</surname><given-names>J</given-names></name><name><surname>Kristinsson</surname><given-names>KG</given-names></name><name><surname>Krizova</surname><given-names>P</given-names></name><name><surname>Kuch</surname><given-names>A</given-names></name><name><surname>Ladhani</surname><given-names>S</given-names></name><name><surname>Lâm</surname><given-names>T-T</given-names></name><name><surname>León</surname><given-names>ME</given-names></name><name><surname>Lindholm</surname><given-names>L</given-names></name><name><surname>Litt</surname><given-names>D</given-names></name><name><surname>Maiden</surname><given-names>MCJ</given-names></name><name><surname>Martin</surname><given-names>I</given-names></name><name><surname>Martiny</surname><given-names>D</given-names></name><name><surname>Mattheus</surname><given-names>W</given-names></name><name><surname>McCarthy</surname><given-names>ND</given-names></name><name><surname>Meehan</surname><given-names>M</given-names></name><name><surname>Meiring</surname><given-names>S</given-names></name><name><surname>Mölling</surname><given-names>P</given-names></name><name><surname>Morfeldt</surname><given-names>E</given-names></name><name><surname>Morgan</surname><given-names>J</given-names></name><name><surname>Mulhall</surname><given-names>R</given-names></name><name><surname>Muñoz-Almagro</surname><given-names>C</given-names></name><name><surname>Murdoch</surname><given-names>D</given-names></name><name><surname>Murphy</surname><given-names>J</given-names></name><name><surname>Musilek</surname><given-names>M</given-names></name><name><surname>Mzabi</surname><given-names>A</given-names></name><name><surname>Novakova</surname><given-names>L</given-names></name><name><surname>Oftadeh</surname><given-names>S</given-names></name><name><surname>Perez-Argüello</surname><given-names>A</given-names></name><name><surname>Pérez-Vázquez</surname><given-names>M</given-names></name><name><surname>Perrin</surname><given-names>M</given-names></name><name><surname>Perry</surname><given-names>M</given-names></name><name><surname>Prevost</surname><given-names>B</given-names></name><name><surname>Roberts</surname><given-names>M</given-names></name><name><surname>Rokney</surname><given-names>A</given-names></name><name><surname>Ron</surname><given-names>M</given-names></name><name><surname>Sanabria</surname><given-names>OM</given-names></name><name><surname>Scott</surname><given-names>KJ</given-names></name><name><surname>Sheppard</surname><given-names>C</given-names></name><name><surname>Siira</surname><given-names>L</given-names></name><name><surname>Sintchenko</surname><given-names>V</given-names></name><name><surname>Skoczyńska</surname><given-names>A</given-names></name><name><surname>Sloan</surname><given-names>M</given-names></name><name><surname>Slotved</surname><given-names>H-C</given-names></name><name><surname>Smith</surname><given-names>AJ</given-names></name><name><surname>Steens</surname><given-names>A</given-names></name><name><surname>Taha</surname><given-names>M-K</given-names></name><name><surname>Toropainen</surname><given-names>M</given-names></name><name><surname>Tzanakaki</surname><given-names>G</given-names></name><name><surname>Vainio</surname><given-names>A</given-names></name><name><surname>van der Linden</surname><given-names>MPG</given-names></name><name><surname>van Sorge</surname><given-names>NM</given-names></name><name><surname>Varon</surname><given-names>E</given-names></name><name><surname>Vohrnova</surname><given-names>S</given-names></name><name><surname>von Gottberg</surname><given-names>A</given-names></name><name><surname>Yuste</surname><given-names>J</given-names></name><name><surname>Zanella</surname><given-names>R</given-names></name><name><surname>Zhou</surname><given-names>F</given-names></name><name><surname>Brueggemann</surname><given-names>AB</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Trends in invasive bacterial diseases during the first 2 years of the COVID-19 pandemic: analyses of prospective surveillance data from 30 countries and territories in the IRIS Consortium</article-title><source>The Lancet Digital Health</source><volume>5</volume><fpage>e582</fpage><lpage>e593</lpage><pub-id pub-id-type="doi">10.1016/S2589-7500(23)00108-5</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Short</surname><given-names>KR</given-names></name><name><surname>Reading</surname><given-names>PC</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Diavatopoulos</surname><given-names>DA</given-names></name><name><surname>Wijburg</surname><given-names>OL</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Increased nasopharyngeal bacterial titers and local inflammation facilitate transmission of Streptococcus pneumoniae</article-title><source>mBio</source><volume>3</volume><elocation-id>e00255-12</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.00255-12</pub-id><pub-id pub-id-type="pmid">23015738</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shrestha</surname><given-names>S</given-names></name><name><surname>Foxman</surname><given-names>B</given-names></name><name><surname>Dawid</surname><given-names>S</given-names></name><name><surname>Aiello</surname><given-names>AE</given-names></name><name><surname>Davis</surname><given-names>BM</given-names></name><name><surname>Berus</surname><given-names>J</given-names></name><name><surname>Rohani</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Time and dose-dependent risk of pneumococcal pneumonia following influenza: a model for within-host interaction between influenza and <italic>Streptococcus pneumoniae</italic></article-title><source>Journal of The Royal Society Interface</source><volume>10</volume><elocation-id>20130233</elocation-id><pub-id pub-id-type="doi">10.1098/rsif.2013.0233</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>DRM</given-names></name><name><surname>Opatowski</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>COVID-19 containment measures and incidence of invasive bacterial disease</article-title><source>The Lancet. Digital Health</source><volume>3</volume><fpage>e331</fpage><lpage>e332</lpage><pub-id pub-id-type="doi">10.1016/S2589-7500(21)00085-6</pub-id><pub-id pub-id-type="pmid">34044998</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>DRM</given-names></name><name><surname>Shirreff</surname><given-names>G</given-names></name><name><surname>Temime</surname><given-names>L</given-names></name><name><surname>Opatowski</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Collateral impacts of pandemic COVID-19 drive the nosocomial spread of antibiotic resistance: A modelling study</article-title><source>PLOS Medicine</source><volume>20</volume><elocation-id>e1004240</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pmed.1004240</pub-id><pub-id pub-id-type="pmid">37276186</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soetaert</surname><given-names>K</given-names></name><name><surname>Petzoldt</surname><given-names>T</given-names></name><name><surname>Setzer</surname><given-names>RW</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Solving differential equations in R: package deSolve</article-title><source>Journal of Statistical Software</source><volume>33</volume><fpage>1</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.18637/jss.v033.i09</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teng</surname><given-names>JLL</given-names></name><name><surname>Fok</surname><given-names>KMN</given-names></name><name><surname>Lin</surname><given-names>KPK</given-names></name><name><surname>Chan</surname><given-names>E</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Lau</surname><given-names>SKP</given-names></name><name><surname>Woo</surname><given-names>PCY</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Substantial decline in invasive pneumococcal disease during coronavirus disease 2019 pandemic in Hong Kong</article-title><source>Clinical Infectious Diseases</source><volume>74</volume><fpage>335</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1093/cid/ciab382</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tinggaard</surname><given-names>M</given-names></name><name><surname>Slotved</surname><given-names>HC</given-names></name><name><surname>Petersen</surname><given-names>RF</given-names></name><name><surname>Hovmand</surname><given-names>N</given-names></name><name><surname>Benfield</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Decreased Pneumococcal carriage among older adults in denmark during the COVID-19 Lockdown</article-title><source>Open Forum Infectious Diseases</source><volume>10</volume><elocation-id>ofad365</elocation-id><pub-id pub-id-type="doi">10.1093/ofid/ofad365</pub-id><pub-id pub-id-type="pmid">37559754</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsay</surname><given-names>SV</given-names></name><name><surname>Bartoces</surname><given-names>M</given-names></name><name><surname>Gouin</surname><given-names>K</given-names></name><name><surname>Kabbani</surname><given-names>S</given-names></name><name><surname>Hicks</surname><given-names>LA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Antibiotic Prescriptions Associated With COVID-19 Outpatient Visits Among Medicare Beneficiaries, April 2020 to April 2021</article-title><source>JAMA</source><volume>327</volume><fpage>2018</fpage><lpage>2019</lpage><pub-id pub-id-type="doi">10.1001/jama.2022.5471</pub-id><pub-id pub-id-type="pmid">35394497</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Laethem</surname><given-names>J</given-names></name><name><surname>Wuyts</surname><given-names>S</given-names></name><name><surname>Van Laere</surname><given-names>S</given-names></name><name><surname>Dirkx</surname><given-names>S</given-names></name><name><surname>Seyler</surname><given-names>L</given-names></name><name><surname>Mertens</surname><given-names>R</given-names></name><name><surname>Ilsen</surname><given-names>B</given-names></name><name><surname>Lacor</surname><given-names>P</given-names></name><name><surname>Pierard</surname><given-names>D</given-names></name><name><surname>Allard</surname><given-names>SD</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Antibiotic Prescriptions Targeting Bacterial Respiratory Infections in Admitted Patients with COVID-19: A Prospective Observational Study</article-title><source>Infectious Diseases and Therapy</source><volume>10</volume><fpage>2575</fpage><lpage>2591</lpage><pub-id pub-id-type="doi">10.1007/s40121-021-00535-2</pub-id><pub-id pub-id-type="pmid">34529255</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Liang</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Prevalence and serotype distribution of nasopharyngeal carriage of Streptococcus pneumoniae in China: a meta-analysis</article-title><source>BMC Infectious Diseases</source><volume>17</volume><elocation-id>765</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-017-2816-8</pub-id><pub-id pub-id-type="pmid">29237402</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Weill</surname><given-names>A</given-names></name><name><surname>Drouin</surname><given-names>J</given-names></name><name><surname>Desplas</surname><given-names>D</given-names></name><name><surname>Cuenot</surname><given-names>F</given-names></name><name><surname>Dray-Spira</surname><given-names>R</given-names></name><name><surname>Zureik</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><source>Usage Des Médicaments de Ville En France Durant L’Épidémie de La COVID-19 – Point de Situation Jusqu’Au 25 Avril 2021. Étude Pharmaco-Épidémiologique à Partir Des Données de Remboursement Du SNDS</source><publisher-name>EPI-PHARE (Groupement d’intérêt scientifique ANSM-Cnam</publisher-name></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willen</surname><given-names>L</given-names></name><name><surname>Ekinci</surname><given-names>E</given-names></name><name><surname>Cuypers</surname><given-names>L</given-names></name><name><surname>Theeten</surname><given-names>H</given-names></name><name><surname>Desmet</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Infant pneumococcal carriage in belgium not affected by COVID-19 containment measures</article-title><source>Frontiers in Cellular and Infection Microbiology</source><volume>11</volume><elocation-id>825427</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2021.825427</pub-id><pub-id pub-id-type="pmid">35111700</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wittman</surname><given-names>SR</given-names></name><name><surname>Martin</surname><given-names>JM</given-names></name><name><surname>Mehrotra</surname><given-names>A</given-names></name><name><surname>Ray</surname><given-names>KN</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Antibiotic Receipt During Outpatient Visits for COVID-19 in the US, From 2020 to 2022</article-title><source>JAMA Health Forum</source><volume>4</volume><elocation-id>e225429</elocation-id><pub-id pub-id-type="doi">10.1001/jamahealthforum.2022.5429</pub-id><pub-id pub-id-type="pmid">36800196</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolter</surname><given-names>N</given-names></name><name><surname>Tempia</surname><given-names>S</given-names></name><name><surname>Cohen</surname><given-names>C</given-names></name><name><surname>Madhi</surname><given-names>SA</given-names></name><name><surname>Venter</surname><given-names>M</given-names></name><name><surname>Moyes</surname><given-names>J</given-names></name><name><surname>Walaza</surname><given-names>S</given-names></name><name><surname>Malope-Kgokong</surname><given-names>B</given-names></name><name><surname>Groome</surname><given-names>M</given-names></name><name><surname>du Plessis</surname><given-names>M</given-names></name><name><surname>Magomani</surname><given-names>V</given-names></name><name><surname>Pretorius</surname><given-names>M</given-names></name><name><surname>Hellferscee</surname><given-names>O</given-names></name><name><surname>Dawood</surname><given-names>H</given-names></name><name><surname>Kahn</surname><given-names>K</given-names></name><name><surname>Variava</surname><given-names>E</given-names></name><name><surname>Klugman</surname><given-names>KP</given-names></name><name><surname>von Gottberg</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>High nasopharyngeal pneumococcal density, increased by viral coinfection, is associated with invasive pneumococcal pneumonia</article-title><source>The Journal of Infectious Diseases</source><volume>210</volume><fpage>1649</fpage><lpage>1657</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiu326</pub-id><pub-id pub-id-type="pmid">24907383</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>A</given-names></name><name><surname>Barrero Guevara</surname><given-names>LA</given-names></name><name><surname>Goult</surname><given-names>E</given-names></name><name><surname>Briga</surname><given-names>M</given-names></name><name><surname>Kramer</surname><given-names>SC</given-names></name><name><surname>Kovacevic</surname><given-names>A</given-names></name><name><surname>Opatowski</surname><given-names>L</given-names></name><name><surname>Domenech de Cellès</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>The interactions of SARS-CoV-2 with cocirculating pathogens: Epidemiological implications and current knowledge gaps</article-title><source>PLOS Pathogens</source><volume>19</volume><elocation-id>e1011167</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1011167</pub-id><pub-id pub-id-type="pmid">36888684</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wyllie</surname><given-names>AL</given-names></name><name><surname>Mbodj</surname><given-names>S</given-names></name><name><surname>Thammavongsa</surname><given-names>DA</given-names></name><name><surname>Hislop</surname><given-names>MS</given-names></name><name><surname>Yolda-Carr</surname><given-names>D</given-names></name><name><surname>Waghela</surname><given-names>P</given-names></name><name><surname>Nakahata</surname><given-names>M</given-names></name><name><surname>Stahlfeld</surname><given-names>AE</given-names></name><name><surname>Vega</surname><given-names>NJ</given-names></name><name><surname>York</surname><given-names>A</given-names></name><name><surname>Allicock</surname><given-names>OM</given-names></name><name><surname>Wilkins</surname><given-names>G</given-names></name><name><surname>Ouyang</surname><given-names>A</given-names></name><name><surname>Siqueiros</surname><given-names>L</given-names></name><name><surname>Strong</surname><given-names>Y</given-names></name><name><surname>Anastasio</surname><given-names>K</given-names></name><name><surname>Alexander-Parrish</surname><given-names>R</given-names></name><name><surname>Arguedas</surname><given-names>A</given-names></name><name><surname>Gessner</surname><given-names>BD</given-names></name><name><surname>Weinberger</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Persistence of Pneumococcal carriage among older adults in the community despite COVID-19 mitigation measures</article-title><source>Microbiology Spectrum</source><volume>11</volume><elocation-id>e0487922</elocation-id><pub-id pub-id-type="doi">10.1128/spectrum.04879-22</pub-id><pub-id pub-id-type="pmid">37036377</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Lambert</surname><given-names>H</given-names></name><name><surname>Cabral</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The impact of COVID-19 on primary health care and antibiotic prescribing in rural China: qualitative study</article-title><source>BMC Health Services Research</source><volume>21</volume><elocation-id>1048</elocation-id><pub-id pub-id-type="doi">10.1186/s12913-021-07082-z</pub-id><pub-id pub-id-type="pmid">34610843</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Secondary pulmonary infection and co-infection in elderly COVID-19 patients during the pandemics in a tertiary general hospital in Beijing, China</article-title><source>Frontiers in Microbiology</source><volume>14</volume><elocation-id>1280026</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2023.1280026</pub-id><pub-id pub-id-type="pmid">37901822</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>N</given-names></name><name><surname>Aylin</surname><given-names>P</given-names></name><name><surname>Rawson</surname><given-names>T</given-names></name><name><surname>Gilchrist</surname><given-names>M</given-names></name><name><surname>Majeed</surname><given-names>A</given-names></name><name><surname>Holmes</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Investigating the impact of COVID-19 on primary care antibiotic prescribing in North West London across two epidemic waves</article-title><source>Clinical Microbiology and Infection</source><volume>27</volume><fpage>762</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2021.02.007</pub-id><pub-id pub-id-type="pmid">33601010</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><sec sec-type="appendix" id="s8"><title>Literature search</title><p>We searched PubMed on December 4, 2023, for published mathematical modeling studies describing coinfection with SARS-CoV-2 and antibiotic-resistant bacteria and including epidemiological transmission of both pathogens. We used the following search query:</p><p>(&quot;model*&quot;[Title/Abstract] OR &quot;models, theoretical&quot;[MeSH Terms] OR &quot;simulat*&quot;[Title/Abstract])</p><p>AND</p><p>(&quot;mathematic*&quot;[MeSH Terms] OR &quot;compartmental&quot;[Title/Abstract] OR &quot;agent-based&quot;[Title/Abstract] OR &quot;individual-based&quot;[Title/Abstract] OR &quot;stochastic*&quot;[Title/Abstract] OR &quot;deterministic&quot;[Title/Abstract] OR &quot;computer-generated&quot;[Title/Abstract] OR &quot;computer simulation&quot;[MeSH Terms] OR &quot;computer&quot;[Title/Abstract] OR &quot;computational&quot;[Title/Abstract] OR &quot;mathematical*&quot;[Title/Abstract] OR &quot;theoretical&quot;[Title/Abstract] OR &quot;prediction&quot;[Title/Abstract] OR &quot;simulat*&quot;[Title/Abstract])</p><p>AND</p><p>(&quot;outbreak*&quot;[Title/Abstract] OR &quot;dynamic*&quot;[Title/Abstract] OR &quot;disseminat*&quot;[Title/Abstract] OR &quot;propagat*&quot;[Title/Abstract] OR &quot;transmi*&quot;[Title/Abstract] OR &quot;cross infection/transmission&quot;[MeSH Terms] OR &quot;spread*&quot;[Title/Abstract] OR &quot;diffus*&quot;[Title/Abstract] OR &quot;circulati*&quot;[Title/Abstract] OR &quot;disease activity&quot;[Title/Abstract] OR &quot;epidemiology&quot;[Title/Abstract] OR &quot;co-infection&quot;[Title/Abstract])</p><p>(&quot;COVID-19&quot;[Title/Abstract] OR &quot;SARS-CoV-2&quot;[Title/Abstract])</p><p>(&quot;bacteria*&quot;[Title/Abstract] OR &quot;antibiotic resist*&quot;[Title/Abstract] OR &quot;antibiotic-resist*&quot;[Title/Abstract] OR &quot;antimicrobial resist*&quot;[Title/Abstract] OR &quot;antimicrobial-resist*&quot;[Title/Abstract]),</p><p>which returned 153 papers. One published study developed a mathematical model including the transmission of both SARS-CoV-2 and antibiotic-resistant bacteria but is specific to the hospital setting (<xref ref-type="bibr" rid="bib95">Smith et al., 2023</xref>). Two bacterial transmission models implicitly accounted for COVID-19 by simulating pandemic-associated social distancing interventions/lockdowns, and corresponding reductions in (i) close-proximity contacts, in the context of transmission of antibiotic-resistance genes among human microbiota (<xref ref-type="bibr" rid="bib81">Rebelo et al., 2021</xref>), and (ii) sexual contacts, in the context of transmission of HIV, gonorrhea and chlamydia (<xref ref-type="bibr" rid="bib47">Jenness et al., 2021</xref>). A third model of <italic>Neisseria meningitidis</italic> transmission also evaluated colonization and infection dynamics over the pandemic period (<xref ref-type="bibr" rid="bib16">Cascante-Vega et al., 2023</xref>). However, none of these models included SARS-CoV-2 infection and transmission, and only the first considered antibiotic resistance. One further transmission modelling study included coinfection with SARS-CoV-2 and influenza-like illness but did not consider bacteria (<xref ref-type="bibr" rid="bib11">Bhowmick et al., 2023</xref>). Our search also returned some statistical models used to analyze epidemiological trends in bacterial coinfection subsequent to SARS-CoV-2 infection (<xref ref-type="bibr" rid="bib109">Zhou et al., 2023</xref>) and changes in the incidence of bacterial disease during the pandemic (<xref ref-type="bibr" rid="bib91">Shaw et al., 2023</xref>), but these did not use transmission modelling approaches to understand or quantify the underlying epidemiological mechanisms driving these trends. Several other modelling studies have described within-host molecular dynamics or airborne fluid particle dynamics, but do not describe pathogen transmission at the host population level. No other relevant articles were identified.</p></sec></app><app id="appendix-2"><title>Appendix 2</title><sec sec-type="appendix" id="s9"><title>Model equations:</title><p>Compartment notation:<disp-formula id="equ1"><mml:math id="m1"><mml:msubsup><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msubsup></mml:math></disp-formula></p><p><italic>X</italic>=SARS-CoV-2 status (S=susceptible, E=exposed, I=infected, and <italic>R</italic>=recovered)</p><p><italic>i</italic>=bacterial carriage (no superscript =no carriage, S=antibiotic-sensitive carriage, <italic>R</italic>=antibiotic-resistant carriage, SR =dual carriage, SS =dual antibiotic-sensitive carriage, RR =dual antibiotic-resistant carriage)</p><p><italic>j</italic>=antibiotic exposure (no subscript =no antibiotic exposure, <italic>a</italic>=exposed to baseline antibiotic treatment, az =exposed to azithromycin treatment)</p><p>Total population size:<disp-formula id="equ2"><mml:math id="m2"><mml:mrow><mml:mtable columnalign="left left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:mi>N</mml:mi><mml:mo>=</mml:mo></mml:mtd><mml:mtd><mml:mi>S</mml:mi><mml:mo>+</mml:mo><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi>E</mml:mi><mml:mo>+</mml:mo><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>+</mml:mo><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi>I</mml:mi><mml:mo>+</mml:mo><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>+</mml:mo><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi>R</mml:mi><mml:mo>+</mml:mo><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula></p><p>Forces of infection:</p><p><italic>S. pneumoniae</italic><disp-formula id="equ3"><mml:math id="m3"><mml:mrow><mml:mtable columnalign="left left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:mtd><mml:mtd><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mi>β</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">(</mml:mo></mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">)</mml:mo></mml:mrow><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi>N</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula><disp-formula id="equ4"><mml:math id="m4"><mml:mrow><mml:mtable columnalign="left left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:mtd><mml:mtd><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mi>f</mml:mi><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mi>β</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">(</mml:mo></mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">)</mml:mo></mml:mrow><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi>N</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula><disp-formula id="equ5"><mml:math id="m5"><mml:mrow><mml:mtable columnalign="left left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:mtd><mml:mtd><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mi>β</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">(</mml:mo></mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>g</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>g</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>+</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>g</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>g</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>+</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>g</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>g</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>+</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>g</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>g</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>+</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>g</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>g</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">)</mml:mo></mml:mrow><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi>N</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula><disp-formula id="equ6"><mml:math id="m6"><mml:mrow><mml:mtable columnalign="left left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:mtd><mml:mtd><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mi>f</mml:mi><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mi>β</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">(</mml:mo></mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>g</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>+</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>g</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>g</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>+</mml:mo><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>g</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>+</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>g</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>g</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>g</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>+</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>g</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>g</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>g</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">)</mml:mo></mml:mrow><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi>N</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula><disp-formula id="equ7"><mml:math id="m7"><mml:mrow><mml:mtable columnalign="center center" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">(</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>g</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mi>β</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mi>β</mml:mi></mml:mrow></mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mspace linebreak="newline"/><mml:mo>+</mml:mo><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">)</mml:mo></mml:mrow><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi>N</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula><disp-formula id="equ8"><mml:math id="m8"><mml:mrow><mml:mtable columnalign="center center" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">(</mml:mo></mml:mrow><mml:mrow><mml:mo maxsize="1.2em" minsize="1.2em">(</mml:mo></mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>g</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo maxsize="1.2em" minsize="1.2em">)</mml:mo></mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mi>β</mml:mi></mml:mrow></mml:msub><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:mrow><mml:mo maxsize="1.2em" minsize="1.2em">(</mml:mo></mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo maxsize="1.2em" minsize="1.2em">)</mml:mo></mml:mrow><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">)</mml:mo></mml:mrow><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi>N</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula><disp-formula id="equ9"><mml:math id="m9"><mml:mrow><mml:mtable columnalign="center center" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">(</mml:mo></mml:mrow><mml:mrow><mml:mo maxsize="1.2em" minsize="1.2em">(</mml:mo></mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>g</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo maxsize="1.2em" minsize="1.2em">)</mml:mo></mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mi>β</mml:mi></mml:mrow></mml:msub><mml:mi>f</mml:mi><mml:mn>2</mml:mn><mml:mi>q</mml:mi><mml:mrow><mml:mo maxsize="1.2em" minsize="1.2em">(</mml:mo></mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo maxsize="1.2em" minsize="1.2em">)</mml:mo></mml:mrow><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">)</mml:mo></mml:mrow><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi>N</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula></p><p>SARS-CoV-2:<disp-formula id="equ10"><mml:math id="m10"><mml:mrow><mml:mtable columnalign="center center" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">(</mml:mo></mml:mrow><mml:mrow><mml:mo maxsize="1.2em" minsize="1.2em">(</mml:mo></mml:mrow><mml:mi>I</mml:mi><mml:mo>+</mml:mo><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo>+</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo maxsize="1.2em" minsize="1.2em">)</mml:mo></mml:mrow><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">)</mml:mo></mml:mrow><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi>N</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula></p><p>Clearance rates of pneumococcal carriage:<disp-formula id="equ11"><mml:math id="m11"><mml:msup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:math></disp-formula></p><p>The equations for SARS-CoV-2 susceptible individuals (no antibiotic treatment):<disp-formula id="equ12"><mml:math id="m12"><mml:mrow><mml:mtable columnalign="left left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo></mml:mstyle></mml:mtd><mml:mtd><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>S</mml:mi><mml:mo>+</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>ω</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:mi>S</mml:mi><mml:mo>+</mml:mo><mml:mi>r</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub><mml:mi>S</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula><disp-formula id="equ13"><mml:math id="m13"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mi>S</mml:mi><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ14"><mml:math id="m14"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mi>S</mml:mi><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>r</mml:mi><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>ω</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ15"><mml:math id="m15"><mml:mrow><mml:mtable columnalign="left left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo></mml:mstyle></mml:mtd><mml:mtd><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mi>S</mml:mi><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>k</mml:mi><mml:mi>c</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula><disp-formula id="equ16"><mml:math id="m16"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mi>S</mml:mi><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>2</mml:mn><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ17"><mml:math id="m17"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mi>S</mml:mi><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>2</mml:mn><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>r</mml:mi><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>The equations for SARS-CoV-2 susceptible individuals (with antibiotic treatment):<disp-formula id="equ18"><mml:math id="m18"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:mi>S</mml:mi><mml:mo>−</mml:mo><mml:mi>r</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ19"><mml:math id="m19"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>ω</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ20"><mml:math id="m20"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>r</mml:mi><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ21"><mml:math id="m21"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>ω</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ22"><mml:math id="m22"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>ω</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:mn>2</mml:mn><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ23"><mml:math id="m23"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>r</mml:mi><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>The equations for SARS-CoV-2 exposed individuals (no antibiotic treatment):<disp-formula id="equ24"><mml:math id="m24"><mml:mrow><mml:mtable columnalign="left left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo></mml:mstyle></mml:mtd><mml:mtd><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>E</mml:mi><mml:mo>+</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>ω</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:mi>E</mml:mi><mml:mo>+</mml:mo><mml:mi>r</mml:mi><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub><mml:mi>S</mml:mi><mml:mo>−</mml:mo><mml:mi>ε</mml:mi><mml:mi>E</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula><disp-formula id="equ25"><mml:math id="m25"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mi>E</mml:mi><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>ε</mml:mi><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ26"><mml:math id="m26"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mi>E</mml:mi><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>r</mml:mi><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>ε</mml:mi><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>ω</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ27"><mml:math id="m27"><mml:mrow><mml:mtable columnalign="left left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo></mml:mstyle></mml:mtd><mml:mtd><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mi>E</mml:mi><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>−</mml:mo><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>ε</mml:mi><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula><disp-formula id="equ28"><mml:math id="m28"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mi>E</mml:mi><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>2</mml:mn><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>ε</mml:mi><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ29"><mml:math id="m29"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mi>E</mml:mi><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>2</mml:mn><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>r</mml:mi><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>ε</mml:mi><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>The equations for SARS-CoV-2 exposed individuals (with antibiotic treatment):<disp-formula id="equ30"><mml:math id="m30"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:mi>E</mml:mi><mml:mo>−</mml:mo><mml:mi>r</mml:mi><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mi>ε</mml:mi><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ31"><mml:math id="m31"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>ω</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:mi>ε</mml:mi><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ32"><mml:math id="m32"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>r</mml:mi><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:mi>ε</mml:mi><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ33"><mml:math id="m33"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>ω</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:mi>ε</mml:mi><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ34"><mml:math id="m34"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>ω</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:mn>2</mml:mn><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:mi>ε</mml:mi><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ35"><mml:math id="m35"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>r</mml:mi><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:mi>ε</mml:mi><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>The equations for SARS-CoV-2 infected individuals (no antibiotic treatment):<disp-formula id="equ36"><mml:math id="m36"><mml:mrow><mml:mtable columnalign="left left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo></mml:mstyle></mml:mtd><mml:mtd><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>I</mml:mi><mml:mo>+</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>ω</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:mi>I</mml:mi><mml:mo>+</mml:mo><mml:mi>r</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>ε</mml:mi><mml:mi>E</mml:mi><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msup><mml:mi>I</mml:mi><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub><mml:mi>I</mml:mi><mml:mo>+</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula><disp-formula id="equ37"><mml:math id="m37"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mi>I</mml:mi><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>ε</mml:mi><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msup><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ38"><mml:math id="m38"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mi>I</mml:mi><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>ω</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>r</mml:mi><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi>ε</mml:mi><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msup><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ39"><mml:math id="m39"><mml:mrow><mml:mtable columnalign="left left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo></mml:mstyle></mml:mtd><mml:mtd><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mi>I</mml:mi><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>ε</mml:mi><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msup><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula><disp-formula id="equ40"><mml:math id="m40"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mi>I</mml:mi><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>2</mml:mn><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>ε</mml:mi><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msup><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ41"><mml:math id="m41"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mi>I</mml:mi><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>2</mml:mn><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>r</mml:mi><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi>ε</mml:mi><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msup><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>The equations for SARS-CoV-2 infected individuals (with antibiotic treatment):<disp-formula id="equ42"><mml:math id="m42"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:mi>I</mml:mi><mml:mo>−</mml:mo><mml:mi>r</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>ε</mml:mi><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msup><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ43"><mml:math id="m43"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>ω</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi>ε</mml:mi><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msup><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ44"><mml:math id="m44"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>r</mml:mi><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi>ε</mml:mi><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msup><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ45"><mml:math id="m45"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>ω</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>ε</mml:mi><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msup><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ46"><mml:math id="m46"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>ω</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:mn>2</mml:mn><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>ε</mml:mi><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msup><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ47"><mml:math id="m47"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>r</mml:mi><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi>ε</mml:mi><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msup><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>The equations for SARS-CoV-2 infected individuals (with azithromycin treatment):<disp-formula id="equ48"><mml:math id="m48"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub><mml:mi>I</mml:mi><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msup><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>ω</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ49"><mml:math id="m49"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msup><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>ω</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ50"><mml:math id="m50"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msup><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>ω</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ51"><mml:math id="m51"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msup><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>ω</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ52"><mml:math id="m52"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msup><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>ω</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:mn>2</mml:mn><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ53"><mml:math id="m53"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msup><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>The equations for SARS-CoV-2 recovered individuals (no antibiotic treatment):<disp-formula id="equ54"><mml:math id="m54"><mml:mrow><mml:mtable columnalign="left left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo></mml:mstyle></mml:mtd><mml:mtd><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>R</mml:mi><mml:mo>+</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>+</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>ω</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:mi>R</mml:mi><mml:mo>+</mml:mo><mml:mi>r</mml:mi><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>+</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msup><mml:mi>I</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula><disp-formula id="equ55"><mml:math id="m55"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mi>R</mml:mi><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msup><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ56"><mml:math id="m56"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mi>R</mml:mi><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>ω</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>r</mml:mi><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msup><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ57"><mml:math id="m57"><mml:mrow><mml:mtable columnalign="left left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo></mml:mstyle></mml:mtd><mml:mtd><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mi>R</mml:mi><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>−</mml:mo><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msup><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula><disp-formula id="equ58"><mml:math id="m58"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mi>R</mml:mi><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>2</mml:mn><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msup><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ59"><mml:math id="m59"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mi>R</mml:mi><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>2</mml:mn><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>r</mml:mi><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msup><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>The equations for SARS-CoV-2 recovered individuals (with antibiotic treatment):<disp-formula id="equ60"><mml:math id="m60"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msup><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:mi>R</mml:mi><mml:mo>−</mml:mo><mml:mi>r</mml:mi><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ61"><mml:math id="m61"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msup><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>ω</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ62"><mml:math id="m62"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msup><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>r</mml:mi><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ63"><mml:math id="m63"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msup><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>ω</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ64"><mml:math id="m64"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msup><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>ω</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:mn>2</mml:mn><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ65"><mml:math id="m65"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msup><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>r</mml:mi><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>The equations for SARS-CoV-2 recovered individuals (with azithromycin treatment):<disp-formula id="equ66"><mml:math id="m66"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msup><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>ω</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ67"><mml:math id="m67"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msup><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>ω</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ68"><mml:math id="m68"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msup><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>ω</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ69"><mml:math id="m69"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msup><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>ω</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ70"><mml:math id="m70"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msup><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>ω</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:mn>2</mml:mn><mml:mi>k</mml:mi><mml:mi>c</mml:mi><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ71"><mml:math id="m71"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msup><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mspace width="thinmathspace"/><mml:mi>τ</mml:mi><mml:mi>a</mml:mi><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>r</mml:mi><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>The equations for invasive pneumococcal disease (IPD) incidence caused by sensitive and resistant strains:<disp-formula id="equ72"><mml:math id="m72"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>I</mml:mi><mml:mi>P</mml:mi><mml:msup><mml:mi>D</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>v</mml:mi></mml:mrow></mml:msub><mml:mi>I</mml:mi><mml:mi>P</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">(</mml:mo></mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">)</mml:mo></mml:mrow></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ73"><mml:math id="m73"><mml:mrow><mml:mtable columnalign="center center" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>I</mml:mi><mml:mi>P</mml:mi><mml:msup><mml:mi>D</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>v</mml:mi></mml:mrow></mml:msub><mml:mi>I</mml:mi><mml:mi>P</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">(</mml:mo></mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mstyle></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">)</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula></p></sec><sec sec-type="appendix" id="s10"><title>Equations for the prevalence of pneumococcal carriage in the population:</title><p>Prevalence of antibiotic-sensitive pneumococcal carriage is calculated as:<disp-formula id="equ74"><mml:math id="m74"><mml:mrow><mml:mtable columnalign="left left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>o</mml:mi><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:mtd><mml:mtd><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">(</mml:mo></mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">)</mml:mo></mml:mrow><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi>T</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mtext> </mml:mtext><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>r</mml:mi><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula></p><p>Prevalence of antibiotic-resistant pneumococcal carriage is calculated as:<disp-formula id="equ75"><mml:math id="m75"><mml:mrow><mml:mtable columnalign="left left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>o</mml:mi><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:mtd><mml:mtd><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">(</mml:mo></mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">)</mml:mo></mml:mrow><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi>T</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mtext> </mml:mtext><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>r</mml:mi><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula></p><p>Total pneumococcal carriage is calculated as:<disp-formula id="equ76"><mml:math id="m76"><mml:mrow><mml:mi>T</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>r</mml:mi><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>o</mml:mi><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>o</mml:mi><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></disp-formula></p><p>Prevalence of total pneumococcal carriage is calculated as:<disp-formula id="equ77"><mml:math id="m77"><mml:mrow><mml:mi>T</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:msub><mml:mi>l</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>o</mml:mi><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>T</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>r</mml:mi><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:math></disp-formula></p></sec><sec sec-type="appendix" id="s11"><title>Equations for within-host interactions:</title><p>Invasive pneumococcal disease (IPD) incidence implementing within-host interactions is only accounted for in the equations for IPD incidence outside of the model equations, and hence has no impact on model dynamics.</p><p>Daily IPD incidence, for the antibiotic-resistant strain is calculated as:<disp-formula id="equ78"><mml:math id="m78"><mml:mrow><mml:mtable columnalign="left left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>I</mml:mi><mml:mi>P</mml:mi><mml:msup><mml:mi>D</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo></mml:mstyle></mml:mtd><mml:mtd><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>v</mml:mi></mml:mrow></mml:msub><mml:mi>I</mml:mi><mml:mi>P</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">(</mml:mo></mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:msub><mml:mi mathvariant="bold-italic">ψ</mml:mi><mml:mrow><mml:mi mathvariant="bold-italic">c</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:msub><mml:mi mathvariant="bold-italic">ψ</mml:mi><mml:mrow><mml:mi mathvariant="bold-italic">c</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:msub><mml:mi mathvariant="bold-italic">ψ</mml:mi><mml:mrow><mml:mi mathvariant="bold-italic">c</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">)</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf25"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>v</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> represents the bacterial invasion rate or progression of carriage to invasive disease and <inline-formula><mml:math id="inf26"><mml:msub><mml:mrow><mml:mi>ψ</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> represents the co-infection interaction term that increases the rate of progression to invasive disease among colonized individuals who are also infected with SARS-CoV-2.</p><p>Daily IPD incidence for the antibiotic-sensitive strain is calculated as:<disp-formula id="equ79"><mml:math id="m79"><mml:mrow><mml:mtable columnalign="left left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>I</mml:mi><mml:mi>P</mml:mi><mml:msup><mml:mi>D</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo></mml:mstyle></mml:mtd><mml:mtd><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>v</mml:mi></mml:mrow></mml:msub><mml:mi>I</mml:mi><mml:mi>P</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">(</mml:mo></mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="bold-italic">ψ</mml:mi><mml:mrow><mml:mi mathvariant="bold-italic">c</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msup><mml:mi>I</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msup><mml:mi>R</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>+</mml:mo><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="bold-italic">ψ</mml:mi><mml:mrow><mml:mi mathvariant="bold-italic">c</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="bold-italic">ψ</mml:mi><mml:mrow><mml:mi mathvariant="bold-italic">c</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em">)</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula></p><p>Due to large uncertainty in the values of <inline-formula><mml:math id="inf27"><mml:msub><mml:mrow><mml:mi>ψ</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> we considered broad range in our analysis estimated from prior modelling studies (<xref ref-type="bibr" rid="bib32">Domenech de Cellès et al., 2019</xref>; <xref ref-type="bibr" rid="bib75">Opatowski et al., 2013</xref>). In the context of ecological interactions between <italic>S. pneumoniae</italic> and influenza, estimations show that influenza co-infection increases the rate of progression from <italic>S. pneumonia</italic> colonization to invasive pneumococcal disease between 49 and 146-fold, on average, depending on the age group (<xref ref-type="bibr" rid="bib32">Domenech de Cellès et al., 2019</xref>; <xref ref-type="bibr" rid="bib75">Opatowski et al., 2013</xref>). Therefore, we implemented the range <inline-formula><mml:math id="inf28"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>1</mml:mn><mml:mo>&lt;</mml:mo><mml:msub><mml:mi>ψ</mml:mi><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mo>&lt;</mml:mo><mml:mn>100</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> for SARS-CoV-2.</p><fig id="app2fig1" position="float"><label>Appendix 2—figure 1.</label><caption><title>Hypothetical within-host interactions in scenario S19 promote the incidence of antibiotic-resistant invasive pneumococcal disease (IPD).</title><p>(<bold>A</bold>) Impacts of ecological interactions between pathogens. When SARS-CoV-2 infection leads to faster progression from pneumococcal colonization to disease , surges in COVID-19 cases accompanied by increasing levels of azithromycin use lead to substantial increases in the daily incidence of antibiotic-resistant IPD. (<bold>B</bold>) Annual excess in cumulative IPD incidence due to synergistic within-host ecological interactions. A rate of disease progression increased by a factor (no within-host interaction) and in scenario S19 applied to the general population resulted in approximately 0.06 and 0.75 additional cases of antibiotic-resistant disease per 100,000 inhabitants over the course of one year, respectively, compared to the scenario S19 assuming no within-host interaction and no azithromycin use indicated by the black arrow (1.17 cases/100,000 inhabitants).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85701-app2-fig1-v2.tif"/></fig><fig id="app2fig2" position="float"><label>Appendix 2—figure 2.</label><caption><title>Model schematic describing co-circulation of SARS-CoV-2 infection and pneumococcal carriage transmission.</title><p>(<bold>A</bold>) Individuals in each of the SARS-CoV-2 transmission model compartments (S, E, I, R) can be either (<bold>B</bold>) uncolonized (U) or colonized by the bacteria (C<sup>S</sup>, C<sup>R</sup>, C<sup>SS</sup>, C<sup>RR</sup>, C<sup>SR</sup>) with or without concomitant antibiotic treatment (subscript <sub>atb</sub> denotes compartments exposed to antibiotics – both standard baseline antibiotic exposure and azithromycin exposure). Full list of model parameters can be found in <xref ref-type="table" rid="app2table2">Appendix 2—table 2</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85701-app2-fig2-v2.tif"/></fig><table-wrap id="app2table1" position="float"><label>Appendix 2—table 1.</label><caption><title>Total number of invasive <italic>S. pneumoniae</italic> isolates from blood or cerebrospinal fluid tested in 2019 and 2020 and reported to EARS-Net (European Antimicrobial Resistance Surveillance Network).</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top"/><th align="left" valign="top" colspan="2">No. of invasive Streptococcus pneumoniae isolates in the EU/EEA</th><th align="left" valign="top"/></tr><tr><th align="left" valign="middle">Country</th><th align="char" char="." valign="middle">2019</th><th align="char" char="." valign="middle">2020</th><th align="left" valign="top">% decrease in the total number of reported invasive isolates from 2019–2020</th></tr></thead><tbody><tr><td align="left" valign="top">Austria</td><td align="char" char="." valign="top">550</td><td align="char" char="." valign="top">301</td><td align="char" char="." valign="top">45.3%</td></tr><tr><td align="left" valign="top">Belgium</td><td align="char" char="." valign="top">1548</td><td align="char" char="." valign="top">858</td><td align="char" char="." valign="top">44.6%</td></tr><tr><td align="left" valign="top">Bulgaria</td><td align="char" char="." valign="top">46</td><td align="char" char="." valign="top">28</td><td align="char" char="." valign="top">39.1%</td></tr><tr><td align="left" valign="top">Croatia</td><td align="char" char="." valign="top">156</td><td align="char" char="." valign="top">55</td><td align="char" char="." valign="top">64.7%</td></tr><tr><td align="left" valign="top">Czechia</td><td align="char" char="." valign="top">387</td><td align="char" char="." valign="top">204</td><td align="char" char="." valign="top">47.3%</td></tr><tr><td align="left" valign="top">Denmark</td><td align="char" char="." valign="top">601</td><td align="char" char="." valign="top">351</td><td align="char" char="." valign="top">41.6%</td></tr><tr><td align="left" valign="top">Estonia</td><td align="char" char="." valign="top">161</td><td align="char" char="." valign="top">80</td><td align="char" char="." valign="top">50.3%</td></tr><tr><td align="left" valign="top">Finland</td><td align="char" char="." valign="top">678</td><td align="char" char="." valign="top">293</td><td align="char" char="." valign="top">56.8%</td></tr><tr><td align="left" valign="top">France</td><td align="char" char="." valign="top">1264</td><td align="char" char="." valign="top">668</td><td align="char" char="." valign="top">47.2%</td></tr><tr><td align="left" valign="top">Germany</td><td align="char" char="." valign="top">2035</td><td align="char" char="." valign="top">1314</td><td align="char" char="." valign="top">35.4%</td></tr><tr><td align="left" valign="top">Hungary</td><td align="char" char="." valign="top">222</td><td align="char" char="." valign="top">124</td><td align="char" char="." valign="top">44.1%</td></tr><tr><td align="left" valign="top">Iceland</td><td align="char" char="." valign="top">44</td><td align="char" char="." valign="top">20</td><td align="char" char="." valign="top">54.5%</td></tr><tr><td align="left" valign="top">Ireland</td><td align="char" char="." valign="top">348</td><td align="char" char="." valign="top">136</td><td align="char" char="." valign="top">60.9%</td></tr><tr><td align="left" valign="top">Italy</td><td align="char" char="." valign="top">1351</td><td align="char" char="." valign="top">685</td><td align="char" char="." valign="top">49.3%</td></tr><tr><td align="left" valign="top">Latvia</td><td align="char" char="." valign="top">79</td><td align="char" char="." valign="top">42</td><td align="char" char="." valign="top">46.8%</td></tr><tr><td align="left" valign="top">Lithuania</td><td align="char" char="." valign="top">120</td><td align="char" char="." valign="top">96</td><td align="char" char="." valign="top">20.0%</td></tr><tr><td align="left" valign="top">Luxembourg</td><td align="char" char="." valign="top">38</td><td align="char" char="." valign="top">24</td><td align="char" char="." valign="top">36.8%</td></tr><tr><td align="left" valign="top">Malta</td><td align="char" char="." valign="top">27</td><td align="char" char="." valign="top">16</td><td align="char" char="." valign="top">40.7%</td></tr><tr><td align="left" valign="top">Netherlands</td><td align="char" char="." valign="top">1552</td><td align="char" char="." valign="top">997</td><td align="char" char="." valign="top">35.8%</td></tr><tr><td align="left" valign="top">Norway</td><td align="char" char="." valign="top">507</td><td align="char" char="." valign="top">243</td><td align="char" char="." valign="top">52.1%</td></tr><tr><td align="left" valign="top">Poland</td><td align="char" char="." valign="top">364</td><td align="char" char="." valign="top">165</td><td align="char" char="." valign="top">54.7%</td></tr><tr><td align="left" valign="top">Portugal</td><td align="char" char="." valign="top">983</td><td align="char" char="." valign="top">588</td><td align="char" char="." valign="top">40.2%</td></tr><tr><td align="left" valign="top">Romania</td><td align="char" char="." valign="top">107</td><td align="char" char="." valign="top">42</td><td align="char" char="." valign="top">60.7%</td></tr><tr><td align="left" valign="top">Slovakia</td><td align="char" char="." valign="top">40</td><td align="char" char="." valign="top">15</td><td align="char" char="." valign="top">62.5%</td></tr><tr><td align="left" valign="top">Slovenia</td><td align="char" char="." valign="top">283</td><td align="char" char="." valign="top">172</td><td align="char" char="." valign="top">39.2%</td></tr><tr><td align="left" valign="top">Spain</td><td align="char" char="." valign="top">1038</td><td align="char" char="." valign="top">611</td><td align="char" char="." valign="top">41.1%</td></tr><tr><td align="left" valign="top">Sweden</td><td align="char" char="." valign="top">1071</td><td align="char" char="." valign="top">551</td><td align="char" char="." valign="top">48.6%</td></tr><tr><td align="left" valign="top">United Kingdom</td><td align="char" char="." valign="top">3468</td><td align="char" char="." valign="top">1412</td><td align="char" char="." valign="top">59.3%</td></tr></tbody></table></table-wrap><table-wrap id="app2table2" position="float"><label>Appendix 2—table 2.</label><caption><title>Summary of the model parameters.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Symbol</th><th align="left" valign="top">Interpretation</th><th align="left" valign="top">Value(s)</th><th align="left" valign="top">References</th></tr></thead><tbody><tr><td align="left" valign="top" colspan="4">SARS-CoV-2 infection parameters:</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf29"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mi>C</mml:mi></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="top">transmission rate of SARS-CoV-2</td><td align="char" char="." valign="top">0.46 days<sup>–1</sup></td><td align="char" char="." valign="top"><xref ref-type="bibr" rid="bib62">Liu et al., 2020</xref></td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf30"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msup><mml:mi>γ</mml:mi><mml:mi>c</mml:mi></mml:msup></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="top">SARS-CoV-2 recovery rate (mild cases)</td><td align="char" char="." valign="top">1/7 days<sup>–1</sup></td><td align="left" valign="top"><xref ref-type="bibr" rid="bib59">Lauer et al., 2020</xref>; <xref ref-type="bibr" rid="bib82">Rhee et al., 2020</xref></td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf31"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>ϵ</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="top">SARS-CoV-2 incubation rate (latent period from exposed to infectious state)</td><td align="char" char="." valign="top">1/5 days<sup>–1</sup></td><td align="char" char="." valign="top"><xref ref-type="bibr" rid="bib35">Elias et al., 2021</xref></td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf32"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>θ</mml:mi><mml:mi>c</mml:mi></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="top">Relative risk of SARS-CoV-2 transmission due to lockdown implementation</td><td align="char" char="." valign="top">0.23</td><td align="char" char="." valign="top"><xref ref-type="bibr" rid="bib88">Salje et al., 2020</xref></td></tr><tr><td align="left" valign="top" colspan="4">Pneumococcal colonization and invasion parameters:</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf33"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="top">transmission rate of antibiotic-sensitive strain</td><td align="left" valign="top">0.056 days<sup>–1<break/></sup>0.046 days<sup>–1<break/></sup>0.034 days<sup>–1</sup></td><td align="left" valign="top"><xref ref-type="bibr" rid="bib28">Davies et al., 2019</xref>; <xref ref-type="bibr" rid="bib73">Olesen et al., 2020</xref></td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf34"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>f</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="top">fitness of antibiotic-resistant strain (assuming there is a fitness cost on transmissibility)</td><td align="char" char="." valign="top">0.9652<break/>0.949<break/>0.926</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib24">Dagan et al., 2008</xref>; <xref ref-type="bibr" rid="bib67">Melnyk et al., 2015</xref></td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf35"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mi>f</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="top">transmission rate of antibiotic-resistant strain</td><td align="left" valign="top"/><td align="left" valign="top">calculated</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf36"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mi>β</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="top">Relative risk of pneumococcal transmission due to lockdown implementation</td><td align="char" char="." valign="top">1 or 0.75</td><td align="left" valign="top">assumed</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf37"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mtable columnalign="center center" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:msup><mml:mi>γ</mml:mi><mml:mi>S</mml:mi></mml:msup><mml:mo>=</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mi>R</mml:mi></mml:msup><mml:mo>=</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msup></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo>=</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:msup><mml:mi>γ</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msup></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="top">rate of natural bacterial clearance (assumed to be the same for antibiotic-sensitive and -resistant strains)</td><td align="left" valign="top">1/20 days<sup>–1<break/></sup>1/30 days<sup>–1<break/></sup>1/45 days<sup>–1</sup></td><td align="left" valign="top"><xref ref-type="bibr" rid="bib1">Abdullahi et al., 2012</xref>; <xref ref-type="bibr" rid="bib28">Davies et al., 2019</xref>; <xref ref-type="bibr" rid="bib34">Ekdahl et al., 1997</xref>; <xref ref-type="bibr" rid="bib43">Högberg et al., 2021</xref><xref ref-type="bibr" rid="bib66">Melegaro et al., 2004</xref></td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf38"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>q</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="top">relative infectiousness with each strain for dually colonized</td><td align="char" char="." valign="top">0.5</td><td align="left" valign="top">assumed<xref ref-type="bibr" rid="bib22">Colijn et al., 2010</xref></td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf39"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="top">fraction of dually colonized returning to single-colonized upon reinfection</td><td align="char" char="." valign="top">0.5</td><td align="left" valign="top">assumed (<xref ref-type="bibr" rid="bib22">Colijn et al., 2010</xref>)</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf40"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="top">probability of acquiring secondary bacterial carriage</td><td align="char" char="." valign="top">0.5</td><td align="left" valign="top">assumed (<xref ref-type="bibr" rid="bib22">Colijn et al., 2010</xref>)</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf41"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="top">probability of transmitting antibiotic-sensitive strain</td><td align="char" char="." valign="top">0.5</td><td align="left" valign="top">assumed (<xref ref-type="bibr" rid="bib22">Colijn et al., 2010</xref>)</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf42"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>g</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="top">probability of a single infection</td><td align="char" char="." valign="top">0.5</td><td align="left" valign="top">assumed (<xref ref-type="bibr" rid="bib22">Colijn et al., 2010</xref>)</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf43"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>v</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="top">pneumococcal invasion rate (summer and winter)</td><td align="left" valign="top">[3x10<sup>-6</sup> day<sup>–1</sup>,9x10<sup>-6</sup> day<sup>–1</sup>] in the elderly and general population, and [1x10<sup>-6</sup> day<sup>–1</sup>, 2.5x10<sup>-6</sup> day<sup>–1</sup>] in &lt;5 years-old</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib32">Domenech de Cellès et al., 2019</xref>; <xref ref-type="bibr" rid="bib75">Opatowski et al., 2013</xref></td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf44"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mi>S</mml:mi></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:msup></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="top">initial states – initial prevalence of the total pneumococcal carriage (antibiotic-sensitive and -resistant) in different populations</td><td align="char" char="." valign="top">10%<break/>20%<break/>30%</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib21">Cohen et al., 2023</xref>; <xref ref-type="bibr" rid="bib83">Rose et al., 2021</xref>; <xref ref-type="bibr" rid="bib86">Rybak et al., 2022</xref>; <xref ref-type="bibr" rid="bib98">Tinggaard et al., 2023</xref>; <xref ref-type="bibr" rid="bib101">Wang et al., 2017</xref></td></tr><tr><td align="left" valign="top" colspan="4">Antibiotic exposure parameters:</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf45"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>ω</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="top">rate of antibiotic-induced pneumococcal clearance for sensitive strains(1/time before antibiotic action)</td><td align="char" char="." valign="top">1/3 days<sup>–1</sup></td><td align="left" valign="top"><xref ref-type="bibr" rid="bib56">Kuitunen et al., 2023</xref></td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf46"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="top">rate of return to antibiotic unexposed compartment (1/duration of antibiotic treatment)</td><td align="char" char="." valign="top">1/7 days<sup>–1</sup></td><td align="left" valign="top"><xref ref-type="bibr" rid="bib41">Grant and Saux, 2021</xref>; <xref ref-type="bibr" rid="bib56">Kuitunen et al., 2023</xref></td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf47"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="top">rate of return to antibiotic unexposed compartment (1/the remainder of how long azithromycin stays in the body)</td><td align="char" char="." valign="top">1/11.5 days<sup>–1</sup></td><td align="left" valign="top">calculated (<xref ref-type="bibr" rid="bib38">Foulds et al., 1990</xref>; <xref ref-type="bibr" rid="bib40">Girard et al., 2005</xref>)</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf48"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>τ</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="top">baseline rate of antibiotic exposure in the community (France)</td><td align="left" valign="top">0.0014 average daily ppc (prescriptions per capita)</td><td align="char" char="." valign="top"><xref ref-type="bibr" rid="bib8">Bara et al., 2022</xref></td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf49"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="top">A reduction factor for antibiotic exposure in the community resulting from changes in healthcare-seeking behavior in response to the COVID-19 pandemic</td><td align="left" valign="top">[0.51, 0.77, 0.84]to represent annual 13%, 18%, and 39% decrease observed in France</td><td align="char" char="." valign="top"><xref ref-type="bibr" rid="bib8">Bara et al., 2022</xref></td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf50"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>z</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="top">A proportion of COVID-19 infected individuals in the community receiving azithromycin</td><td align="left" valign="top">[0–0.20]testing between 0% and 20%</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib99">Tsay et al., 2022</xref>; <xref ref-type="bibr" rid="bib104">Wittman et al., 2023</xref></td></tr><tr><td align="left" valign="top" colspan="4">Pathogenicity (invasive pneumococcal disease risk):</td></tr><tr><td align="left" valign="top"><inline-formula><mml:math id="inf51"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>I</mml:mi><mml:mi>P</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td align="left" valign="top">A reduction factor for the risk of developing an invasive pneumococcal disease (IPD) due to the absence of influenza-like-illnesses (ILIs) after lockdown implementation</td><td align="left" valign="top">1 (pre-lockdown)<break/>0.2 (lockdown)<break/>0.4 (post-lockdown) for an average of 0.5 in 2020</td><td align="char" char="." valign="top"><xref ref-type="bibr" rid="bib91">Shaw et al., 2023</xref></td></tr></tbody></table></table-wrap></sec></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.85701.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bonten</surname><given-names>Marc J</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0575yy874</institution-id><institution>University Medical Center Utrecht</institution></institution-wrap><country>Netherlands</country></aff></contrib></contrib-group></front-stub><body><p>The mathematical modeling approach disentangles the impacts of the COVID-19 pandemic on antibiotic resistance in Streptococcus pneumoniae in the community setting and identifies the three most plausible driving mechanisms responsible for the observed trends in invasive isolates and pneumococcal carriage. The significance of the findings is important for our understanding of the changed epidemiology of invasive pneumococcal infections during the COVID19 pandemic. The strength of the evidence is graded as solid, derived from a well-described mathematical model evaluating multiple scenarios.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.85701.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Bonten</surname><given-names>Marc J</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0575yy874</institution-id><institution>University Medical Center Utrecht</institution></institution-wrap><country>Netherlands</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Cooper</surname><given-names>Ben S</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>University of Oxford</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for sending your article entitled &quot;A modeling study on the impact of COVID-19 pandemic responses on the community transmission of antibiotic-resistant bacteria&quot; for peer review at <italic>eLife</italic>. Your article is being evaluated by 2 peer reviewers, and the evaluation is being overseen by a Reviewing Editor and Jos van der Meer as the Senior Editor.</p><p>Both reviewers raised concerns about the design of the model (it not being non-neutral) and the assumptions made for antibiotic use in the community.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>The authors have developed a mathematical model to investigate the impact of the SARS-CoV-2 pandemic on the spread of antibiotic-susceptible and antibiotic-resistant strains. The strength is the proof of concept, which shows the direction of incidence and resistance levels certain scenarios have, I am less convinced by the exact numerical values.</p><p>I was wondering about the model structure, which is not a neutral null model. For instance, why is superinfection possible with two serotypes if one is susceptible and one is resistant, but not if they are both susceptible or resistant?</p><p>As a result of the non-neutrality, the strain with the lowest prevalence has a selective advantage over the other strain as the pool of individuals they can infect is larger for the low-prevalent strain. Moreover, if c=0.05, in absence of AB use, about 10% of individuals will carry resistant strains, despite c&gt;0. Hence there is a hidden mechanism that promotes the strain with the lowest prevalence. I would prefer to see a neutral null model, although I expect that the directions on incidence and resistance levels will not change a lot.</p><p>I do not understand the parameter choice in Figure 3. According to Figure 3, over 50% of the strains are resistant. However, in Figure 1 no country had a pre-pandemic resistance proportion for penicillin or macrolide resistance of 50% or more.</p><p>Details, I would not use the word rate for the proportion/fraction resistance. For me, the rate is an incidence per time unit.</p><p>In line 263, I think mentioning of a relative increase may be more intuitively understandable than an absolute increase.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>In this manuscript the authors propose a mathematical model to explore the effects of the COVID-19 pandemic on the epidemiology of S. pneumoniae, considering both direct effects of SARS-CoV-2 infection, which is assumed to be capable of increasing the rate of progression from colonization with S. pneumoniae to invasive diseases, and indirect effects. The indirect effects are assumed to be the result of (i) changes in contact patterns between individuals (eg through population-wide &quot;lockdowns&quot; and isolation of COVID-19 cases), and (ii) changes in antibiotic consumption which is assumed to be the result of both widespread antibiotic prophylaxis amongst those infected with SARS-CoV-2 and changes in healthcare seeking behaviour. The questions addressed are of widespread interest, and the authors are to be congratulated for a first attempt at addressing this difficult problem. Strengths of the work include a well-motivated research question, a largely clear exposition of the model and findings, and a generally well-written manuscript. I have no concerns about the implementation of the models. I do, however, have a number of concerns about the model assumptions that lead me to question whether the observed changes in the incidence of invasive disease with S. pneumoniae and in the prevalence of resistance amongst invasive isolates are really driven by the mechanisms encapsulated by the proposed models. I expand on these below.</p><p>One concern is that this study focuses on the community transmission of bacteria, and (unless I have fundamentally misunderstood the work) a central assumption seems to be that high rates of antibiotics were used in the community as prophylaxis amongst patients with COVID-19. As S2.2 explains, in the scenarios considered 18.1%, 33.0%, and 55.1% of patients received antibiotic prophylaxis during each COVID infection. The authors state &quot;As reported in Langford et al. [3], a meta-analysis on antibiotic prescribing in patients with COVID-19, prophylactic antibiotic prescribing in the inpatient/outpatient setting was estimated at 59.3%. Therefore, the values above that we use in our model are conservative compared to this estimate.&quot; There are two issues here: first I couldn't find where the number of 59.3% in the Langford et al. paper came from (searching for 59 in the manuscript gave no relevant hits). In fact, this paper reports even higher rates of antibiotic use &quot;The majority of patients with COVID-19 received antibiotics (71.9%, 95%CI 56.1 to 87.7%).&quot; (elsewhere in the paper also reported as 71.8%). The second (and more important) issue is that even though the scope of Langford et al. included hospital and community settings, in all 24 of the included studies the setting was either ICU (n=5) or hospital (n=19). There is no reason to think these numbers are at all representative of the community setting (the focus of the manuscript) and the assumption that in 18% of COVID-19 infections (including, presumably, subclinical infections) antibiotics were taken prophylactically in the community does not seem credible to me (indeed, from personal experience, I am not aware of a single person who took antibiotics prophylactically in the community while infected with COVID). This might well just reflect my ignorance – perhaps there were countries where antibiotic prophylaxis in the community was widespread, but this has not been shown in the paper by Langford et al., and given that this is a central premise of the model and something that is presumably driving a lot of the results this is surely something where the data supporting this assumption needs to be made very clear if indeed such data exists. If, as I suspect is true in most settings, antibiotic prophylaxis during COVID infection in the community was negligible then I do think there is a need to make appropriate changes to the manuscript.</p><p>A second concern is in the treatment of the progression from colonisation to invasive disease. The authors assume that infection with SARS-CoV-2 increases the rate of progression (and consider up to 100-fold increases). This itself is reasonable. However, as the authors acknowledge, other respiratory viral infections also have this effect (SI-8: &quot;estimations show that influenza co-infection increases the rate of progression from S. pneumonia colonization to invasive pneumococcal disease between 49 and 146-fold, on average, depending on the age group&quot;). Since a major effect of the changes in contact patterns in response to the pandemic was that in many countries other respiratory infections, including influenza, did not circulate as usual, wouldn't this be expected to also have a substantial impact on the rate of progression from colonization to invasive disease? i.e. if it is important to consider the impact of SARS-CoV-2 on the progression, why not also consider the effect of other viral pathogens at the same time? A similar concern applies to antibiotic use. We know that in interpandemic periods a lot of antibiotic use in the community is given in response to viral respiratory infections, and since we know that changes in contact patterns had a profound impact on many such viral respiratory infections, is it not also likely that these had an effect on antibiotic use? Or is the assumption that such changes are just absorbed into changes in health-seeking behaviour?</p><p>A third concern is really a question about whether there might be another mechanism that could be explaining the generally increasing trends in penicillin and macrolide resistance in invasive pneumococcal disease summarised in figure 1. We know that the S. pneumoniae serotypes which have a longer carriage duration are more likely to be resistant (see, for example, Lehtinen et al., PNAS 2017), and also that these have a higher reproduction number (the shorter duration of carriage serotypes being maintained by negative frequency-dependent selection). We would therefore surely expect these less resistant serotypes (with lower reproduction numbers and shorter durations of carriage) to be more impacted by social distancing measures as they would be the first serotypes to have reproduction numbers reduced to below one. This would then be a completely different mechanism to explain observed changes in resistance patterns. Clearly, a lot of work would be needed to establish whether or not this can explain observed changes, though I feel the same is true of the explanatory mechanisms proposed in this paper (increased antibiotic use) given that the current paper lacks any country-specific antibiotic use data or attempt to see if different changes in patterns of antibiotic use can explain the different changes in resistance seen in different countries.</p><p>1. lines 118-120 highlight azithromycin as a particular concern for overuse, but this is difficult to square with the review the authors cite from Langford which reports macrolides as accounting for only 6.5% of antibiotic prescribing in COVID patients. This review suggests fluoroquinolones and β-lactams accounted for over 80% of prescribed antibiotics</p><p>2. On first looking at the manuscript I was quite concerned that the changes in resistance in figure 1 might reflect changes in health-seeking behaviour rather than real changes in the underlying epidemiology, for example, if certain types of isolates are less likely to be resistant and these types were reported less frequently. Now that I realise that the data in figure 1 all come from invasive isolates (as stated on line 176) this explanation seems less likely. It would be helpful if figure 1 could be labelled appropriately to make it clear that the data shown represents only invasive isolates.</p><p>3. line 248 &quot;some respiratory viruses are known to favor bacterial disease&quot; I don't think &quot;favor&quot; is the right word here. Perhaps &quot;increase the risks of&quot;?</p><p>4. Figure 3 would be easier to read if the subgraphs were labelled with the scenario. Also, it wasn't clear to me what the three graphs in panel C represent.</p><p>5. Table S3. I think A=20 in all the scenarios so that a minimum of 18% of patients infected with SARS-CoV-2 are given antibiotics prophylactically. It would increase readability if this was made explicit in the table.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.85701.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>The authors have developed a mathematical model to investigate the impact of the SARS-CoV-2 pandemic on the spread of antibiotic-susceptible and antibiotic-resistant strains. The strength is the proof of concept, which shows the direction of incidence and resistance levels certain scenarios have, I am less convinced by the exact numerical values.</p><p>I was wondering about the model structure, which is not a neutral null model. For instance, why is superinfection possible with two serotypes if one is susceptible and one is resistant, but not if they are both susceptible or resistant?</p><p>As a result of the non-neutrality, the strain with the lowest prevalence has a selective advantage over the other strain as the pool of individuals they can infect is larger for the low-prevalent strain. Moreover, if c=0.05, in absence of AB use, about 10% of individuals will carry resistant strains, despite c&gt;0. Hence there is a hidden mechanism that promotes the strain with the lowest prevalence. I would prefer to see a neutral null model, although I expect that the directions on incidence and resistance levels will not change a lot.</p></disp-quote><p>Thank you for your comment, we indeed used the initial model structure for simplicity. However, we acknowledge the importance of model neutrality. In this new version, we modified the component of the model pertaining to pneumococcal carriage, encompassing all three dually infected states, and accounted for the simultaneous transmission of a dual infection, such as in Colijn et al., (J R Soc Interface 2010) and updated equations for the forces of infection accordingly (Appendix 2). These changes did not affect the model’s results.</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85701-sa2-fig1-v2.tif"/></fig><disp-quote content-type="editor-comment"><p>I do not understand the parameter choice in Figure 3. According to Figure 3, over 50% of the strains are resistant. However, in Figure 1 no country had a pre-pandemic resistance proportion for penicillin or macrolide resistance of 50% or more.</p></disp-quote><p>We thank the reviewer for raising that point. Our model initialization was overestimating the observed resistance rate in France for invasive isolates in 2019. The previous version of the model initially only aimed at tracking trends instead of exact numbers. This new version is much more closely applied to the French setting. We adjusted the values of the implemented fitness cost of drug resistance for <italic>S. pneumoniae</italic> associated with lower transmissibility so that the model simulations do not exceed 20% of resistance at baseline.</p><disp-quote content-type="editor-comment"><p>Details, I would not use the word rate for the proportion/fraction resistance. For me, the rate is an incidence per time unit.</p></disp-quote><p>We changed this throughout the manuscript and removed the term rate.</p><disp-quote content-type="editor-comment"><p>In line 263, I think mentioning of a relative increase may be more intuitively understandable than an absolute increase.</p></disp-quote><p>We made the appropriate change.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>In this manuscript the authors propose a mathematical model to explore the effects of the COVID-19 pandemic on the epidemiology of S. pneumoniae, considering both direct effects of SARS-CoV-2 infection, which is assumed to be capable of increasing the rate of progression from colonization with S. pneumoniae to invasive diseases, and indirect effects. The indirect effects are assumed to be the result of (i) changes in contact patterns between individuals (eg through population-wide &quot;lockdowns&quot; and isolation of COVID-19 cases), and (ii) changes in antibiotic consumption which is assumed to be the result of both widespread antibiotic prophylaxis amongst those infected with SARS-CoV-2 and changes in healthcare seeking behaviour. The questions addressed are of widespread interest, and the authors are to be congratulated for a first attempt at addressing this difficult problem. Strengths of the work include a well-motivated research question, a largely clear exposition of the model and findings, and a generally well-written manuscript. I have no concerns about the implementation of the models. I do, however, have a number of concerns about the model assumptions that lead me to question whether the observed changes in the incidence of invasive disease with S. pneumoniae and in the prevalence of resistance amongst invasive isolates are really driven by the mechanisms encapsulated by the proposed models. I expand on these below.</p></disp-quote><p>We express our gratitude for acknowledging and appreciating our efforts. We also thank the reviewer for raising these different points that were addressed in this new version. We believe that we now encompass most of possible mechanistic hypotheses that could affect pneumococcal epidemiology trends over the study period.</p><disp-quote content-type="editor-comment"><p>One concern is that this study focuses on the community transmission of bacteria, and (unless I have fundamentally misunderstood the work) a central assumption seems to be that high rates of antibiotics were used in the community as prophylaxis amongst patients with COVID-19. As S2.2 explains, in the scenarios considered 18.1%, 33.0%, and 55.1% of patients received antibiotic prophylaxis during each COVID infection. The authors state &quot;As reported in Langford et al. [3], a meta-analysis on antibiotic prescribing in patients with COVID-19, prophylactic antibiotic prescribing in the inpatient/outpatient setting was estimated at 59.3%. Therefore, the values above that we use in our model are conservative compared to this estimate.&quot; There are two issues here: first I couldn't find where the number of 59.3% in the Langford et al. paper came from (searching for 59 in the manuscript gave no relevant hits). In fact, this paper reports even higher rates of antibiotic use &quot;The majority of patients with COVID-19 received antibiotics (71.9%, 95%CI 56.1 to 87.7%).&quot; (elsewhere in the paper also reported as 71.8%). The second (and more important) issue is that even though the scope of Langford et al. included hospital and community settings, in all 24 of the included studies the setting was either ICU (n=5) or hospital (n=19). There is no reason to think these numbers are at all representative of the community setting (the focus of the manuscript) and the assumption that in 18% of COVID-19 infections (including, presumably, subclinical infections) antibiotics were taken prophylactically in the community does not seem credible to me (indeed, from personal experience, I am not aware of a single person who took antibiotics prophylactically in the community while infected with COVID). This might well just reflect my ignorance – perhaps there were countries where antibiotic prophylaxis in the community was widespread, but this has not been shown in the paper by Langford et al., and given that this is a central premise of the model and something that is presumably driving a lot of the results this is surely something where the data supporting this assumption needs to be made very clear if indeed such data exists. If, as I suspect is true in most settings, antibiotic prophylaxis during COVID infection in the community was negligible then I do think there is a need to make appropriate changes to the manuscript.</p></disp-quote><p>First of all, we believe that Reviewer #2 was referring to a different paper by the same author. We drew our antibiotic prescribing estimates listed in the appendix from:</p><p>Langford BJ, So M, Raybardhan S, Leung V, Soucy J-PR, Westwood D, et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect. 2021;27: 520–531. (https://doi.org/10.1016/j.cmi.2020.12.018).</p><p>while we believe that the Reviewer #2 is referring to:</p><p>Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial coinfection and secondary infection in patients with COVID-19: a living rapid review and metaanalysis. Clin Microbiol Infect. 2020;26: 1622–1629. doi:10.1016/j.cmi.2020.07.016 (https://www.sciencedirect.com/science/article/pii/S1198743X20304237?via%3Dihub)</p><p>Reference to 59.3% can be found on the bottom of page 523 of the Langford et al., 2021 manuscript (https://doi.org/10.1016/j.cmi.2020.12.018), direct citation below:</p><p>“Antibiotic prescribing by setting/severity</p><p>Antibiotic prescribing was lowest in the mixed inpatient/outpatient setting at 59.3% (95% CI 38.7% to 77.1%), followed by the inpatient hospital setting at 74.8% (95% CI 67.8-80.7%) and highest in the ICU setting at 86.4% (95% CI 73.7-93.6%).”</p><p>In Langford et al., 2021, out of 154 studies in total included in the meta-analysis, 12 studies included mixed hospital/outpatient setting that we were interested in (pg. 523, Table 1). These 12 publications from mixed hospital/outpatient setting are also listed out in Langford et al., 2021 supplement. 4062 patients in total from mixed hospital/outpatient setting were included in the analysis and it was estimated that 59.3% used antibiotics (pg. 525, Figure 5).</p><p>This was the largest systematic review of antibiotic use that included COVID cases in outpatient setting and we agree that mixed hospital/outpatient setting estimates of antibiotic use (59.3%) might not be the ideal representative of antibiotic use for COVID cases in the community setting.</p><p>For this reason, in the previous version of our article, we assumed that antibiotic use in COVID19 infected individuals in the community will be lower than this estimated number for a mixed setting, and we tested three possibilities in our scenarios using lower values (18.1%, 33.0%, and 55.1%). For example, Tsay et al., 2022 JAMA (doi:10.1001/jama.2022.5471) found that in the US population (age 65+) during the first year of the COVID-19 pandemic, 30% of outpatient visits for COVID-19 among Medicare beneficiaries were linked to an antibiotic prescription, 50.7% of which were for azithromycin. This suggests that the use of antibiotics for treating COVID infection differs between age groups (and possibly countries), and, in our model, we wanted to test a wide range of antibiotic exposures.</p><p>Interestingly, reported trends in antibiotic consumption over the period highlight an increase in macrolide consumption (Nandi et al. 2023 e Clinical Medicine). Following discussions with experts, we also investigated the impact of incorporating specifically addressed azithromycin exposure (by comparison to β-lactams) during the early stages of the pandemic (Appendix 2 – Figure 2) to account for differences in resistance selection due to longer drug persistence in the body.</p><p>In this new version, we investigated lower levels of antibiotic use in COVID-19 patients by varying azithromycin exposure from 0% to 20% of COVID-19 infected individuals. This is outlined in detail all model assumptions in the new version of the manuscript.</p><disp-quote content-type="editor-comment"><p>A second concern is in the treatment of the progression from colonisation to invasive disease. The authors assume that infection with SARS-CoV-2 increases the rate of progression (and consider up to 100-fold increases). This itself is reasonable. However, as the authors acknowledge, other respiratory viral infections also have this effect (SI-8: &quot;estimations show that influenza co-infection increases the rate of progression from S. pneumonia colonization to invasive pneumococcal disease between 49 and 146-fold, on average, depending on the age group&quot;). Since a major effect of the changes in contact patterns in response to the pandemic was that in many countries other respiratory infections, including influenza, did not circulate as usual, wouldn't this be expected to also have a substantial impact on the rate of progression from colonization to invasive disease? i.e. if it is important to consider the impact of SARS-CoV-2 on the progression, why not also consider the effect of other viral pathogens at the same time? A similar concern applies to antibiotic use. We know that in interpandemic periods a lot of antibiotic use in the community is given in response to viral respiratory infections, and since we know that changes in contact patterns had a profound impact on many such viral respiratory infections, is it not also likely that these had an effect on antibiotic use? Or is the assumption that such changes are just absorbed into changes in health-seeking behaviour?</p></disp-quote><p>We agree that it is very important to acknowledge the impact of reduced influenza and other respiratory virus circulation on the rate of progression from colonization to invasive disease for <italic>S. pneumoniae</italic> and we thank you for this suggestion, it is something we did not incorporate in the prior version of the model. It is well-known that viral infections can create a conducive environment for invasive pneumococcal diseases. Therefore, the reduction in influenza (and other respiratory viruses’) transmission over the pandemic period and more specifically during the lockdowns likely contributed to the decrease in IPDs.</p><p>To verify this hypothesis, we introduced an additional parameter into our model that modulates the progression from colonization to disease. Specifically, we considered a reduced invasion risk during the lockdown period and other periods throughout the year when influenza and other ILIs were circulating less than usual. According to recent publications describing carriage studies during the lockdowns in different countries, we also included a new constraint regarding pneumococcal carriage during the lockdown. We indeed assumed that the levels of bacterial colonization remained constant or decreased only slightly during the lockdown period due to reduced social contacts. This new insight into pneumococcal epidemiology over that period gives an advantage to the hypothesis of a reduction of infection risk associated with reduced viral transmission rather than a strong change in transmission and carriage due to lockdown and contact restrictions.</p><p>Changes in the community antibiotic use for any reason are absorbed into changes in the healthcare-seeking behavior during the pandemic. Across 31 scenarios, we assume a decrease of 18% in the overall community antibiotic use based on data from France in 2020 (Bara et al., 2022 <italic>Antibiotics</italic>, doi: 10.3390/antibiotics11050643).</p><disp-quote content-type="editor-comment"><p>A third concern is really a question about whether there might be another mechanism that could be explaining the generally increasing trends in penicillin and macrolide resistance in invasive pneumococcal disease summarised in figure 1. We know that the S. pneumoniae serotypes which have a longer carriage duration are more likely to be resistant (see, for example, Lehtinen et al., PNAS 2017), and also that these have a higher reproduction number (the shorter duration of carriage serotypes being maintained by negative frequency-dependent selection). We would therefore surely expect these less resistant serotypes (with lower reproduction numbers and shorter durations of carriage) to be more impacted by social distancing measures as they would be the first serotypes to have reproduction numbers reduced to below one. This would then be a completely different mechanism to explain observed changes in resistance patterns. Clearly, a lot of work would be needed to establish whether or not this can explain observed changes, though I feel the same is true of the explanatory mechanisms proposed in this paper (increased antibiotic use) given that the current paper lacks any country-specific antibiotic use data or attempt to see if different changes in patterns of antibiotic use can explain the different changes in resistance seen in different countries.</p></disp-quote><p>The duration of bacterial carriage, as examined by Lehtinen et al. PNAS 2017, is a hypothesis that warrants further exploration in the context of the COVID pandemic. We tested this hypothesis in our model as an additional mechanism and described it in the new version of the manuscript. Current manuscript describes country-specific antibiotic use (France) and the model tests different changes in patterns of antibiotic use that reflect different age groups. After assessment, the assumption on duration could not explain on its own the changes during 2020.</p><p>We believe that most obvious and plausible mechanisms are now included and assessed in this new version. They were confronted to experts of the domain.</p><disp-quote content-type="editor-comment"><p>1. lines 118-120 highlight azithromycin as a particular concern for overuse, but this is difficult to square with the review the authors cite from Langford which reports macrolides as accounting for only 6.5% of antibiotic prescribing in COVID patients. This review suggests fluoroquinolones and β-lactams accounted for over 80% of prescribed antibiotics</p></disp-quote><p>In the updated version of the manuscript, we have incorporated numerous additional studies documenting a surge in azithromycin utilization during the initial stages of the pandemic.</p><p>Similar to our response to the first comment, we were referring to Langford et al., 2021 article: Macrolides accounted for 18.9% of antibiotic prescribing in COVID patients. On the other hand, an article doi:10.1016/j.cmi.2020.07.016, also by Langford focuses on the increased use of antibiotics in the incidence of bacterial co-infections presenting with COVID, and provides evidence to support studies by Knight <italic>eLife</italic>, 2021 and Rusic in Life, 2021, expressing concern that there is COVID-19 associated antimicrobial overuse or misuse. Study by Rusic, 2021 is the one that specifically refers to azithromycin use during the early pandemic.</p><p>Citation below from Langford et al., 2021 (paper not cited on line 121, but the one we can add here as well states): “Of ten classes of antibiotics studied, the most common antibiotic classes prescribed were fluoroquinolones (n = 612, 20.0%), macrolides (n = 579, 18.9%), b-lactam/blactamase inhibitors (n = 459, 15.0%) and cephalosporins (n = 459, 15.0%).”</p><p>During the first lockdown in France, community azithromycin consumption increased by 25.9%, with the increase varying from 13.4% to 47.3% depending on the week (Weill et al., 2021), while the overall number of azithromycin prescriptions across France in 2020 increased by 10.1% relative to 2019 (Bara et al., 2022).</p><disp-quote content-type="editor-comment"><p>2. On first looking at the manuscript I was quite concerned that the changes in resistance in figure 1 might reflect changes in health-seeking behaviour rather than real changes in the underlying epidemiology, for example, if certain types of isolates are less likely to be resistant and these types were reported less frequently. Now that I realise that the data in figure 1 all come from invasive isolates (as stated on line 176) this explanation seems less likely. It would be helpful if figure 1 could be labelled appropriately to make it clear that the data shown represents only invasive isolates.</p></disp-quote><p>We thank the reviewer for raising this was unclear. We now changed this to “invasive isolates” both within text and in the figure caption.</p><disp-quote content-type="editor-comment"><p>3. line 248 &quot;some respiratory viruses are known to favor bacterial disease&quot; I don't think &quot;favor&quot; is the right word here. Perhaps &quot;increase the risks of&quot;?</p></disp-quote><p>We made the appropriate change.</p><disp-quote content-type="editor-comment"><p>4. Figure 3 would be easier to read if the subgraphs were labelled with the scenario. Also, it wasn't clear to me what the three graphs in panel C represent.</p></disp-quote><p>Figure 3 has now been replaced with Table 1.</p><disp-quote content-type="editor-comment"><p>5. Table S3. I think A=20 in all the scenarios so that a minimum of 18% of patients infected with SARS-CoV-2 are given antibiotics prophylactically. It would increase readability if this was made explicit in the table.</p></disp-quote><p>Parameter A has now been removed from the model and replaced with separate compartments for azithromycin exposure.</p></body></sub-article></article>